https://crcwarriors.org/ 2026-08-22 daily 1.0 https://crcwarriors.org/ensayos-clinicos 2026-08-22 daily 0.9 https://crcwarriors.org/medicamentos 2026-08-22 weekly 0.9 https://crcwarriors.org/noticias-cientificas 2026-08-22 daily 0.8 https://crcwarriors.org/noticias 2026-08-22 daily 0.8 https://crcwarriors.org/combinaciones 2026-08-01 weekly 0.8 https://crcwarriors.org/eficacia 2026-08-01 weekly 0.8 https://crcwarriors.org/eficacia/kras 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/braf 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/msi 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/biomarker-unselected 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/her2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/msi-h 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/mmr 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ras 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/mss 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/egfr 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/pik3ca 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/nras 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/tp53 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/all 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ras%2Fbraf 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ntrk 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/apc 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/met 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/tmb 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ddr 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/alk 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/pten 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ret 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/vegf 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/atm 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/smad4 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/arid1a 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/mlh1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/pd-l1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/erbb2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/fbxw7 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/rad51 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ros1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/tie2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/blm 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ccnd1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/pole 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ccne1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/fgfr2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/brca1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/cdh17 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/mutyh 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ntrk2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/pms2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/brca2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/egfr+pathway 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ntrk3 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ctnnb1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/msh2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/msi-h%2Fdmmr 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/nf1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/palb2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/erbb3 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ntrk1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/prex2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/rb1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/bcl2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/chek2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/erbb4 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/fgfr3 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/idh2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/smarca4 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/tgfbr2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/arid1b 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/cdk4 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/cna 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/igf1r 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/line-1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/myc 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/nthl1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/pi3k+pathway 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/pold1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/sox9 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/vegfa 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/arid2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/cdk6 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/fgfr1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/hpv 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/jag1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/map2k1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/rad51c 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ras%2Fbraf%2Fegfr%2Fpik3ca%2Fmap2k1%2Fmet%2Fret%2Falk%2Fros1%2Fntrk%2F 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/smad2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/stk11 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/vegfr 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/actl6b 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/cdkn2a 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/idh1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/keap1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/msh6 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/notch1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/pathogenic+variants 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/pik3r1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/rad51d 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/tcf7l2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/wild-type 2026-08-01 monthly 0.7 https://crcwarriors.org/nuestra-historia 2026-08-01 monthly 0.7 https://crcwarriors.org/contacto 2026-08-01 monthly 0.6 https://crcwarriors.org/ayuda 2026-08-01 monthly 0.6 https://crcwarriors.org/colabora 2026-08-01 monthly 0.6 https://crcwarriors.org/ensayo/NCT07201259/analisis-de-las-diferencias-en-el-microbioma-intestinal-de-pacientes-con-cancer-y-diferentes-niveles-de-funcion-ovarica-y-resultados-de-fertilidad-tras-la-terapia-con-inhibidores-de-puntos-de-control 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07201259/exploring-gut-microbiome-differences-in-female-cancer-patients-with-varied-ovarian-function-and-fertility-outcomes-following-immune-checkpoint-inhibitor-therapy 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06722183/futibatinib-en-combinacion-con-quimio-inmunoterapia-en-el-cancer-colorrectal-y-otras-entidades-tumorales-solidas 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06722183/futibatinib-in-combination-with-chemo-immunotherapy-in-colorectal-cancer-and-other-solid-tumor-entities 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07406633/kqb198-en-combinacion-con-imatinib-en-participantes-con-gist-avanzado-metastasico-en-primera-linea-de-tratamiento 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07406633/kqb198-in-combination-with-imatinib-in-participants-with-advanced-metastatic-gist-in-1st-line-setting-synergist-1st-line 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07236983/biodiversidad-de-la-microbiota-intestinal-en-pacientes-con-tumores-solidos-tratados-con-inhibidores-de-puntos-de-control-inmunitario-icpi-un-estudio-prospectivo-monocentrico-para-identificar-las 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07236983/gut-microbiota-gm-biodiversity-in-patients-with-solid-tumors-treated-with-immune-checkpoint-inhibitors-icis-a-monocenter-prospective-study-to-identify-the-interactions-between-gm-and-icis 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT04443543/un-estudio-de-cohorte-prospectivo-con-diseno-adaptativo-sobre-la-estrategia-de-observacion-y-espera-en-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT04443543/an-adaptive-design-prospective-cohort-study-of-watch-and-wait-strategy-in-patients-with-locally-advanced-rectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06293625/personalizacion-y-optimizacion-de-la-quimioterapia-neoadyuvante-en-el-cancer-colorrectal-localmente-avanzado-pero-resecable-en-pacientes-de-edad-avanzada-de-70-anos-o-mas 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06293625/personalising-and-refining-neo-adjuvant-chemotherapy-in-locally-advanced-but-resecable-colon-cancer-in-the-elderly-of-70-years-old-or-more 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07297030/sib-rt-combinado-con-capox-y-un-inhibidor-de-pd-1-para-el-cancer-colorrectal-de-alto-riesgo 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07297030/sib-rt-combined-with-capox-and-pd-1-for-high-risk-rectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06405139/irinotecano-nanoliposomal-oxaliplatino-mas-capecitabina-como-terapia-de-conversion-en-el-cancer-colorrectal-localmente-avanzado 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06405139/nanoliposomal-irinotecan-oxaliplatin-plus-capecitabine-as-conversion-therapy-of-locally-advanced-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07735624/rectify-1-botensilimab-balstilimab-como-tratamiento-neoadyuvante-en-el-cancer-colorrectal-en-estadio-temprano-mss-pmmr 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07735624/rectify-1-neoadjuvant-botensilimab-balstilimab-in-mss-pmmr-early-rectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07158164/farmacogenomica-de-dpyd-y-ajuste-de-la-dosis-de-fluoropirimidinas-fp 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07158164/dpyd-pharmacogenomics-and-fluoropyrimidine-fp-dose-adjustment 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07503639/ensayo-clinico-umbrella-de-terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07503639/umbrella-trial-of-neoadjuvant-therapy-for-locally-advanced-colorectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06790212/quimioterapia-neoadyuvante-con-capox-mas-ivonescimab-frente-a-capox-en-el-cancer-colorrectal-localmente-avanzado 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06790212/neoadjuvant-capox-plus-ivonescimab-versus-capox-for-locally-advanced-colon-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07505472/comparacion-de-la-eficacia-y-la-seguridad-de-un-ciclo-corto-de-radioterapia-seguido-de-quimioterapia-con-capeox-mas-toripalimab-con-o-sin-surufatinib-concomitante-en-la-terapia-neoadyuvante-para-el 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07505472/efficacy-and-safety-comparison-of-short-course-radiotherapy-followed-by-capeox-chemotherapy-plus-toripalimab-with-or-without-concurrent-surufatinib-in-neoadjuvant-therapy-for-mid-to-low-localized 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07740720/un-estudio-sobre-la-duracion-del-tratamiento-con-dostarlimab-en-pacientes-no-tratados-con-cancer-colorrectal-localmente-avanzado-con-deficiencia-en-la-reparacion-de-desajustes-dmmr-y-alta 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07740720/a-study-of-the-duration-of-dostarlimab-in-untreated-mismatch-repair-deficient-dmmr-microsatellite-instability-high-msi-h-locally-advanced-rectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06055439/un-estudio-de-fase-1-2-para-evaluar-chm-2101-una-terapia-celular-t-con-receptor-quimerico-de-antigeno-17-car-autologa 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06055439/a-phase-1-2-study-to-evaluate-chm-2101-an-autologous-cadherin-17-chimeric-antigen-receptor-car-t-cell-therapy 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07622771/radioterapia-neoadyuvante-combinada-con-nalirifox-y-adebrelimab-en-cancer-colorrectal-localmente-avanzado-pmmr-mss-un-ensayo-clinico-prospectivo-aleatorizado-de-fase-ii 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07622771/neoadjuvant-radiotherapy-combined-with-nalirifox-and-adebrelimab-in-pmmr-mss-locally-advanced-rectal-cancer-a-prospective-randomized-phase-ii-clinical-trial 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06770270/pucotenlimab-mas-radioterapia-y-quimioterapia-para-el-tratamiento-neoadyuvante-del-cancer-de-recto-localmente-avanzado-pucrt 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06770270/pucotenlimab-plus-radiotherapy-and-chemotherapy-for-neoadjuvant-treatment-of-locally-advanced-rectal-cance-pucrt 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06923345/radioterapia-de-larga-duracion-modificada-seguida-de-quimioterapia-e-inhibidor-de-pd-1-para-pacientes-con-cancer-colorrectal-localmente-avanzado-de-riesgo-alto-y-con-msi-pmmr-estudio-modifi-rc-i 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06923345/modified-long-course-radiotherapy-followed-by-chemotherapy-and-pd-1-inhibitor-for-mss-pmmr-high-risk-mid-low-larc-modifi-rc-i 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06337760/jovenes-adultos-con-canceres-gastrointestinales-y-neuroendocrinos 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06337760/young-adults-with-gastro-intestinal-gi-and-neuroendocrine-cancers 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07755124/privacion-dietetica-de-arginina-combinada-con-quimiorradioterapia-para-el-tratamiento-neoadyuvante-del-cancer-de-recto-un-ensayo-clinico-aleatorizado-y-controlado 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07755124/dietary-arginine-deprivation-combined-with-chemoradiotherapy-for-neoadjuvant-treatment-of-rectal-cancer-a-randomized-controlled-trial 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06751940/vacuna-con-celulas-dendriticas-cargadas-con-neoantigenos-y-terapia-convencional-de-segunda-linea-para-el-ccrc-que-progresa-tras-el-tratamiento-de-primera-linea 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06751940/neoantigen-loaded-dc-vaccine-and-conventional-second-line-therapy-for-crc-progressed-after-first-line-treatment 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05856305/terapia-de-radiacion-estereotactica-en-tumores-del-tracto-nervioso-con-o-sin-clorofilina 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05856305/scrt-in-tnt-with-or-without-chlorophyllin 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07764120/calidad-de-vida-de-los-pacientes-despues-de-la-reseccion-de-cancer-de-recto 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07764120/quality-of-life-of-patients-after-rectal-cancer-resection 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07764497/quimioterapia-por-infusion-intraarterial-hepatica-en-pacientes-con-metastasis-hepaticas-de-cancer-colorrectal-irresecable 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07764497/hepatic-arterial-infusion-chemotherapy-in-patients-with-inoperable-colorectal-cancer-liver-metastasis 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07636382/ablacion-del-plexo-celiaco-para-el-dolor-mediante-radioterapia-estereotactica-sin-necesidad-de-simulacion-en-pacientes-con-dolor-celiaco-relacionado-con-el-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07636382/simulation-free-celiac-plexus-pain-ablation-using-stereotactic-body-radiotherapy-in-patients-with-cancer-related-celiac-pain 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07765667/nct-inhibidor-de-pd1-dieta-cetogenica-y-o-vitamina-c-para-el-cancer-colorrectal-avanzado-larc 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07765667/nct-pd1-ketogenic-diet-and-or-vitamin-c-for-larc 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06403735/un-estudio-clinico-de-fase-i-de-qlc1101-en-pacientes-con-tumores-solidos-avanzados 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06403735/a-phase-i-clinical-study-of-qlc1101-in-patients-with-advanced-solid-tumors 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07200141/aumento-simultaneo-de-la-dosis-en-la-radioterapia-neoadyuvante-para-el-cancer-de-recto 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07200141/simultaneous-boost-in-neoadjuvant-radiotherapy-for-rectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05571644/tratamiento-neoadyuvante-con-mfolfoxiri-mas-cadonilimab-ak104-frente-a-mfolfox6-en-cancer-colorrectal-localmente-avanzado 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05571644/neoadjuvant-treatment-with-mfolfoxiri-plus-cadonilimab-ak104-versus-mfolfox6-in-locally-advanced-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07136077/un-ensayo-de-fase-ii-con-fruquintinib-y-tislelizumab-en-pacientes-con-enfermedad-residual-minima-definida-por-ctdna-tras-la-finalizacion-de-la-quimioterapia-adyuvante-en-el-cancer-colorrectal 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07136077/a-phase-2-trial-of-fruquintinib-and-tislelizumab-in-ctdna-defined-minimal-residual-disease-in-colorectal-cancer-after-completion-of-adjuvant-chemotherapy 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07646639/diferentes-dosis-de-radioterapia-estereotactica-scrt-mas-capox-bloqueo-de-pd-1-e-il-2-en-el-cancer-colorrectal-localmente-avanzado-larc 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07646639/different-dose-scrt-plus-capox-pd-1-blockade-and-il-2-in-larc 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05723562/un-estudio-de-dostarlimab-en-pacientes-con-cancer-colorrectal-localmente-avanzado-dmmr-msi-h-no-tratados-previamente 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05723562/a-study-of-dostarlimab-in-untreated-dmmr-msi-h-locally-advanced-rectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05523245/prediccion-de-la-eficacia-de-la-terapia-neoadyuvante-en-pacientes-con-cancer-colorrectal-localmente-avanzado-mediante-una-plataforma-de-inteligencia-artificial-basada-en-la-resonancia-magnetica 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05523245/predicting-the-efficacy-of-neoadjuvant-therapy-in-patients-with-locally-advanced-rectal-cancer-using-an-ai-platform-based-on-multi-parametric-mri 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07346469/exploracion-de-los-efectos-de-los-iones-de-magnesio-en-la-neuropatia-periferica-la-concentracion-serica-de-iones-de-magnesio-la-calidad-del-sueno-y-la-calidad-de-vida-en-pacientes-con-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07346469/exploring-the-effects-of-magnesium-ions-on-peripheral-neuropathy-serum-magnesium-ion-concentration-sleep-quality-and-quality-of-life-in-patients-with-colorectal-cancer-receiving-chemotherapy 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06477991/eficacia-de-la-estrategia-de-observacion-y-espera-o-de-la-cirugia-tras-la-inmunoterapia-neoadyuvante-en-el-cancer-colorrectal-localmente-avanzado-con-dmmr-msi-h-guiada-por-el-seguimiento-dinamico-de 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06477991/the-efficacy-of-watch-and-wait-strategy-or-surgery-after-neoadjuvant-immunotherapy-for-locally-advanced-colorectal-cancer-with-dmmr-msi-h-guided-by-mrd-dynamic-monitoring-a-single-center-open-label 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06647680/quimioterapia-neoadyuvante-e-inhibidor-de-pd-1-para-el-cancer-colorrectal-localmente-avanzado-control-01 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06647680/neoadjuvant-chemotherapy-and-pd-1-inhibitor-for-locally-advanced-rectal-cancer-control-01 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07038122/reduccion-del-margen-de-reseccion-tras-la-terapia-neoadyuvante-en-canceres-localmente-avanzados-de-la-union-rectosigmoidea-y-del-recto-superior 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07038122/reducing-the-resection-range-after-neoadjuvant-therapy-for-locally-advanced-upper-rectal-and-rectosigmoid-junction-cancers 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06252142/estudio-que-evalua-si-la-estrategia-de-esperar-y-observar-es-adecuada-en-el-cancer-de-recto 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06252142/study-for-wait-and-watch-suitable-in-rectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06276686/ejercicio-para-mejorar-la-eficacia-de-la-quimiorradioterapia-prolongada-en-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06276686/exercise-for-improving-long-course-chemoradiotherapy-efficacy-in-people-with-locally-advanced-rectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07523763/inmunoterapia-neoadyuvante-a-dosis-bajas-en-el-cancer-colorrectal-localmente-avanzado-con-deficiencia-de-mmr 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07523763/neoadjuvant-low-dose-immunotherapy-in-locally-advanced-mmr-deficient-colorectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05507112/time-en-inmunoterapia-combinada-con-quimiorradioterapia-neoadyuvante-en-el-cancer-de-recto 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05507112/time-in-immunotherapy-combined-with-ncrt-for-rectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT03981497/ablacion-por-microondas-para-el-tratamiento-de-tumores-renales-pequenos-y-neoplasias-hepaticas-primarias-y-secundarias 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT03981497/microwave-ablation-for-treatment-of-small-renal-tumors-and-primary-and-secondary-liver-neoplasms 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05601505/estrategia-de-tratamiento-neoadyuvante-guiada-por-el-adn-tumoral-circulante-para-el-cancer-colorrectal-localmente-avanzado 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05601505/circulating-tumor-dna-guided-neoadjuvant-treatment-strategy-for-locally-advanced-rectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06645808/imagen-pet-de-dos-vartumabs-en-pacientes-con-tumores-solidos 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06645808/pet-imaging-of-two-vartumabs-in-patients-with-solid-tumors 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05663775/mesalazina-como-tratamiento-profilactico-para-prevenir-la-colitis-tras-el-tratamiento-con-ipilimumab-nivolumab-ipi-nivo 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05663775/prophylactic-mesalamine-to-prevent-colitis-following-treatment-with-ipilimumab-nivolumab-ipi-nivo 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT02359565/pembrolizumab-en-el-tratamiento-de-pacientes-jovenes-con-gliomas-de-alto-grado-recurrentes-progresivos-o-refractarios-gliomas-intrinsecos-del-tronco-encefalico-difusos-tumores-cerebrales-hipermutados 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT02359565/pembrolizumab-in-treating-younger-patients-with-recurrent-progressive-or-refractory-high-grade-gliomas-diffuse-intrinsic-pontine-gliomas-hypermutated-brain-tumors-ependymoma-or-medulloblastoma 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07359989/leucina-mas-quimiorradioterapia-para-el-tratamiento-neoadyuvante-del-cancer-colorrectal-localmente-avanzado 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07359989/leucine-plus-radiochemotherapy-for-neoadjuvant-treatment-of-locally-advanced-rectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06662643/un-ensayo-clinico-que-compara-la-anastomosis-de-turnbull-cutait-escalonada-con-la-anastomosis-directa-mas-ileostomia-profilactica-en-el-tratamiento-del-cancer-rectal-bajo-despues-de-la-reseccion-del 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06662643/a-clinical-trial-comparing-staged-turnbull-cutait-pull-through-anastomosis-with-direct-anastomosis-plus-prophylactic-ileostomy-in-the-treatment-of-low-rectal-cancer-after-internal-sphincter-resection 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05585814/capeox-en-combinacion-con-bevacizumab-mas-un-anticuerpo-anti-pd1-como-terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado-con-estabilidad-microsatelital 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05585814/capeox-combined-with-bevacizumab-plus-anti-pd1-antibody-as-neoadjuvant-therapy-for-microsatellite-stable-locally-advanced-rectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07154316/ensayo-clinico-fase-ii-aleatorizado-y-controlado-que-compara-la-quimiorradioterapia-neoadyuvante-lcrt-frente-a-la-radioterapia-neoadyuvante-de-corta-duracion-scrt-combinada-con-capox-un-inhibidor-de 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07154316/phase-ii-rct-of-lcrt-vs-scrt-capox-pd-1i-cox-2i-in-mss-locally-advanced-rectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06052332/eficacia-y-seguridad-de-la-terapia-neoadyuvante-convencional-frente-a-la-terapia-neoadyuvante-total-en-pacientes-de-edad-avanzada-con-cancer-colorrectal-localmente-avanzado 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06052332/efficacy-and-safety-of-conventional-neoadjuvant-therapy-versus-total-neoadjuvant-therapy-in-older-patients-with-locally-advanced-rectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07555210/estudio-piloto-de-los-cambios-en-la-densidad-mineral-osea-durante-la-inmunoterapia-anti-pd-1 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07555210/pilot-study-of-bone-mineral-density-changes-during-anti-pd-1-immunotherapy 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07365592/quimioterapia-neoadyuvante-anticuerpo-anti-pd-1-y-sitagliptina-para-el-cancer-colorrectal-localmente-avanzado-con-pmmr 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07365592/neoadjuvant-chemotherapy-anti-pd-1-antibody-and-sitagliptin-for-locally-advanced-pmmr-crc 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07366554/factores-epigeneticos-del-adenoma-colorrectal-en-la-poblacion-coreana 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07366554/epigenetic-factors-of-colorectal-adenoma-in-korean 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07549906/iparomlimab-tuvonralimab-neoadyuvante-mas-capeox-frente-a-iparomlimab-tuvonralimab-mas-capeox-y-propranolol-para-el-cancer-colorrectal-localmente-avanzado-pmmr-un-estudio-prospectivo-unicentrico-y 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07549906/neoadjuvant-iparomlimab-tuvonralimab-plus-capeox-versus-iparomlimab-tuvonralimab-plus-capeox-and-propranolol-for-locally-advanced-pmmr-colon-cancer-a-prospective-single-center-multi-cohort-study 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06698757/diferentes-ciclos-de-sintilimab-neoadyuvante-preoperatorio-en-cancer-colorrectal-localmente-avanzado-con-deficiencia-en-la-reparacion-de-errores-de-emparejamiento-alta-inestabilidad-de-microsatelites 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06698757/different-cycles-of-preoperative-neoadjuvant-sintilimab-in-mismatch-repair-deficient-microsatellite-instability-high-locally-advanced-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07363863/patron-de-tratamiento-y-resultados-en-el-carcinoma-rectal-localmente-avanzado 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07363863/pattern-of-treatment-and-outcomes-of-locally-advanced-rectal-carcinoma 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06312982/una-serie-de-casos-de-quimiorradioterapia-neoadyuvante-combinada-con-inmunoterapia-para-el-cancer-de-recto-localmente-avanzado 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06312982/a-series-of-neoadjuvant-chemoradiotherapy-combined-with-immunotherapy-for-locally-advanced-rectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06210971/quimiorradiacion-neoadyuvante-con-nal-iri-y-capecitabina-guiada-por-el-estado-de-ugt1a1-en-pacientes-con-cancer-de-recto 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06210971/neoadjuvant-chemoradiation-with-nal-iri-and-capecitabine-guided-by-ugt1a1-status-in-patients-with-rectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06990633/sindrome-de-lynch-en-la-cirugia-del-cancer-colorrectal 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06990633/lynch-syndrome-in-colorectal-cancer-surgery 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07372300/electrohipertermia-modulada-en-combinacion-con-terapia-multimodal-para-el-cancer-de-recto-localmente-avanzado 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07372300/modulated-electro-hyperthermia-in-combination-with-multimodal-therapy-for-locally-advanced-rectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05426005/cadonilimab-para-el-cancer-colorrectal-avanzado-msi-h-dmmr-que-no-responde-al-bloqueo-de-pd-1-pd-l1 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05426005/cadonilimab-for-pd-1-pd-l1-blockade-refractory-msi-h-dmmr-advanced-colorectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06326879/un-estudio-comparativo-entre-pacientes-con-cancer-colorrectal-de-inicio-temprano-y-pacientes-con-cancer-colorrectal-de-inicio-tardio 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06326879/a-comparative-study-between-early-onset-colorectal-cancer-and-late-onset-colorectal-cancer-patients 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06234007/radioterapia-de-corta-duracion-seguida-de-fruquintinib-mas-adebrelimab-y-capox-en-el-tratamiento-neoadyuvante-completo-del-cancer-colorrectal-localmente-avanzado-un-estudio-multicentrico-de-un-solo 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06234007/short-course-radiotherapy-followed-by-fruquintinib-plus-adebrelimab-and-capox-in-the-full-course-neoadjuvant-treatment-of-locally-advanced-rectal-cancer-a-multicenter-single-arm-open-label-study 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07183124/modelado-tridimensional-para-la-deteccion-del-cancer-colorrectal-localmente-avanzado-con-margenes-de-reseccion-circunferencial-positivos 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07183124/3d-modeling-for-detecting-locally-advanced-rectal-cancer-with-positive-circumferential-resection-margin 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT02572141/quimioterapia-perioperatoria-con-folfox-o-capox-frente-a-quimioterapia-postoperatoria-para-el-cancer-colorrectal-localmente-avanzado-optical 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT02572141/folfox-or-capox-perioperative-chemotherapy-versus-postoperative-chemotherapy-for-locally-advanced-colon-cancer-optical 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT03466424/radioterapia-de-corta-duracion-5-x-6-gy-7-gy-8-gy-seguida-de-quimioterapia-neoadyuvante-para-el-cancer-de-recto-localmente-avanzado 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT03466424/short-course-radiotherapy-5x6gy-7gy-8gy-followed-by-neo-adjuvant-chemotherapy-for-locally-advanced-rectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06179602/estudio-de-cohorte-prospectivo-sobre-la-ablacion-termica-de-tumores-hepaticos-malignos 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06179602/prospective-cohort-study-on-thermal-ablation-of-malignant-liver-tumors 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06775951/pertinencia-de-la-indicacion-para-la-colonoscopia-una-evaluacion-del-impacto-clinico-y-economico 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06775951/appropriateness-of-colonoscopy-indication-an-evaluation-of-the-clinical-and-economic-impact 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05228431/regimen-terapeutico-sandwich-modificado-para-el-cancer-colorrectal-localmente-avanzado 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05228431/modified-sandwich-therapeutic-regimen-for-locally-advanced-rectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07382635/protocolo-de-ensayo-clinico-para-evaluar-la-eficacia-y-la-seguridad-del-sistema-de-cirugia-toracoabdominal-endoscopica-en-la-cirugia-laparoscopica-remota-para-urologia-cirugia-general-ginecologia-y 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07382635/clinical-trial-protocol-for-evaluating-the-efficacy-and-safety-of-thoracoabdominal-endoscopic-surgery-system-in-remote-laparoscopic-surgery-for-urology-general-surgery-gynecology-and-thoracic-surgery 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05576480/scrt-penpulimab-en-combinacion-con-capeox-en-el-tratamiento-neoadyuvante-del-cancer-colorrectal-localmente-avanzado-mss 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05576480/scrt-sequential-penpulimab-in-combination-with-capeox-in-the-neoadjuvant-treatment-of-mss-locally-advanced-rectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT04512937/cirugia-asistida-por-navegacion-computarizada-para-el-cancer-colorrectal-localmente-avanzado-y-recurrente 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT04512937/computer-navigation-assisted-surgery-for-locally-advanced-and-recurrent-rectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07394192/radioterapia-de-corta-duracion-con-preservacion-de-los-ganglios-linfaticos-que-drenan-el-tumor-seguida-de-inhibidores-de-pd-1-en-el-cancer-de-recto-en-estadio-ii-iii-con-pmmr-mss 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07394192/short-course-radiotherapy-with-tumor-draining-lymph-node-preservation-followed-by-pd-1-inhibitors-in-pmmr-mss-stage-ii-iii-rectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06154538/inhibidores-de-los-puntos-de-control-inmunitario-quimioterapia-frente-a-quimioterapia-en-el-tratamiento-neoadyuvante-del-cancer-colorrectal-localmente-avanzado 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06154538/immune-checkpoint-inhibitors-chemotherapy-versus-chemotherapy-in-the-neoadjuvant-treatment-of-locally-advanced-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06948539/evaluar-la-tolerabilidad-y-la-farmacocinetica-de-tqb2101-para-inyeccion-en-pacientes-con-tumores-malignos-avanzados 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06948539/to-evaluate-the-tolerability-and-pharmacokinetics-of-tqb2101-for-injection-in-patients-with-advanced-malignant-tumors 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06765616/inyeccion-de-adebrelimab-pd-l1-combinada-con-radioterapia-de-corta-duracion-y-quimioterapia-para-la-terapia-neoadyuvante-del-cancer-colorrectal-localmente-avanzado 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06765616/adebrelimab-injection-pd-l1-combined-with-short-course-radiotherapy-and-chemotherapy-for-neoadjuvant-therapy-of-locally-advanced-rectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06879899/vigilancia-guiada-por-la-enfermedad-residual-minima-en-el-cancer-de-recto-localmente-avanzado-de-localizacion-media-o-baja-surveillance-iii 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06879899/mrd-guided-surveillance-in-locally-advanced-mid-low-rectal-cancer-surveillance-iii 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07393048/aplicacion-y-exploracion-de-la-tecnologia-de-deteccion-personalizada-de-ctdna-mrd-para-predecir-la-eficacia-de-la-terapia-neoadyuvante-en-el-cancer-de-recto 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07393048/application-and-exploration-of-personalized-ctdna-mrd-detection-technology-in-predicting-the-efficacy-of-neoadjuvant-therapy-for-rectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06762405/prodige-90-ffcd-2204-dostarlimab-neoadyuvante-con-radioterapia-de-corta-duracion-en-una-estrategia-de-observacion-y-espera-para-pacientes-con-cancer-colorrectal-localmente-avanzado-inestable-en 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06762405/prodige-90-ffcd-2204-neoadjuvant-dostarlimab-with-short-course-radiotherapy-in-a-watch-and-wait-strategy-for-microsatellite-unstable-or-mismatch-repair-deficient-locally-advanced-rectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06940388/tratamiento-neoadyuvante-total-con-o-sin-tislelizumab-para-el-cancer-colorrectal-localmente-avanzado 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06940388/total-neoadjuvant-treatment-with-or-without-tislelizumab-for-locally-advanced-rectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07106359/evaluacion-inicial-de-una-intervencion-conductual-sobre-los-servicios-de-asesoramiento-genetico-para-familias-con-riesgo-de-sindrome-de-lynch 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07106359/initial-testing-of-a-behavioral-intervention-about-genetic-services-for-families-at-risk-of-lynch-syndrome 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07404228/estudio-multidimensional-disenado-para-desarrollar-un-marco-metodologico-basado-en-datos-de-resonancia-magnetica-rm-con-el-fin-de-predecir-la-respuesta-patologica-completa-pcr-en-pacientes-con-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07404228/multidimensional-study-designed-to-develop-a-methodological-framework-based-on-mri-data-to-predict-pathological-complete-response-pcr-in-patients-with-locally-advanced-rectal-cancer-after-neoadjuvant 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07580027/radioterapia-preoperatoria-adaptativa-concomitante-con-quimioterapia-para-el-adenocarcinoma-rectal-ensayo-adaptativo-de-cancer-rectal-02 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07580027/preoperative-adaptive-radiotherapy-concomitant-to-chemotherapy-for-rectal-adenocarcinoma-adaptive-rectal-cancer-trial-02 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05646511/tnt-de-quimiorradioterapia-qrt-capox-frente-a-qrt-capoxiri-para-el-cancer-colorrectal-localmente-avanzado 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05646511/tnt-of-scrt-capox-vs-scrt-capoxiri-for-locally-advanced-rectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT04223102/microbioma-y-cancer-de-recto 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT04223102/microbiome-and-rectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07113275/un-ensayo-clinico-que-compara-la-radioterapia-de-ciclo-largo-frente-a-la-radioterapia-de-ciclo-corto-seguida-de-inmunoterapia-combinada-con-terapia-neoadyuvante-total-tnt-frente-a-la-radioterapia-de 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07113275/a-clinical-trial-comparing-long-course-versus-short-course-radiotherapy-followed-by-immunotherapy-combined-with-total-neoadjuvant-therapy-tnt-to-long-course-radiotherapy-followed-by-tnt-in-locally 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05136326/quimiorradioterapia-preoperatoria-con-capecitabina-y-temozolomida-en-cancer-colorrectal-localmente-avanzado-con-expresion-de-mgmt-silenciada-y-mss 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05136326/preoperative-chemoradiotherapy-with-capecitabine-and-temozolomide-in-mgmt-silenced-mss-locally-advanced-rectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06229340/leflunomida-o-combinacion-de-un-inhibidor-de-mek-e-hidroxicloroquina-para-pacientes-con-mutaciones-en-ras-que-no-responden-al-tratamiento 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06229340/leflunomide-or-combination-of-mek-inhibitor-and-hydroxychloroquine-for-refractory-patients-with-ras-mutations 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT03525262/terapia-oncologica-para-el-cancer-de-prostata-que-garantiza-la-preservacion-de-los-nervios-y-los-vasos-sanguineos-poten-c 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT03525262/prostate-oncologic-therapy-while-ensuring-neurovascular-conservation-poten-c 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05999812/ensayo-clinico-de-acido-al-trans-retinoico-bevacizumab-y-atezolizumab-en-cancer-colorrectal 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05999812/clinical-trial-of-all-trans-retinoic-acid-bevacizumab-and-atezolizumab-in-colorectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06888843/estudio-para-evaluar-el-uso-de-capecitabina-en-monoterapia-y-en-combinacion-con-oxaliplatino-en-pacientes-ancianos-como-quimioterapia-adyuvante-para-el-cancer-colorrectal-localmente-avanzado 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06888843/study-to-evaluate-the-use-of-capecitabine-in-monotherapy-and-in-combination-with-oxaliplatin-in-elderly-patients-as-adjuvant-chemotherapy-for-locally-advanced-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06207981/estudio-de-fase-iii-que-evalua-la-quimioterapia-de-induccion-seguida-de-quimiorradioterapia-en-comparacion-con-la-quimiorradioterapia-estandar-para-el-carcinoma-de-celulas-escamosas-localmente 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06207981/phase-iii-study-evaluating-induction-chemotherapy-followed-by-chemoradiotherapy-compared-to-standard-chemoradiotherapy-for-locally-advanced-scca 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06229041/tratamiento-neoadyuvante-total-inmunoterapia-para-cancer-colorrectal-localmente-avanzado-de-alto-riesgo-tnti 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06229041/total-neoadjuvant-treatment-immunotherapy-for-high-risk-locally-advanced-rectal-cancer-tnti 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06035133/tratamiento-del-cancer-colorrectal-localmente-avanzado-con-radioterapia-eliminacion-de-la-terapia-tnt-y-terapia-neoadyuvante 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06035133/treatment-of-low-locally-advanced-rectal-cancer-with-radiotherapy-removal-tnt-plus-neoadjuvant-therapy 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT03997435/folfoxiri-con-o-sin-intensificacion-para-el-cancer-de-recto 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT03997435/folfoxiri-with-or-without-intensification-for-rectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07118800/estudio-que-evalua-dos-estrategias-de-tratamiento-para-el-cancer-de-recto-en-pacientes-75-anos 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07118800/study-evaluating-two-treatment-strategies-for-rectal-cancer-in-patients-75-years-old 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06979882/investigacion-de-la-dinamica-de-la-metilacion-multigenica-en-la-vigilancia-de-la-respuesta-al-tratamiento-en-el-carcinoma-intestinal 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06979882/investigating-multigene-methylation-dynamics-in-treatment-response-surveillance-for-intestinal-carcinoma 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05054959/quimioterapia-de-consolidacion-frente-a-quimioterapia-de-induccion-en-la-terapia-neoadyuvante-total-del-cancer-de-recto-con-alto-riesgo-de-recurrencia 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05054959/consolidation-versus-induction-chemotherapy-in-total-neoadjuvant-therapy-of-rectal-cancer-with-high-risk-for-recurrence 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07425054/quimiocirradiacion-adaptada-a-la-respuesta-del-adn-tumoral-circulante-de-vph-tratamiento-con-retifanlimab-en-cancer-anal-en-estadio-avanzado 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07425054/cthpvdna-response-adapted-chemoradiation-retifanlimab-treatment-in-locally-advanced-anal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05148767/terapia-con-irinotecan-basada-en-ugt1a1-para-el-cancer-colorrectal-localmente-avanzado 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05148767/ugt1a1-based-irinotecan-therapy-for-locally-advanced-rectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05984485/la-eficacia-de-la-cirugia-primaria-de-reseccion-total-del-mesorrecto-tme-frente-a-la-quimioterapia-neoadyuvante-combinada-con-la-cirugia-tme-en-el-cancer-colorrectal-localmente-avanzado-de-bajo-riesgo 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05984485/the-efficacy-of-primary-total-mesorectal-excision-tme-surgery-versus-neoadjuvant-chemotherapy-combined-with-tme-surgery-in-low-risk-locally-advanced-rectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07414082/talin-1-serico-y-cripto-1-en-el-cancer-colorrectal 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07414082/serum-talin-1-and-cripto-1-in-colorectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT03875781/estudio-de-no-inferioridad-de-la-quimioterapia-preoperatoria-sin-irradiacion-pelvica-para-el-cancer-de-recto 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT03875781/non-inferiority-study-of-preoperative-chemotherapy-without-pelvic-irradiation-for-rectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06831981/hipertermia-con-quimiorradioterapia-en-el-cancer-de-recto 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06831981/hyperthermia-with-chemoradiotherapy-in-rectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07277842/pd-1-folfoxiri-frente-a-capox-como-terapia-neoadyuvante-total-para-cancer-de-recto-pmmr 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07277842/pd-1-folfoxiri-vs-capox-as-total-neoadjuvant-therapy-for-pmmr-low-rectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06424522/un-programa-de-manejo-intestinal-enema-rectal-retrogrado-para-el-tratamiento-del-sindrome-de-reseccion-anterior-baja-en-pacientes-con-cancer-de-recto 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06424522/a-bowel-management-program-retrograde-rectal-enema-for-the-treatment-of-low-anterior-resection-syndrome-in-rectal-cancer-patients 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07192627/reseccion-endoscopica-con-dispositivo-de-corte-esd-en-el-cancer-colorrectal-localmente-avanzado-tras-quimiorradioterapia-qrt 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07192627/esd-in-locally-advanced-rectal-cancer-following-crt 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06812728/quimioterapia-neoadyuvante-con-folfirinox-y-quimiorradioterapia-preoperatoria-para-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06812728/neoadjuvant-folfirinox-and-preoperative-chemoradiotherapy-for-locally-advanced-rectal-cancer-patients 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07080411/la-eficacia-de-la-radioterapia-adaptativa-en-linea-guiada-por-resonancia-magnetica-para-el-cancer-de-recto-localmente-avanzado 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07080411/the-efficacy-of-mr-guided-online-adaptive-radiotherapy-for-locally-advanced-rectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06856447/el-papel-de-la-coenzima-q10-en-la-profilaxis-de-la-neuropatia-periferica-inducida-por-oxaliplatino-en-pacientes-con-cancer-colorrectal 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06856447/the-role-of-coenzyme-q10-in-the-prophylaxis-of-oxaliplatin-induced-peripheral-neuropathy-in-patients-with-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06304545/tratamiento-del-cancer-de-recto-con-quimiorradioterapia-concurrente-a-largo-plazo-combinada-con-camrelizumab 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06304545/treatment-of-rectal-cancer-with-long-term-concurrent-chemoradiotherapy-combined-with-camrelizumab 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07655856/abordaje-combinado-inicial-de-la-arteria-mesenterica-inferior-seguido-de-un-abordaje-medial-completo-para-la-movilizacion-laparoscopica-de-la-flexura-esplenica-en-el-cancer-colorrectal-izquierdo 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07655856/inferior-mesenteric-artery-first-combined-with-complete-medial-approach-for-laparoscopic-splenic-flexure-mobilization-in-left-sided-colorectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05201430/quimioterapia-neoadyuvante-con-folfoxiri-frente-a-capeox-en-el-cancer-colorrectal-localmente-avanzado 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05201430/neoadjuvant-folfoxiri-versus-capeox-chemotherapy-for-local-advanced-rectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07661017/gutcheck-optimizacion-de-una-aplicacion-movil-de-salud-personalizada-para-pacientes-que-han-sobrevivido-a-un-cancer-gastrointestinal 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07661017/gutcheck-optimization-of-a-personalized-mobile-health-app-for-survivors-of-gastrointestinal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05450029/quimiorradioterapia-neoadyuvante-mas-sintilimab-para-el-cancer-colorrectal-localmente-avanzado-de-riesgo-intermedio-alto-segun-el-indice-de-inmunidad 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05450029/neoadjuvant-chemoradiotherapy-plus-sintilimab-for-intermediate-high-immunoscore-locally-advanced-rectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06063928/unidos-contra-el-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06063928/confronting-cancer-as-a-community 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05009069/un-estudio-de-atezolizumab-con-o-sin-tiragolumab-tras-la-quimiorradioterapia-neoadyuvante-en-participantes-con-cancer-colorrectal-localmente-avanzado 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05009069/a-study-of-atezolizumab-with-or-without-tiragolumab-following-neoadjuvant-chemoradiotherapy-in-participants-with-locally-advanced-rectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06542588/radioterapia-de-corta-duracion-seguida-de-quimioterapia-neoadyuvante-hlx07-y-serplulimab-en-el-cancer-colorrectal-localmente-avanzado-larc 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06542588/short-course-radiotherapy-followed-by-neoadjuvant-chemotherapy-hlx07and-serplulimab-in-larc 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07134101/terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado-en-el-recto-inferior-smarti-rc01 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07134101/neoadjuvant-therapy-for-locally-advanced-low-rectal-cancer-smarti-rc01 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07433673/gemcitabina-cisplatino-nab-paclitaxel-gap-y-cemiplimab-para-el-cancer-de-las-vias-biliares-localmente-avanzado-btc 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07433673/gemcitabine-cisplatin-nab-paclitaxel-gap-and-cemiplimab-for-locally-advanced-biliary-tract-cancer-btc 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06643429/impacto-de-los-factores-ambientales-y-la-metabolomica-en-el-cancer-colorrectal 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06643429/impact-of-environmental-factors-and-metabolomics-on-colorectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT02113384/cancer-colorrectal-localmente-avanzado-celulas-tumorales-exfoliadas-del-peritoneo 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT02113384/locally-advanced-rectal-cancer-exfoliated-peritoneal-tumor-cells 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05563922/estrategia-de-preservacion-organica-mediante-quimiorradioterapia-neoadyuvante-total-para-el-carcinoma-rectal-bajo 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05563922/organ-preservation-strategy-of-total-neoadjuvant-chemoradiotherapy-for-low-rectal-carcinoma 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT04230759/radioterapia-y-quimioterapia-con-o-sin-durvalumab-para-el-carcinoma-anal-localmente-avanzado-un-ensayo-multicentrico-aleatorizado-de-fase-ii-del-grupo-de-estudio-del-cancer-anal-aleman 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT04230759/radiochemotherapy-durvalumab-for-locally-advanced-anal-carcinoma-a-multicenter-randomized-phase-ii-trial-of-the-german-anal-cancer-study-group 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07239466/un-estudio-piloto-que-evalua-la-suplementacion-con-hidroxibutirato-en-combinacion-con-radioterapia-de-corta-duracion-seguida-de-inmunoterapia-combinada-con-terapia-neoadyuvante-con-capeox-en 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07239466/a-pilot-study-evaluating-hydroxybutyrate-supplementation-concomitant-to-short-course-radiotherapy-followed-by-immunotherapy-combined-with-capeox-neoadjuvant-therapy-in-patients-with-locally-advanced 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07450612/biopsia-liquida-y-aprendizaje-automatico-para-la-deteccion-temprana-del-cancer-colorrectal-adenomas-canceres-de-lynch-y-enfermedad-residual 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07450612/liquid-biopsy-and-machine-learning-for-early-colorectal-cancer-adenomas-lynch-cancers-and-residual-disease-detection 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT04815525/el-riesgo-a-largo-plazo-de-neoplasia-colorrectal-avanzada-despues-de-la-colonoscopia-un-estudio-de-cohorte-basado-en-la-poblacion-en-hong-kong 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT04815525/the-longterm-risk-of-advanced-colorectal-neoplasia-after-colonoscopy-a-population-based-cohort-study-in-hong-kong 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06441565/fruquintinib-solo-o-en-combinacion-con-hai-folfox-para-el-cancer-colorrectal-refractario 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06441565/fruquintinib-with-or-without-hai-folfox-for-refractory-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07279077/radioterapia-de-baja-dosis-con-conservacion-de-los-ganglios-linfaticos-administrada-de-forma-concurrente-con-quimioterapia-e-inhibidor-de-pd-1-en-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07279077/node-sparing-low-dose-radiotherapy-concurrent-with-chemotherapy-and-pd-1-inhibitor-in-pmmr-mss-high-risk-locally-advanced-colon-cancer-a-prospective-single-arm-phase-ii-trial 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05722288/alimentacion-con-horarios-restringidos-frente-a-asesoramiento-nutricional-para-la-reduccion-de-los-efectos-secundarios-del-tratamiento-con-radioterapia-o-quimiorradioterapia-en-pacientes-con-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05722288/time-restricted-eating-versus-nutritional-counseling-for-the-reduction-of-radiation-or-chemoradiation-tx-side-effects-in-patients-with-prostate-cervical-or-rectal-cancers 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT04713618/cambios-en-la-salud-pelvica-la-funcion-sexual-y-la-calidad-de-vida-en-mujeres-con-cancer-pelvico-que-se-someten-a-radioterapia 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT04713618/changes-in-pelvic-health-sexual-function-and-quality-of-life-in-women-with-pelvic-cancer-undergoing-radiation-therapy 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06099951/tratamiento-neoadyuvante-total-para-cancer-colorrectal-localmente-avanzado-con-pmmr-anticuerpo-anti-pd-1-con-folfoxiri-y-radioterapia-preoperatoria 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06099951/total-neoadjuvant-treatment-for-pmmr-locally-advanced-low-rectal-cancer-anti-pd-1-antibody-with-folfoxiri-and-preoperative-radiation-therapy 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT04677413/radioterapia-ultrafraccionada-para-el-cancer-de-recto 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT04677413/ultra-fractionated-radiotherapy-for-rectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT04749108/estudio-que-evalua-el-tratamiento-personalizado-del-carcinoma-rectal-localmente-avanzado 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT04749108/study-evaluating-the-tailored-management-of-locally-advanced-rectal-carcinoma 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05965531/tratamiento-del-cancer-colorrectal-localmente-avanzado-con-quimioterapia-con-tas-102-mas-radioterapia-neoadyuvante 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05965531/treating-locally-advanced-rectal-cancer-with-tas-102-chemotherapy-plus-neoadjuvant-radiotherapy 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07461246/red-italiana-de-poliposis-adenomatosa-familiar-rete-italiana-poliposi-adenomatosa-familiare 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07461246/familial-adenomatous-poliposys-italian-network-rete-italiana-poliposi-adenomatosa-familiare 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06949111/radioterapia-terapia-sistemica-como-terapia-de-conversion-para-cancer-de-colon-pmmr-mss-t4m0-neo-color 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06949111/radiotherapy-systemic-therapy-as-conversion-therapy-for-pmmr-mss-t4m0-colon-cancer-neo-color 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06931808/trasplante-de-microbiota-intestinal-radioterapia-combinada-con-quimioterapia-y-sintilimab-en-cancer-colorrectal-avanzado-localizado 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06931808/intestinal-microbiota-transplantation-radiochemotherapy-and-sintilimab-in-localized-advanced-colon-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07283939/estudio-del-algoritmo-pagoda-para-ajustar-las-dosis-de-quimioterapia-y-prevenir-retrasos-no-previstos-en-el-tratamiento 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07283939/studying-the-pagoda-algorithm-for-chemotherapy-dose-changes-to-prevent-unplanned-treatment-delays 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05245786/un-estudio-de-investigacion-anticuerpo-m5a-marcado-con-64cu-en-combinacion-con-quimioterapia-y-radioterapia-estandar-en-el-cancer-colorrectal-localmente-avanzado 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05245786/an-investigational-scan-64cu-labeled-m5a-antibody-in-combination-with-soc-chemotherapy-and-radiotherapy-in-locally-advanced-rectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06402864/evaluacion-del-contacto-con-rayos-x-y-la-braquiterapia-para-la-preservacion-del-recto-en-el-adenocarcinoma-rectal-de-estadio-intermedio 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06402864/evaluation-contact-x-ray-brachytherapy-for-rectal-preservation-in-intermediate-substage-rectal-adenocarcinoma 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05969847/preservacion-de-organos-tras-la-terapia-neoadyuvante-total-basada-en-enverolimab-para-el-cancer-colorrectal-localmente-avanzado-en-estadio-muy-temprano 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05969847/organ-preservation-following-enverolimab-based-total-neoadjuvant-therapy-for-locally-advanced-very-low-rectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT02843191/quimioterapia-de-consolidacion-para-el-cancer-de-recto-localmente-avanzado-ya-sea-de-localizacion-media-o-baja-tras-la-quimiorradioterapia-neoadyuvante-concurrente 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT02843191/consolidation-chemotherapy-for-locally-advanced-mid-or-low-rectal-cancer-after-neoadjuvant-concurrent-chemoradiotherapy 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06745895/acciones-integrales-para-la-educacion-y-el-cribado-del-cancer-colorrectal-y-la-hepatitis-c 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06745895/multilevel-action-toward-colorectal-cancer-and-hepatitis-c-education-and-screening 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06832917/radioterapia-de-corta-duracion-scrt-seguida-de-6-ciclos-de-cadonilimab-mas-mfolfox6-como-terapia-neoadyuvante-para-pacientes-con-cancer-colorrectal-localmente-avanzado-larc-un-ensayo-multicentrico-de 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06832917/short-course-radiation-scrt-followed-by-6-cycles-of-cadonilimab-plus-mfolfox6-as-neoadjuvant-therapy-for-patients-with-locally-advanced-rectal-cancer-larc-a-multicenter-two-arm-parallel-open-label 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT04495088/quimioterapia-folfox-preoperatoria-frente-a-quimioterapia-postoperatoria-adaptada-al-riesgo-en-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT04495088/preoperative-folfox-versus-postoperative-risk-adapted-chemotherapy-in-patients-with-locally-advanced-rectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06783491/eficacia-del-uso-de-la-quimioterapia-neoadyuvante-con-o-sin-hipertermia-intraabdominal-en-el-tratamiento-del-cancer-colorrectal-localmente-avanzado 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06783491/efficacy-of-the-use-of-neoadjuvant-with-without-hyperthermic-intraperitoneal-chemotherapy-in-the-treatment-of-locally-advanced-colon-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06616870/estudio-del-papel-predictivo-y-pronostico-de-las-variantes-farmacogeneticas-y-radiogenicas-en-la-respuesta-al-tratamiento-neoadyuvante-con-quimiorradiacion-en-pacientes-con-cancer-colorrectal 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06616870/study-of-the-predictive-and-prognostic-role-of-pharmacogenetic-and-radiogenic-variants-on-the-response-to-neoadjuvant-chemoradiation-therapy-in-patients-with-locally-advanced-rectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07472868/quimioterapia-neoadyuvante-con-folfoxiri-y-quimiorradioterapia-frente-a-quimioterapia-neoadyuvante-con-capox-folfox-y-quimiorradioterapia-seguida-de-cirugia-o-una-estrategia-de-observacion-activa-en 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07472868/neoadjuvant-folfoxiri-and-chemoradiotherapy-versus-neoadjuvant-capox-folfox-and-chemoradiotherapy-followed-by-surgery-or-a-watch-and-wait-approach-in-high-risk-locally-advanced-rectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT03840239/tnt-para-aumentar-la-tasa-de-respuesta-completa-clinica-en-el-cancer-colorrectal-localizado-en-la-parte-distal 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT03840239/tnt-to-increase-the-clinical-complete-response-rate-for-distal-larc 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT04166604/lonsurf-y-uso-de-g-csf-mantener-la-dosis-e-intensidad-adecuadas-para-optimizar-la-eficacia-del-tratamiento 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT04166604/lonsurf-and-g-csf-use-being-on-a-right-dose-intensity-to-optimize-treatment-efficacy 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07486492/utilizando-bacterias-beneficiosas-del-intestino-para-potenciar-el-tratamiento-inmunologico-del-cancer-colorrectal-avanzado 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07486492/using-healthy-gut-bacteria-to-boost-immune-treatment-for-advanced-bowel-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT04041310/nous-209-vacuna-genetica-para-el-tratamiento-de-tumores-solidos-con-inestabilidad-de-microsatelites 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT04041310/nous-209-genetic-vaccine-for-the-treatment-of-microsatellite-unstable-solid-tumors 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06563388/radioterapia-ablativa-estereotactica-sabr-para-el-tratamiento-de-pacientes-con-cancer-metastasico-ensayo-id-comet 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06563388/stereotactic-ablative-radiotherapy-sabr-for-the-treatment-of-patients-with-metastatic-cancer-id-comet-trial 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07224841/desarrollo-de-un-panel-de-biomarcadores-basado-en-la-metilacion-de-la-cfdna-5mc-5hmc-para-predecir-la-eficacia-de-las-terapias-dirigidas-en-el-mcrc 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07224841/development-of-a-cfdna-5mc-5hmc-based-biomarker-panel-to-predict-targeted-therapy-efficacy-in-mcrc 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06972498/estudio-multicentrico-prospectivo-ivosimab-quimioterapia-como-tratamiento-neoadyuvante-para-metastasis-hepaticas-de-crc-pmmr-mss-resecable 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06972498/a-prospective-multicenter-study-ivosimab-chemotherapy-as-neoadjuvant-for-resectable-pmmr-mss-crc-liver-mets 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07255664/un-ensayo-de-fase-i-iia-fih-que-evalua-la-viabilidad-de-la-administracion-de-inmunoterapia-basada-en-til-en-pacientes-con-crc-metastasico-y-cancer-de-pancreas 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07255664/a-fih-phase-i-iia-trial-assessing-feasibility-of-administrations-of-til-based-immunotherapy-in-patients-with-metastatic-crc-and-pc 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07490119/becotatug-vedotina-en-combinacion-con-cetuximab-en-el-tratamiento-en-lineas-posteriores-del-cancer-colorrectal-metastasico-con-ras-tipo-salvaje 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07490119/becotatug-vedotin-combined-with-cetuximab-in-the-later-line-treatment-of-metastatic-ras-wild-type-colorectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05239650/estudio-clinico-de-fase-ii-para-evaluar-la-eficacia-y-la-seguridad-de-hlx07-hlx10-mfolfox6-o-hlx07-en-monoterapia-en-pacientes-con-mcrc 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05239650/phase-ii-clinical-study-to-evaluate-the-efficacy-and-safety-of-hlx07-hlx10-mfolfox6-or-hlx07-monotherapy-in-patients-with-mcrc 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05959356/cetuximab-y-envafolimab-mas-mfolfoxiri-como-tratamiento-de-primera-linea-para-el-cancer-colorrectal-metastasico-irresecable-del-lado-izquierdo-con-ras-braf-de-tipo-salvaje-y-mss 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05959356/cetuximab-and-envafolimab-plus-mfolfoxiri-as-first-line-treatment-for-ras-braf-wild-type-mss-unresectable-left-side-metastatic-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07612007/hrx215-un-farmaco-inhibidor-de-mkk4-de-primera-generacion-para-el-tratamiento-de-pacientes-con-metastasis-hepaticas-de-cancer-colorrectal-despues-de-someterse-a-una-embolizacion-de-la-vena-porta 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07612007/hrx215-a-first-generation-mkk4-inhibitor-drug-for-the-treatment-of-patients-with-colorectal-liver-metastasis-after-undergoing-a-portal-vein-embolization 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06936527/xs-03-en-combinacion-con-folfox-o-folfiri-y-bevacizumab-para-el-tratamiento-de-pacientes-con-cancer-colorrectal-metastasico-con-mutacion-en-el-gen-ras 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06936527/xs-03-in-combination-with-folfox-or-folfiri-and-bevacizumab-for-treatment-of-metastatic-colorectal-cancer-patients-with-ras-mutation 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07300150/un-estudio-de-pt0511-en-participantes-con-tumores-solidos-avanzados-con-mutacion-o-amplificacion-de-kras 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07300150/a-study-of-pt0511-in-participants-with-kras-mutated-or-amplified-advanced-solid-tumors 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT03776591/colecolectomia-derecha-abierta-versus-colecolectomia-minimamente-invasiva-laparoscopica-para-el-cancer-de-colon-derecho 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT03776591/open-d3-right-hemicolectomy-compared-to-laparoscopic-cme-for-right-sided-colon-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06513221/un-estudio-prospectivo-de-cancer-colorrectal-metastasico-de-tipo-mss-que-recibe-multiples-lineas-de-quimioterapia-estandar-bevacizumab-en-combinacion-con-adebrelimab 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06513221/a-prospective-study-of-mss-type-metastatic-colorectal-cancer-receiving-multiple-lines-of-standard-chemotherapy-bevacizumab-combined-with-adebrelimab 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06681038/tratamiento-antitumoral-sistemico-con-o-sin-quimioterapia-en-aerosol-intraabdominal-a-presion-para-metastasis-peritoneales-de-cancer-de-colon-pipox02 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06681038/systemic-antitumor-treatment-with-or-without-pressurized-intraperitoneal-aerosol-chemotherapy-for-colon-peritoneal-metastases-pipox02 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07503808/un-estudio-de-ide034-en-participantes-adultos-con-tumores-solidos-avanzados-localmente-o-metastasicos 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07503808/a-study-of-ide034-in-adult-participants-with-locally-advanced-metastatic-solid-tumors-types 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07007728/iparolimab-tuvonralimab-en-combinacion-con-bevacizumab-y-capeox-como-terapia-de-conversion-para-metastasis-hepaticas-del-cancer-colorrectal 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07007728/iparomlimab-tuvonralimab-combined-with-bevacizumab-and-capeox-as-conversion-therapy-for-colorectal-cancer-liver-metastasis 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07503756/js212-terapias-combinadas-en-el-cancer-colorrectal-metastasico 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07503756/js212-combination-therapies-in-metastatic-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06959693/un-estudio-clinico-para-evaluar-la-eficacia-y-la-seguridad-de-envafolimab-en-combinacion-con-cetuximab-y-mfolfox6-en-pacientes-con-cancer-colorrectal-metastasico-mcrc-mss-y-ras-braf-de-tipo-salvaje 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06959693/a-clinical-study-to-evaluate-the-efficacy-and-safety-of-envafolimab-combined-with-cetuxima-and-mfolfox6-in-patients-with-mss-ras-braf-wild-type-metastatic-colorectal-cancer-mcrc 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06135571/estudio-sobre-los-patrones-de-metastasis-en-el-ganglio-linfatico-numero-253-en-el-cancer-de-colon-y-recto-izquierdo 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06135571/study-on-the-no-253-lymph-node-metastasis-patterns-in-left-sided-colon-and-rectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07509398/fmt-en-combinacion-con-la-terapia-estandar-de-primera-linea-en-el-cancer-colorrectal-inicialmente-irresecable 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07509398/fmt-combined-with-standard-first-line-therapy-in-initially-unresectable-colorectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06111105/guia-mrd-01-crc-validacion-clinica-y-evaluacion-comparativa-de-los-mejores-diagnosticos-de-ctadn-en-el-cancer-colorrectal 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06111105/guide-mrd-01-crc-clinical-validation-and-benchmarking-of-top-performing-ctdna-diagnostics-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05565417/estudio-del-anticuerpo-monoclonal-imt-009-en-pacientes-con-tumores-solidos-avanzados-o-linfomas 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05565417/study-of-the-monoclonal-antibody-imt-009-in-patients-with-advanced-solid-tumors-or-lymphomas 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07321106/un-estudio-para-investigar-la-seguridad-la-tolerabilidad-la-farmacocinetica-y-la-actividad-antitumoral-de-cbi-1214-un-activador-de-celulas-t-en-participantes-con-cancer-colorrectal-avanzado-o 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07321106/a-study-to-investigate-the-safety-tolerability-pharmacokinetics-and-anti-tumor-activity-of-cbi-1214-t-cell-engager-in-participants-with-advanced-or-metastatic-mss-msi-l-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06973343/sintilimab-mas-bevacizumab-y-quimioterapia-en-pacientes-con-cancer-colorrectal-mss-pmmr-sin-metastasis-hepaticas 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06973343/sintilimab-plus-bevacizumab-and-chemotherapy-in-mss-pmmr-colorectal-with-no-liver-metastasis 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07623174/un-estudio-de-fruquintinib-en-adultos-con-cancer-colorrectal-metastasico-en-polonia 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07623174/a-study-of-fruquintinib-in-adults-with-metastatic-colorectal-cancer-in-poland 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07318389/ascend-crc-perfilado-y-abordaje-de-la-resistencia-tumoral-dinamica-en-pacientes-con-cancer-colorrectal-metastasico 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07318389/ascend-crc-profiling-and-targeting-dynamic-tumor-resistance-in-patients-with-metastatic-colorectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT04046445/estudio-de-fase-1b-para-evaluar-atp128-vsv-gp128-y-bi-754091-en-pacientes-con-cancer-colorrectal-en-estadio-iv 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT04046445/phase-1b-study-to-evaluate-atp128-vsv-gp128-and-bi-754091-in-patients-with-stage-iv-colorectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT04595747/evaluacion-del-farmaco-antitumoral-rogaratinib-bay-1163877-para-el-tratamiento-del-sarcoma-avanzado-con-alteracion-en-el-receptor-del-factor-de-crecimiento-de-fibroblastos-fgfr-1-4-y-en-pacientes-con 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT04595747/testing-the-anti-cancer-drug-rogaratinib-bay-1163877-for-treatment-of-advanced-sarcoma-with-alteration-in-fibroblast-growth-factor-receptor-fgfr-1-4-and-in-patients-with-sdh-deficient 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05746897/un-estudio-de-fase-i-abierto-multicentrico-y-de-primera-administracion-en-humanos-de-nm1f-anti-pvrig-en-pacientes-con-tumores-solidos-avanzados 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05746897/a-first-in-human-phase-i-open-label-multicenter-study-of-nm1f-anti-pvrig-in-patients-with-advanced-solid-tumors 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06126419/aplicacion-de-la-terapia-con-insulina-en-dosis-altas-para-mejorar-la-funcion-y-regeneracion-hepatica 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06126419/application-of-high-dose-insulin-therapy-to-improve-liver-function-and-regeneration 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT02394769/intervencion-con-aspirina-para-la-reduccion-del-riesgo-de-cancer-colorrectal 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT02394769/aspirin-intervention-for-the-reduction-of-colorectal-cancer-risk 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05427487/estudio-de-ivx037-administrado-intratumoralmente-en-pacientes-con-tumores-solidos-avanzados-o-metastasicos 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05427487/study-of-intratumoral-ivx037-in-patients-with-advanced-or-metastatic-solid-tumours 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06609434/el-papel-y-la-seguridad-de-la-ablacion-por-radiofrecuencia-en-las-metastasis-hepaticas-recurrentes-del-cancer-colorrectal 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06609434/the-role-and-safety-of-radiofrequency-ablation-in-recurrent-liver-metastasis-of-colorectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05704985/evaluacion-de-la-seguridad-y-los-biomarcadores-mediante-el-uso-de-dk210-egfr-en-tumores-localmente-avanzados-o-metastasicos-egfr 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05704985/evaluating-safety-and-biomarkers-using-dk210-egfr-for-locally-advanced-or-metastatic-egfr-tumors 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06678919/registro-agmt-de-cancer-colorrectal-metastasico-mcrc-en-tercera-linea-de-tratamiento-y-posteriores 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06678919/agmt-metastatic-colorectal-cancer-registry-mcrc-third-line-and-beyond 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06449937/tratamiento-local-hepatico-para-metastasis-de-cancer-colorrectal-multiorganico 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06449937/local-liver-treatment-for-multi-organ-colorectal-cancer-metastases 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06200831/reseccion-simultanea-frente-a-reseccion-escalonada-del-cancer-colorrectal-con-metastasis-hepaticas-sincronicas 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06200831/simultaneous-vs-staged-resection-of-colorectal-cancer-with-synchronous-liver-metastases 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT04754672/entrenamiento-de-aptitud-aerobica-o-de-masa-muscular-para-mejorar-el-resultado-en-el-cancer-colorrectal 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT04754672/aerobic-fitness-or-muscle-mass-training-to-improve-colorectal-cancer-outcome 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07536113/evaluacion-de-la-eficacia-y-la-seguridad-de-la-seleccion-basada-en-el-adn-tumoral-circulante-ctdna-para-un-nuevo-tratamiento-con-anti-egfr-en-una-cohorte-de-pacientes-con-cancer-colorrectal 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07536113/assessing-the-efficacy-and-safety-of-ctdna-driven-selection-for-anti-egfr-retreatment-in-a-real-world-metastatic-colorectal-cancer-patients-cohort-the-realchallenge-study 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06549907/un-estudio-exploratorio-de-biomarcadores-sobre-el-bloqueo-dual-de-pd1-pdl1-y-ctla4-y-la-terapia-antiangiogenica 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06549907/a-biomarker-exploratory-study-of-dual-blockade-of-pd1-pdl1-and-ctla4-and-anti-angiogenic-therapy 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05652894/un-estudio-de-hx008-en-comparacion-con-la-quimioterapia-en-el-tratamiento-de-primera-linea-de-pacientes-con-cancer-colorrectal-metastasico-msi-h-dmmr 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05652894/a-study-of-hx008-compared-to-chemotherapy-in-the-first-line-treatment-of-subjects-with-msi-h-dmmr-metastatic-colorectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06728072/adicion-de-antibioticos-al-regimen-de-tratamiento-inicial-para-el-cancer-colorrectal 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06728072/addition-of-antibiotics-to-upfront-treatment-regimen-for-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05462613/regorafenib-combinado-con-quimioterapias-a-dosis-bajas-y-aspirina-seguido-de-quimioterapias-estandar-en-el-cancer-colorrectal-metastasico 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05462613/regorafenib-with-low-dose-chemotherapies-and-aspirin-followed-by-standard-chemotherapies-in-metastatic-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07134205/estudio-de-jmt101-en-combinacion-con-irinotecan-como-tratamiento-en-3a-linea-en-el-cancer-colorrectal-metastasico 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07134205/the-study-of-jmt101-combined-with-irinotecan-as-a-3rd-line-treatment-in-metastatic-colorectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT03526835/un-estudio-del-anticuerpo-bispecifico-mcla-158-en-pacientes-con-tumores-solidos-avanzados 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT03526835/a-study-of-bispecific-antibody-mcla-158-in-patients-with-advanced-solid-tumors 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06607458/evaluacion-de-la-seguridad-y-la-eficacia-del-tratamiento-con-melfalan-a-dosis-altas-administrado-directamente-en-el-higado-seguido-de-tratamiento-con-un-farmaco-oncologico-aprobado-o-con-el-farmaco 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06607458/evaluation-of-the-safety-and-efficacy-of-treatment-w-high-dose-melphalan-given-directly-into-the-liver-followed-by-treatment-w-approved-cancer-treatment-or-approved-cancer-treatment-alone-in-patients 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05747716/terapia-de-radiacion-estereotactica-sbrt-combinada-con-fruquintinib-mas-un-anticuerpo-anti-pd-1-ctla-4-como-tratamiento-de-tercera-linea-en-pacientes-con-mcrc 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05747716/sbrt-combined-with-fruquintinib-plus-pd-1-ctla-4-antibody-for-third-line-treatment-in-mcrc 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT02838836/deteccion-de-celulas-tumorales-y-adn-en-la-sangre-la-orina-y-la-medula-osea-de-pacientes-con-canceres-solidos 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT02838836/tumor-cell-and-dna-detection-in-the-blood-urine-and-bone-marrow-of-patients-with-solid-cancers 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07355764/ma-crc-ii-016-shr-1811 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06848842/ivonescimab-mas-quimioterapia-en-pacientes-con-metastasis-hepaticas-de-cancer-colorrectal-inicialmente-irresecable 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06848842/ivonescimab-plus-chemotherapy-in-patients-with-initially-unresectable-colorectal-cancer-liver-metastases 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT04587128/terapia-anti-egfr-en-lineas-tempranas-para-facilitar-el-retratamiento-en-pacientes-seleccionados-con-mcrc 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT04587128/early-line-anti-egfr-therapy-to-facilitate-retreatment-for-select-patients-with-mcrc 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07551778/terapia-con-celulas-nk-alogenicas-combinada-con-el-tratamiento-de-mantenimiento-estandar-en-tumores-solidos-avanzados 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07551778/allogeneic-nk-cell-therapy-combined-with-standard-maintenance-treatment-in-advanced-solid-tumors 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07025239/ql1706-en-inyeccion-combinado-con-bevacizumab-y-xelox-frente-a-placebo-combinado-con-bevacizumab-y-xelox-como-tratamiento-de-primera-linea-del-cancer-colorrectal-metastasico-irresecable 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07025239/ql1706-injection-plus-bevacizumab-and-xelox-vs-placebo-plus-bevacizumab-and-xelox-as-first-line-treatment-of-unresectable-metastatic-colorectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06922383/un-estudio-clinico-de-arfolitixorina-en-pacientes-con-mcrc 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06922383/a-clinical-study-of-arfolitixorin-in-patients-with-mcrc 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06423937/fruquintinib-mas-camrelizumab-y-haic-en-el-tratamiento-del-cancer-colorrectal-avanzado-no-msi-h 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06423937/fruquintinib-plus-camrelizumab-and-haic-in-the-treatment-of-non-msi-h-advanced-colorectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07364656/analisis-de-la-presencia-y-los-efectos-sobre-la-funcion-cardiaca-de-los-autoanticuerpos-anti-nav1-5-en-pacientes-con-tumores-metastasicos 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07364656/analysis-of-the-presence-and-cardiac-functional-effects-of-anti-nav1-5-autoantibodies-in-patients-with-metastatic-tumors 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05253651/un-estudio-de-tucatinib-en-combinacion-con-trastuzumab-y-mfolfox6-frente-al-tratamiento-estandar-en-el-cancer-colorrectal-metastasico-her2-en-primera-linea 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05253651/a-study-of-tucatinib-with-trastuzumab-and-mfolfox6-versus-standard-of-care-treatment-in-first-line-her2-metastatic-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07365527/sonoporacion-y-respuesta-del-microambiente-tumoral-en-metastasis-hepaticas-de-cancer-colorrectal 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07365527/sonoporation-and-tumor-microenvironment-response-in-colorectal-liver-metastases 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06980454/comparacion-de-la-farmacocinetica-en-la-fase-i-de-hlx05-frente-a-erbitux-r-en-hombres-chinos-sanos-seguridad-inmunogenicidad-y-farmacocinetica 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06980454/phase-i-pk-comparison-of-hlx05-vs-erbitux-r-in-healthy-chinese-males-safety-immunogenicity-and-pharmacokinetics 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07088393/diagnostico-mediante-inteligencia-artificial-de-los-diferentes-patrones-de-crecimiento-histopatologico-de-las-metastasis-hepaticas-del-cancer-colorrectal 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07088393/artificial-intelligence-diagnosis-of-different-histopathological-growth-patterns-of-colorectal-cancer-liver-metastasis 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05359393/una-terapia-combinada-que-incluye-inmunoterapia-anti-pd-1-en-cancer-de-recto-mss-con-metastasis-distal-resecable 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05359393/a-combination-therapy-including-anti-pd-1-immunotherapy-in-mss-rectal-cancer-with-resectable-distal-metastasis 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07056374/anastomosis-adaptativa-para-la-reseccion-anterior-en-el-cancer-sigmoideo-y-del-recto-proximal-o-en-lesiones-premalignas 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07056374/adaptive-anastomosis-for-anterior-resection-in-sigmoid-and-proximal-rectal-cancer-or-premalignant-lesions 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05902520/terapia-celular-adoptiva-que-utiliza-linfocitos-infiltrantes-tumorales-cd8-especificos-del-cancer-en-pacientes-adultos-con-tumores-solidos 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05902520/adoptive-cell-therapy-using-cancer-specific-cd8-tumor-infiltrating-lymphocytes-in-adult-patients-with-solid-tumors 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07171554/evaluacion-de-una-prueba-diagnostica-para-identificar-los-mejores-farmacos-para-el-tratamiento-del-cancer-colorrectal-metastasico 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07171554/evaluation-of-a-diagnostic-test-to-identify-the-best-drugs-for-treatment-of-metastatic-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05674526/un-estudio-de-fase-1b-de-wu-nk-101-en-combinacion-con-cetuximab 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05674526/a-phase-1b-study-of-wu-nk-101-in-combination-with-cetuximab 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT03428477/epa-para-el-ensayo-clinico-sobre-metastasis-2 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT03428477/epa-for-metastasis-trial-2 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT03488953/trasplante-de-higado-con-donante-vivo-y-hepatectomia-en-dos-etapas-para-pacientes-con-metastasis-hepaticas-irresecables-aisladas-de-cancer-colorrectal 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT03488953/living-donor-liver-transplantation-with-two-stage-hepatectomy-for-patients-with-isolated-irresectable-colorectal-liver-metastases 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05797077/terapia-de-mantenimiento-postoperatoria-para-metastasis-hepaticas-resecables-del-cancer-colorrectal-guiada-por-ctdna 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05797077/postoperation-maintenance-therapy-for-resectable-liver-metastases-of-colorectal-cancer-guided-by-ctdna 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT01792934/quimioterapia-y-reseccion-quirurgica-maxima-de-las-metastasis-de-cancer-colorrectal-multiorganico 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT01792934/chemotherapy-and-maximal-tumor-debulking-of-multi-organ-colorectal-cancer-metastases 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07570914/infusion-intraarterial-hepatica-de-irinotecan-liposomal-mas-oxaliplatino-y-capecitabina-como-terapia-adyuvante-para-metastasis-hepaticas-del-cancer-colorrectal 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07570914/hepatic-arterial-infusion-of-liposomal-irinotecan-plus-oxaliplatin-and-capecitabine-as-adjuvant-therapy-for-colorectal-cancer-liver-metastases 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05700656/galunisertib-en-combinacion-con-capecitabina-en-el-tratamiento-del-cancer-colorrectal-avanzado-con-microsatelites-estables-mss 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05700656/galunisertib-combined-with-capecitabine-in-advanced-crc-with-pm 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT03957902/evaluacion-de-biomarcadores-directos-de-la-accion-del-acido-acetilsalicilico-para-desarrollar-una-terapia-de-quimioprevencion-de-precision-contra-el-cancer-colorrectal 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT03957902/assessment-of-direct-biomarkers-of-aspirin-action-to-develop-a-precision-chemoprevention-therapy-of-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06714357/acido-valproico-para-potenciar-la-eficacia-del-tratamiento-anti-egfr-y-prevenir-revertir-la-resistencia-en-el-cancer-colorrectal 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06714357/valproic-acid-to-potentiate-anti-egfr-treatment-efficacy-and-prevent-revert-resistance-in-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05141721/un-estudio-de-una-vacuna-neoantigenica-especifica-para-el-paciente-en-combinacion-con-el-bloqueo-de-los-puntos-de-control-inmunitario-en-pacientes-con-cancer-colorrectal-metastasico 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05141721/a-study-of-a-patient-specific-neoantigen-vaccine-in-combination-with-immune-checkpoint-blockade-for-patients-with-metastatic-colorectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06559059/evaluacion-de-la-implementacion-de-un-programa-integral-virtual-de-oncologia-a-multiples-niveles-en-veteranos-diagnosticados-con-cancer-de-pulmon-cancer-colorrectal-cancer-de-prostata-y-cancer-de 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06559059/evaluating-the-implementation-of-a-comprehensive-multilevel-virtual-oncology-program-among-veterans-diagnosed-with-lung-colorectal-prostate-and-breast-cancers-in-the-us-department-of-veterans-affairs 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06446050/celulas-madre-mesenquimales-modificadas-con-quimiocinas-y-moleculas-coestimuladoras-para-el-tratamiento-del-cancer-colorrectal-avanzado 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06446050/chemokine-and-co-stimulatory-molecule-modified-mesenchymal-stem-cells-for-the-treatment-of-advanced-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07410676/ebnk-001-celulas-nk-alogenicas-con-dosis-bajas-de-il-15-pembrolizumab-en-tumores-solidos-avanzados 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07410676/ebnk-001-allogeneic-nk-cells-with-low-dose-il-15-pembrolizumab-in-advanced-solid-tumors 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07415031/un-estudio-de-tumores-solidos-para-el-tratamiento-a-largo-plazo-de-pacientes-con-cancer-que-participaron-en-estudios-con-adagrasib 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07415031/a-solid-tumor-study-for-long-term-treatment-of-cancer-patients-who-participated-in-adagrasib-studies 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06118762/estudio-clinico-de-fruquintinib-en-combinacion-con-raltitrexed-para-el-tratamiento-del-cancer-colorrectal-metastasico 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06118762/clinical-study-of-fruquintinib-combined-with-raltitrexed-in-the-treatment-of-metastatic-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT02521844/un-estudio-para-evaluar-la-seguridad-y-la-tolerabilidad-de-etc-1922159-como-agente-unico-y-en-combinacion-con-pembrolizumab-en-tumores-solidos-avanzados 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT02521844/a-study-to-evaluate-the-safety-and-tolerability-of-etc-1922159-as-a-single-agent-and-in-combination-with-pembrolizumab-in-advanced-solid-tumours 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06657222/primer-estudio-en-humanos-de-tub-030-en-pacientes-con-tumores-solidos-avanzados 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06657222/first-in-human-study-of-tub-030-in-patients-with-advanced-solid-tumors 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT04585035/estudio-para-evaluar-d-1553-en-sujetos-con-tumores-solidos 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT04585035/study-to-evaluate-d-1553-in-subjects-with-solid-tumors 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07054047/mejorando-el-diagnostico-y-el-tratamiento-de-los-pacientes-con-cancer-de-recto 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07054047/improving-diagnosis-and-treatment-for-patients-with-rectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07198958/registro-de-eventos-adversos-inmunologicos-en-pacientes-onco-hematologicos-tratados-con-inmunoterapia 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07198958/immune-adverse-events-registry-in-onco-hematologic-patients-treated-with-immunotherapy 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT02314169/nivolumab-con-o-sin-ipilimumab-en-el-tratamiento-de-pacientes-con-cancer-metastasico-del-conducto-anal-refractario 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT02314169/nivolumab-with-or-without-ipilimumab-in-treating-patients-with-refractory-metastatic-anal-canal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06792695/un-estudio-de-nuevas-intervenciones-y-combinaciones-terapeuticas-en-participantes-con-cancer-colorrectal 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06792695/a-study-of-novel-study-interventions-and-combinations-in-participants-with-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07433283/nanoparticulas-de-carbono-cargadas-con-hierro-en-el-tratamiento-de-tumores-solidos-avanzados 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07433283/carbon-nanoparticle-loaded-iron-in-the-treatment-of-advanced-solid-tumor 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07662031/tovecimig-mas-folfiri-en-segunda-linea-para-el-cancer-colorrectal-metastasico 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07662031/tovecimig-plus-folfiri-in-second-line-metastatic-colorectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07279454/el-estudio-eat-fibre 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07279454/the-eat-fibre-study 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06446557/desescalada-o-cambio-de-tratamiento-segun-la-variacion-del-adn-tumoral-circulante-tras-2-ciclos-de-quimioterapia-combinada-mas-terapia-dirigida-en-el-cancer-colorrectal-metastasico-irresecable 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06446557/de-scalation-or-switch-of-treatment-according-to-circulating-tumor-dna-variation-after-2-cycles-of-doublet-chemotherapy-plus-targeted-agent-in-metastatic-unresectable-colorectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07067385/vacuna-de-arnm-personalizada-contra-el-cancer-para-el-tratamiento-de-tumores-solidos-gastrointestinales 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07067385/personalized-mrna-cancer-vaccine-for-gastrointestinal-solid-tumor-treatment 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT04929223/un-estudio-que-evalua-la-seguridad-y-la-eficacia-de-las-terapias-dirigidas-en-subpoblaciones-de-pacientes-con-cancer-colorrectal-metastasico-intrinsic 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT04929223/a-study-evaluating-the-safety-and-efficacy-of-targeted-therapies-in-subpopulations-of-patients-with-metastatic-colorectal-cancer-intrinsic 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05838768/estudio-de-hro761-en-monoterapia-o-en-combinacion-en-pacientes-con-cancer-que-presenten-alteraciones-especificas-en-el-adn-denominadas-inestabilidad-de-microsatelites-o-deficiencia-en-la-reparacion 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05838768/study-of-hro761-alone-or-in-combination-in-cancer-patients-with-specific-dna-alterations-called-microsatellite-instability-or-mismatch-repair-deficiency 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07189871/177lu-betabart-en-pacientes-con-tumores-solidos-metastasicos-o-localmente-avanzados-inoperables-o-tumores-solidos-recurrentes-refractarios 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07189871/177lu-betabart-in-patients-with-relapsed-refractory-locally-advanced-inoperable-or-metastatic-solid-tumors 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06733038/folfoxiri-mas-bevacizumab-con-o-sin-atezolizumab-como-tratamiento-de-primera-linea-en-pacientes-con-cancer-colorrectal-metastasico-pmmr-e-ic-alto 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06733038/folfoxiri-plus-bevacizumab-with-or-without-atezolizumab-as-1st-line-treatment-of-pmmr-and-is-ic-high-metastatic-colorectal-cancer-patients 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06883084/relevancia-clinica-de-la-regresion-patologica-en-los-ganglios-linfaticos-en-el-cancer-colorrectal-localmente-avanzado 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06883084/clinical-relevance-of-pathologic-regression-in-lymph-node-for-locally-advanced-rectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05240950/celulas-car-t-anti-cea-para-el-tratamiento-de-metastasis-hepaticas-de-cancer-colorrectal 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05240950/anti-cea-car-t-cells-to-treat-colorectal-liver-metastases 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05954429/un-estudio-para-evaluar-el-tratamiento-de-tercera-linea-con-fruquintinib-en-combinacion-con-serplulimab-en-pacientes-con-cancer-colorrectal-metastasico-avanzado-no-limitado-al-higado-un-estudio-de 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05954429/a-study-to-explore-the-third-line-treatment-of-fruquintinib-combined-with-serplulimab-in-advanced-non-liver-limited-metastatic-colorectal-cancer-a-single-center-phase-2-study 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT04854668/un-estudio-de-la-combinacion-de-anlotinib-clorhidrato-en-capsulas-con-quimioterapia-como-tratamiento-de-primera-linea-en-sujetos-con-cancer-colorrectal-metastasico-ras-braf-tipo-salvaje 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT04854668/a-study-of-anlotinib-hydrochloride-capsule-combined-with-chemotherapy-as-first-line-treatment-in-subjects-with-ras-braf-wild-metastatic-colorectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT04616495/trasplante-hepatico-en-pacientes-con-metastasis-hepaticas-irresecables-de-cancer-colorrectal 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT04616495/liver-transplantation-in-patients-with-unresectable-colorectal-liver-metastases 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07201194/acupuntura-holistica-para-pacientes-con-nauseas-inducidas-por-la-quimioterapia 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07201194/holistic-acupuncture-for-patients-with-chemotherapy-induced-nausea 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07446270/eficacia-de-tunlametinib-en-combinacion-con-un-anticuerpo-monoclonal-anti-egfr-en-pacientes-con-tumores-gastrointestinales-avanzados-con-mutaciones-en-ras 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07446270/efficacy-of-tunlametinib-in-combination-with-anti-egfr-monoclonal-antibody-in-patients-with-ras-mutated-advanced-gastrointestinal-malignancies 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT04430725/ablacion-por-microondas-o-reseccion-en-cuna-para-el-tratamiento-de-lesiones-pulmonares-de-sarcoma-y-colorrectales-estudio-allume 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT04430725/microwave-ablation-or-wedge-resection-for-the-treatment-of-lung-sarcoma-and-colorectal-lesions-allume-study 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06434597/un-estudio-clinico-de-comprimidos-de-sph5030-en-el-tratamiento-de-pacientes-con-cancer-de-las-vias-biliares-o-cancer-colorrectal-her2-positivo-mutado 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06434597/a-clinical-study-of-sph5030-tablets-in-the-treatment-of-her2-positive-mutated-biliary-tract-or-colorectal-cancer-patients 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06856837/ikf-aio-quintis-evaluacion-de-fruquintinib-en-combinacion-con-tislelizumab-en-cancer-colorrectal-metastasico-con-microsatelites-estables-reparacion-deficiente-de-errores-de-apareamiento-mss-pmmr-sin 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06856837/ikf-aio-quintis-evaluating-fruquintinib-in-combination-with-tislelizumab-in-microsatellite-stable-proficient-mismatch-repair-mss-pmmr-metastatic-colorectal-cancer-without-active-liver-metastases 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07457541/imagenes-moleculares-de-la-expresion-de-la-proteina-de-activacion-de-fibroblastos-mediante-el-uso-de-fapi-marcado-con-tecnecio-99m-hynic 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07457541/molecular-imaging-of-fibroblast-activation-protein-expression-using-labeled-technetium-99m-hynic-fapi 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07281716/inmunoterapia-combinada-para-el-tratamiento-del-cancer-colorrectal-metastasico-mss-resistente-a-la-quimioterapia 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07281716/combination-immunotherapy-for-the-treatment-of-chemotherapy-refractory-metastatic-mss-crc 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT03829462/evaluacion-de-la-combinacion-de-regorafenib-e-irinotecan-frente-a-regorafenib-en-monoterapia-en-pacientes-con-cancer-colorrectal-metastasico 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT03829462/assessing-a-regorafenib-irinotecan-combination-versus-regorafenib-alone-in-metastatic-colorectal-cancer-patients 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT04444921/ea2176-ensayo-clinico-de-fase-iii-con-carboplatino-y-paclitaxel-nivolumab-en-pacientes-con-cancer-anal-metastasico 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT04444921/ea2176-phase-3-clinical-trial-of-carboplatin-and-paclitaxel-nivolumab-in-metastatic-anal-cancer-patients 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06575127/folfoxiri-modificado-mas-terapia-dirigida-como-tratamiento-de-primera-linea-para-el-cancer-colorrectal-avanzado-un-estudio-prospectivo-de-fase-ii 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06575127/modified-folfoxiri-plus-target-therapy-as-a-first-line-treatment-for-advanced-colorectal-cancer-a-prospective-phase-two-study 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07705334/un-estudio-de-shy-onc6-un-nuevo-inhibidor-del-proteasoma-en-adultos-con-tumores-solidos-avanzados-o-metastasicos 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07705334/a-study-of-shy-onc6-a-novel-proteasome-inhibitor-in-adults-with-advanced-or-metastatic-solid-tumors 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT04575922/nivolumab-ipilimumab-radioterapia-en-pacientes-con-mcrc-mss 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT04575922/nivolumab-ipilimumab-rt-in-mss-mcrc 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT04847063/respuesta-individual-al-tratamiento-con-quimioterapia-hipertermica-intraperitoneal-hipec-de-la-carcinomatosis-peritoneal-procedente-de-mesotelioma-peritoneal-o-proliferacion-mesotelial-atipica-o-de 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT04847063/individual-response-to-hyperthermic-intraperitoneal-chemotherapy-hipec-treatment-of-peritoneal-carcinomatosis-from-peritoneal-mesothelioma-or-atypical-mesothelial-proliferation-or-from-ovarian 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06949982/eficacia-y-seguridad-de-la-hidroxicloroquina-en-combinacion-con-metotrexato-capecitabina-y-bevacizumab-frente-a-regorafenib-en-participantes-con-cancer-colorrectal-metastasico-refractario-con 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06949982/efficacy-and-safety-of-hydroxychloroquine-combined-with-methotrexate-capecitabine-and-bevacizumab-vs-regorafenib-in-participants-with-refractory-metastatic-colorectal-cancer-with-mutations-in-ras 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT03401294/conversion-de-cancer-colorrectal-metastasico-irresecable-a-resecable 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT03401294/conversion-from-unresectable-to-resectable-metastatic-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07211230/estudio-del-biobanco-de-colagenasa 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07211230/collagenase-biobank-study 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07005453/precision-y-sostenibilidad-de-la-evaluacion-scale-eye-para-medir-el-tamano-de-los-polipos-de-forma-fiable 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07005453/accuracy-and-sustainability-of-scale-eye-evaluation-for-measuring-reliable-polyp-size 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05815082/quimioterapia-adyuvante-guiada-por-ctdna-en-metastasis-hepaticas-del-cancer-colorrectal 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05815082/ctdna-guided-adjuvant-chemotherapy-in-liver-metastasis-of-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05933876/el-impacto-de-la-radioterapia-en-el-cancer-oligometastasico 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05933876/the-impact-of-radiotherapy-on-oligometastatic-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05861505/ensayo-collision-relapse 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05861505/collision-relapse-trial 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06679673/shr-1701-en-combinacion-con-shr2554-y-bp102-para-el-cmmr 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06679673/shr-1701-combined-with-shr2554-and-bp102-for-mcrc 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07491159/fruquintinib-mas-un-inhibidor-de-puntos-de-control-en-combinacion-o-de-forma-secuencial-junto-con-tas-102-en-pacientes-con-cancer-colorrectal-que-han-progresado-tras-recibir-una-terapia-estandar-de 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07491159/fruquintinib-plus-checkpoint-inhibitor-combined-or-sequential-tas-102-in-colorectal-cancer-patients-who-progressed-on-second-line-standard-therapy-a-prospective-multi-cohort-single-centered-phase-ib 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05806931/administracion-secuencial-de-tas-ox-en-combinacion-con-tas-iri-alternada-con-bevacizumab-para-el-tratamiento-de-pacientes-con-cancer-colorrectal-metastasico-en-lineas-de-tratamiento-avanzadas 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05806931/sequential-tas-ox-alternating-with-tas-iri-plus-bevacizumab-for-late-line-metastatic-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07722754/bevacizumab-sintilimab-cetuximab-e-irinotecan-en-el-cancer-colorrectal-metastasico-refractario-con-ras-de-tipo-salvaje-ensayo-bond-4 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07722754/bevacizumab-sintilimab-cetuximab-and-irinotecan-in-refractory-ras-wild-type-metastatic-colorectal-cancer-bond-4-trial 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05694936/combinacion-de-valproato-sodico-con-el-tratamiento-estandar-con-anticuerpos-monoclonales-dirigidos-al-egfr-receptor-del-factor-de-crecimiento-epidermico-en-pacientes-con-cancer-colorrectal-metastasico 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05694936/combining-sodium-valproate-with-standard-of-care-egfr-epidermal-growth-factor-receptor-monoclonal-antibody-treatment-in-patients-with-metastatic-colorectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT03869892/estudio-de-fase-iii-sobre-el-tratamiento-de-primera-linea-en-pacientes-con-cancer-colorrectal-metastasico-que-no-son-candidatos-para-recibir-terapia-intensiva 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT03869892/phase-iii-study-in-first-line-treatment-of-patients-with-metastatic-colorectal-cancer-who-are-not-candidate-for-intensive-therapy 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07494578/estudio-observacional-sobre-la-combinacion-de-fluoropirimidina-y-bevacizumab-en-pacientes-con-mcrc 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07494578/observational-study-regarding-the-combination-of-fluoropyrimidine-and-bevacizumab-in-patients-with-mcrc 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06449989/comparacion-de-la-concordancia-molecular-genetica-del-tumor-primario-y-las-metastasis-cerebrales-del-cancer-colorrectal 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06449989/comparison-of-molecular-genetic-concordance-of-the-primary-tumor-and-brain-metastases-of-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07502014/un-estudio-clinico-de-iparomlimab-y-tuvonralimab-en-combinacion-con-fruquintinib-y-radioterapia-heterogenea-en-comparacion-con-fruquintinib-como-tratamiento-de-tercera-linea-y-en-lineas-posteriores 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07502014/a-clinical-study-of-iparomlimab-and-tuvonralimab-combined-with-fruquintinib-and-heterogeneous-radiotherapy-versus-fruquintinib-as-third-line-and-subsequent-line-treatment-for-metastatic-colorectal 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06090994/prevencion-de-la-recurrencia-y-la-metastasis-del-cancer-colorrectal-mediante-la-comparacion-de-huaier-con-la-monoterapia-con-capecitabina 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06090994/prevention-of-recurrence-and-metastasis-of-colorectal-cancer-by-comparing-huaier-with-capecitabine-monotherapy 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07729605/folfiri-mas-bevacizumab-y-ql1706-como-tratamiento-de-segunda-linea-para-el-mcrc 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07729605/folfiri-plus-bevacizuamb-and-ql1706-in-second-line-treatment-for-mcrc 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06821048/estudio-de-la-terapia-car-t-dirigida-contra-el-cea-ptc13-en-el-tratamiento-de-tumores-solidos-malignos-avanzados-cea-positivos 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06821048/study-of-cea-targeting-car-t-ptc13-in-the-treatment-of-cea-positive-advanced-malignant-solid-tumors 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT04991948/estudio-del-tratamiento-con-pembrolizumab-tras-la-administracion-de-cyad-101-con-acondicionamiento-previo-con-folfox-en-el-cancer-colorrectal-metastasico 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT04991948/study-of-pembrolizumab-treatment-after-cyad-101-with-folfox-preconditioning-in-metastatic-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT01762813/evaluacion-de-los-resultados-clinicamente-relevantes-y-analisis-de-biomarcadores-para-su-integracion-traslacional-en-el-cancer-colorrectal 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT01762813/assessment-of-clinically-related-outcomes-and-biomarker-analysis-for-translational-integration-in-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06944548/evaluacion-del-efecto-de-la-actividad-fisica-adaptada-sobre-la-modificacion-del-metabolismo-lipidico-durante-la-quimioterapia-para-el-cancer-colorrectal-metastasico 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06944548/evaluation-of-the-effect-of-adapted-physical-activity-on-the-modification-of-lipid-metabolism-during-chemotherapy-for-metastatic-colorectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07224724/deteccion-de-metastasis-extrahepaticas-derivadas-de-exosomas-mediante-biopsia-liquida-en-metastasis-hepaticas-del-cancer-colorrectal 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07224724/exosome-derived-extrahepatic-metastasis-detection-by-liquid-biopsy-in-colorectal-cancer-liver-metastases 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT04678583/reseccion-anatomica-de-metastasis-hepaticas-en-pacientes-con-cancer-colorrectal-con-mutaciones-en-los-genes-ras 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT04678583/anatomical-resection-of-liver-metastases-in-patients-with-ras-mutated-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07621159/un-estudio-de-fase-ib-ii-de-hdm2017-en-combinacion-con-el-tratamiento-estandar-en-el-cancer-colorrectal-avanzado 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07621159/a-phase-ib-ii-study-of-hdm2017-in-combination-with-standard-of-care-in-advanced-colorectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06202183/ejercicio-fisico-y-microbiota-intestinal-en-pacientes-con-cancer-colorrectal-de-inicio-temprano-que-reciben-quimioterapia-el-ensayo-courage 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06202183/exercise-for-gut-microbiome-in-patients-with-young-onset-colorectal-cancer-undergoing-chemotherapy-the-courage-trial 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06258525/same-en-la-prevencion-de-la-lesion-hepatica-asociada-a-oxaliplatino 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06258525/same-in-prevention-of-oxaliplatin-associated-liver-injury 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT04798898/mejora-de-la-supervivencia-en-metastasis-hepaticas-de-cancer-colorrectal-mediante-la-inmunostimulacion-inducida-por-ablacion-por-radiofrecuencia 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT04798898/improving-survival-of-colorectal-liver-metastases-by-rfa-mediated-immunostimulation 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07031570/eficacia-y-seguridad-de-la-combinacion-de-deb-tace-con-haic-frente-a-haic-sola-en-pacientes-con-metastasis-hepaticas-irresecables-de-cancer-colorrectal-crlm 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07031570/efficacy-and-safety-of-deb-tace-combined-with-haic-versus-haic-alone-in-patients-with-unresectable-crlm 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05854498/irinotecan-liposomal-en-combinacion-con-tas102-y-bevacizumab-para-pacientes-con-cancer-colorrectal-metastasico 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05854498/liposomal-irinotecan-with-tas102-and-bevacizumab-for-patients-with-metastatic-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06470178/un-estudio-en-el-mundo-real-sobre-la-terapia-neoadyuvante-de-conversion-para-el-cancer-colorrectal-con-quimioterapia-y-agentes-dirigidos-antiangiogenicos 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06470178/a-real-world-study-of-neoadjuvant-conversion-therapy-for-colorectal-cancer-with-chemotherapy-and-anti-angiogenic-targeted-agents 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06992258/un-ensayo-aleatorizado-de-fase-ii-que-compara-fruquintinib-y-tas-102-con-fruquintinib-en-pacientes-con-cancer-colorrectal-avanzado-metastasico-refractario 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06992258/a-randomized-phase-2-trial-of-fruquintinib-and-tas-102-as-compared-to-fruquintinib-in-patients-with-refractory-advanced-metastatic-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06787105/fruquintinib-en-pacientes-con-cancer-colorrectal-metastasico 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06787105/fruquintinib-in-patients-with-metastatic-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06184698/irinotecan-liposomal-y-leucovorina-5-fluorouracilo-mas-bevacizumab-en-el-cancer-colorrectal-metastasico 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06184698/liposomal-irinotecan-and-leucovorin-5-fluorouracil-plus-bevacizumab-in-metastatic-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06343116/nimotuzumab-en-combinacion-con-trifluridina-tipiracil-en-el-tratamiento-del-cancer-colorrectal-metastasico-refractario 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06343116/nimotuzumab-combined-with-trifluridine-tipiracil-in-the-treatment-of-refractory-metastatic-colorectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06107413/estudio-para-evaluar-los-eventos-adversos-y-los-cambios-en-la-actividad-de-la-enfermedad-en-participantes-adultos-previamente-tratados-que-reciben-abbv-400-por-via-intravenosa-iv-en-combinacion-con 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06107413/study-to-assess-adverse-events-and-change-in-disease-activity-in-previously-treated-adult-participants-receiving-intravenous-iv-abbv-400-with-unresectable-metastatic-colorectal-cancer-in-combination 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07631884/estudio-exploratorio-sobre-la-eficacia-y-la-seguridad-del-trastuzumab-rezetecan-en-el-tratamiento-de-tumores-solidos-avanzados-con-expresion-de-her2 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07631884/exploratory-study-on-the-efficacy-and-safety-of-trastuzumab-rezetecan-in-the-treatment-of-her2-expressiong-advanced-solid-tumor 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05131919/pembrolizumab-para-el-tratamiento-de-cancer-colorrectal-localmente-avanzado-irresecable-y-no-metastasico-con-dmmr 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05131919/pembrolizumab-for-locally-advanced-irresectable-non-metastatic-dmmr-colorectal-cancers 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06255379/estudio-de-fruquintinib-en-combinacion-con-tegafur-gimeracil-y-oteracil-en-pacientes-con-cancer-colorrectal-metastasico 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06255379/study-of-fruquintinib-combined-with-tegafur-gimeracil-oteracil-in-patients-with-metastatic-colorectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06522919/tratamiento-secuencial-con-inmunoterapia-y-quimioterapia-que-consiste-en-la-administracion-de-pembrolizumab-mas-vacuna-de-celulas-dendriticas-seguido-de-trifluridina-tipiracil-mas-bevacizumab-en 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06522919/sequential-immunochemotherapy-treatment-with-pembrolizumab-plus-dendritic-cell-dc-vaccine-followed-by-trifluridine-tipiracil-plus-bevacizumab-in-refractory-mismatch-repair-proficient-pmmr-or 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07035886/un-estudio-para-monitorizar-el-tratamiento-con-fruzaqla-en-adultos-con-cancer-colorrectal-metastasico-mcrc-en-corea-del-sur 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07035886/a-study-to-monitor-the-fruzaqla-treatment-of-adults-with-metastatic-colorectal-cancer-mcrc-in-south-korea 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT02012699/repositorio-integral-de-cancer-para-la-investigacion-oncologica 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT02012699/integrated-cancer-repository-for-cancer-research 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06195111/un-estudio-en-el-mundo-real-de-un-regimen-que-contiene-trifluridina-tipiracil-para-el-tratamiento-de-pacientes-con-mcrc-estudio-reflect 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06195111/a-real-world-study-of-trifluridine-tipiracil-containing-regimen-for-the-treatment-of-patients-with-mcrc-reflect-study 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06646341/emvi-como-factor-determinante-de-la-metastasis-en-el-cancer-colorrectal 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06646341/emvi-as-a-determinant-of-metastasis-in-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05462236/inhibidor-de-mnk-aum001-en-combinacion-con-pembrolizumab-o-irinotecan-para-el-tratamiento-del-cancer-colorrectal-metastasico 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05462236/mnk-inhibitor-aum001-in-combination-with-either-pembrolizumab-or-irinotecan-to-treat-metastatic-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07071844/between-bevacizumab-y-trifluridina-tipiracil-administrados-cada-dos-semanas-para-reducir-la-neutropenia-de-grado-3-4-en-pacientes-con-mcrc 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07071844/between-biweekly-bevacizumab-trifluridine-tipiracil-to-reduce-grade-3-4-neutropenia-in-mcrc-patients 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT02804815/add-aspirin-un-ensayo-clinico-que-evalua-los-efectos-de-la-aspirina-sobre-la-recurrencia-de-la-enfermedad-y-la-supervivencia-tras-la-terapia-primaria-en-tumores-solidos-no-metastasicos-comunes 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT02804815/add-aspirin-a-trial-assessing-the-effects-of-aspirin-on-disease-recurrence-and-survival-after-primary-therapy-in-common-non-metastatic-solid-tumours 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05057052/crioablacion-combinada-con-sintilimab-mas-regorafenib-en-metastasis-hepaticas-de-cancer-colorrectal-previamente-tratadas 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05057052/cryoablation-combined-with-sintilimab-plus-regorafenib-in-previously-treated-colorectal-cancer-liver-metastasis 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06593548/lvosidenib-ak112-en-combinacion-con-capeox-y-radioterapia-en-pacientes-con-cancer-colorrectal-metastasico-irresecable-de-tipo-mss 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06593548/lvosidenib-ak112-combined-with-capeox-and-radiotherapy-in-patients-with-unresectable-metastatic-mss-type-colorectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06958419/radioterapia-de-curso-corto-con-preservacion-de-los-ganglios-linfaticos-combinada-con-quimioterapia-bevacizumab-e-inhibidor-de-pd-1-en-cancer-colorrectal-metastasico-pmmr-mss-modifi-crc 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06958419/node-sparing-short-course-radiotherapy-plus-chemotherapy-bevacizumab-and-pd-1-inhibitor-in-metastatic-pmmr-mss-colorectal-cancer-modifi-crc 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT04230187/bevacizumab-mas-mfolfoxiri-como-tratamiento-de-primera-linea-para-pacientes-con-cancer-colorrectal-metastasico-irresecable 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT04230187/bevacizumab-plus-mfolfoxiri-as-first-line-treatment-for-patients-with-unresectable-metastatic-colorectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT03657641/regorafenib-y-pembrolizumab-en-el-tratamiento-de-participantes-con-cancer-colorrectal-avanzado-o-metastasico 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT03657641/regorafenib-and-pembrolizumab-in-treating-participants-with-advanced-or-metastatic-colorectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06867822/ensayo-clinico-de-proagio-en-cancer-colorrectal-avanzado-o-metastasico 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06867822/trial-of-proagio-in-advanced-metastatic-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06440902/exploracion-de-estrategias-terapeuticas-para-el-cancer-colorrectal-metastasico-con-mutacion-nras-de-tipo-salvaje-basada-en-el-adn-tumoral-circulante 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06440902/exploration-of-therapeutic-strategies-for-neoras-wild-type-metastatic-colorectal-cancer-based-on-circulating-tumor-dna 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07175636/ql1706-radioterapia-y-quimioterapia-a-corto-plazo-para-el-cancer-colorrectal-mss 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07175636/ql1706-with-short-course-radiotherapy-and-chemotherapy-for-mss-rectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06911970/impacto-del-ejercicio-aerobico-en-la-respuesta-inmune-antitumoral-en-pacientes-que-reciben-tratamiento-contra-el-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06911970/impact-of-aerobic-exercise-on-the-anticancer-immune-response-in-patients-receiving-cancer-treatment 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07542262/estudio-clinico-de-fase-ii-abierto-de-un-unico-centro-para-evaluar-la-eficacia-y-la-seguridad-de-la-inmunoterapia-a-dosis-bajas-en-el-tratamiento-de-pacientes-con-cancer-colorrectal-y-cancer-gastrico 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07542262/low-dose-immunotherapy-in-metastatic-and-locally-advanced-colorectal-and-gastric-msi-dmmr-cancers 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06590259/un-estudio-sobre-la-eficacia-y-la-seguridad-de-la-ablacion-multimodal-combinada-con-terapia-sistemica-en-el-tratamiento-de-la-crclm 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06590259/a-study-on-the-efficacy-and-safety-of-multi-mode-ablation-combined-with-systemic-therapy-in-the-treatment-of-crclm 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06974110/estudio-de-moma-341-administrado-por-via-oral-en-participantes-con-tumores-solidos-avanzados-o-metastasicos 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06974110/study-of-orally-administered-moma-341-in-participants-with-advanced-or-metastatic-solid-tumors 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07194616/ensayo-clinico-sobre-celulas-tumorales-circulantes-en-cancer-de-recto 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07194616/rectal-cancer-ctc-trial 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06353854/cohorte-nacional-prospectiva-para-evaluar-biomarcadores-predictivos-de-resistencia-a-la-inmunoterapia-en-pacientes-con-cancer-colorrectal-metastasico-msi-dmmr-coresim 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06353854/prospective-national-cohort-evaluating-predictive-biomarkers-of-resistance-to-immunotherapy-in-patients-with-msi-dmmr-metastatic-colorectal-cancer-coresim 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06820463/un-estudio-para-evaluar-los-eventos-adversos-y-la-eficacia-de-la-administracion-intravenosa-iv-de-telisotuzumab-adizutecan-en-combinacion-con-oxaliplatino-iv-fluorouracilo-acido-folinico-leucovorina 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06820463/a-study-to-evaluate-the-adverse-events-and-efficacy-of-intravenous-iv-of-telisotuzumab-adizutecan-in-combination-with-iv-oxaliplatin-fluorouracil-folinic-acid-leucovorin-bevacizumab-panitumumab-in 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07268677/un-estudio-clinico-de-un-solo-brazo-que-evalua-la-combinacion-de-pirfenidona-y-sintilimab-con-la-quimioterapia-neoadyuvante-estandar-en-pacientes-con-cancer-colorrectal-y-metastasis-peritoneal 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07268677/a-single-arm-clinical-study-evaluating-pirfenidone-and-sintilimab-in-combination-with-standard-neoadjuvant-chemotherapy-for-colorectal-cancer-patients-with-peritoneal-metastasis 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06841159/radioterapia-estereotactica-adaptativa-ultrafraccionada-y-personalizada-pulsar-combinada-con-terapia-anti-pd1-quimioterapia-y-terapia-dirigida-para-el-cancer-colorrectal-metastasico 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06841159/personalized-ultrafractionated-stereotactic-adaptive-radiotherapy-pulsar-combined-with-anti-pd1-chemotherapy-and-target-therapy-for-metastatic-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05129787/ablacion-frente-a-reseccion-de-metastasis-hepaticas-del-cancer-colorrectal 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05129787/ablation-vs-resection-of-colorectal-cancer-liver-metastases 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05447611/papel-de-la-empatia-en-los-resultados-del-tratamiento-curativo-del-cancer-colorrectal-no-metastasico 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05447611/role-of-empathy-in-curative-treatment-outcomes-of-non-metastatic-colorectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06551207/cadonilimab-en-combinacion-con-fruquintinib-y-radioterapia-estereotactica-ablativa-sbrt-como-tratamiento-de-tercera-linea-y-en-lineas-posteriores-en-pacientes-con-crc-mss 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06551207/cadonilimab-combined-with-fruquintinib-and-sbrt-as-athird-line-and-posterior-line-treatment-in-patients-with-mss-crc 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05310643/nivolumab-e-ipilimumab-en-pacientes-con-mcrc-dmmr-msi-refractarios-a-anti-pd1 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05310643/nivolumab-and-ipilimumab-in-anti-pd1-resistant-dmmr-msi-mcrc 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06555133/y-90-capecitabina-y-atezolizumab-para-el-cancer-colorrectal-oligo-metastasico 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06555133/y-90-capecitabine-and-atezolizumab-for-oligometastatic-crc 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06505551/estudio-de-fase-i-ii-de-celulas-t-con-receptores-de-celulas-t-autologas-scg142-en-pacientes-con-carcinoma-positivo-para-hpv16-52 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06505551/phase-1-2-study-of-autologous-scg142-tcr-t-cells-in-patients-with-hpv16-52-positive-carcinoma 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06185556/ensayo-coldfire-iii-eficacia-de-la-electroforesis-irreversible-y-la-radioterapia-estereotactica-corporal-en-metastasis-hepaticas-de-cancer-colorrectal-perivasculares-y-peribiliares 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06185556/coldfire-iii-trial-efficacy-of-irreversible-electroporation-and-stereotactic-body-radiotherapy-for-perivascular-and-peribiliary-colorectal-liver-metastases 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06616259/tratamiento-de-primera-linea-con-mcapox-cetuximab-frente-a-mfolfox6-cetuximab-en-pacientes-con-cmmr-no-operable-del-lado-izquierdo-con-ras-braf-tipo-salvaje-y-mss-un-estudio-multicentrico 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06616259/first-line-treatment-of-mcapox-cetuximab-vs-mfolfox6-cetuximab-for-ras-braf-wild-type-mss-unresectable-left-sided-mcrc-a-multicenter-randomized-controlled-phase-iii-study 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05759728/un-estudio-de-cna3103-celulas-car-t-autologas-dirigidas-a-lgr5-administrado-a-sujetos-con-cancer-colorrectal-metastasico 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05759728/a-study-of-cna3103-lgr5-targeted-autologous-car-t-cells-administered-to-subjects-with-metastatic-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT02595957/programa-de-investigacion-en-servicios-genomicos 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT02595957/genomic-services-research-program 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06134388/sulfasalazina-en-pacientes-con-cancer-colorrectal-metastasico 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06134388/sulfasalazine-in-patients-with-metastatic-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07362836/fruquintinib-frente-a-bevacizumab-mas-quimioterapia-en-el-tratamiento-de-segunda-linea-del-cancer-colorrectal-metastasico-con-mutacion-en-los-genes-ras-fru-ras 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07362836/fruquintinib-versus-bevacizumab-plus-chemotherapy-in-second-line-ras-mutant-metastatic-colorectal-cancer-fru-ras 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05688280/inyeccion-intratumoral-de-ip-001-tras-ablacion-termica-en-pacientes-con-crc-nsclc-y-sts 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05688280/intratumoral-injection-of-ip-001-following-thermal-ablation-in-patients-with-crc-nsclc-and-sts 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06192680/irinotecano-liposomal-y-capecitabina-mas-bevacizumab-como-terapia-de-segunda-linea-en-el-cancer-colorrectal-metastasico 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06192680/liposomal-irinotecan-and-capecitabine-plus-bevacizumab-as-second-line-therapy-in-metastatic-colorectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06356584/fruquintinib-en-combinacion-con-sintilimab-radioterapia-para-el-tratamiento-en-tercera-linea-del-cancer-colorrectal-con-metastasis-hepaticas 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06356584/fruquintinib-combined-with-sintilimab-radiotherapy-for-third-line-treatment-of-colorectal-cancer-with-liver-metastases 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06825624/artemis-102-combinaciones-con-hs-20093-en-pacientes-con-cancer-colorrectal-metastasico-avanzado 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06825624/artemis-102-hs-20093-combinations-in-patients-with-advanced-metastatic-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05556473/pet-ct-con-f-triptofano-en-canceres-humanos 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05556473/f-tryptophan-pet-ct-in-human-cancers 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06764680/quimioterapia-oral-terapia-dirigida-e-inmunoterapia-con-o-sin-radioterapia-como-terapia-de-tercera-linea-o-posterior-para-el-cancer-colorrectal-avanzado-mss-pmmr 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06764680/oral-chemotherapy-targeted-therapy-and-immunotherapy-with-without-radiotherapy-as-3rd-or-later-line-therapy-for-advanced-mss-pmmr-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT03919461/ensayo-internacional-sobre-la-prevencion-de-metastasis-del-cancer-colorrectal-2 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT03919461/colorectal-metastasis-prevention-international-trial-2 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06940921/sbrt-ldrt-cadonilimab-para-el-cancer-gastrico-colorrectal-y-ovarico-avanzado-con-metastasis-peritoneales 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06940921/sbrt-ldrt-cadonilimab-for-advanced-gastric-colorectal-and-ovarian-cancers-with-peritoneal-metastases 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06808685/estudio-nacional-multicentrico-en-el-mundo-real-para-evaluar-la-eficacia-y-la-seguridad-del-bevacizumab-biosimilar-elovie 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06808685/real-world-multicenter-national-study-to-evaluate-the-effectiveness-and-safety-of-biosimilar-bevacizumab-elovie 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06321081/estudio-ice-combinacion-de-irinotecan-mas-cetuximab-y-envafolimab-como-regimen-de-retreatment-en-mcrc 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06321081/ice-study-combination-of-irinotecan-plus-cetuximab-and-envafolimab-as-a-rechallenge-regimen-in-mcrc 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06848465/terapia-de-radiacion-intrahepatica-guiada-por-imagenes-combinada-con-inmunoterapia-y-quimioterapia-para-el-cancer-colorrectal-con-metastasis-hepaticas 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06848465/ldrt-combined-with-immunochemotherapy-for-colorectal-cancer-with-liver-metastasis 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07262619/eik1005-002-un-estudio-de-investigacion-clinica-que-evalua-eik1005-un-inhibidor-de-la-helicasa-de-werner-como-monoterapia-y-en-combinacion-con-pembrolizumab-en-participantes-con-tumores-solidos 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07262619/eik1005-002-a-clinical-research-study-evaluating-eik1005-a-werner-helicase-inhibitor-as-monotherapy-and-in-combination-with-pembrolizumab-in-participants-with-advanced-solid-tumors-including 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05217446/un-estudio-de-encorafenib-mas-cetuximab-administrados-en-combinacion-con-pembrolizumab-en-comparacion-con-pembrolizumab-solo-en-pacientes-con-cancer-colorrectal-metastasico-no-tratado-previamente 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05217446/a-study-of-encorafenib-plus-cetuximab-taken-together-with-pembrolizumab-compared-to-pembrolizumab-alone-in-people-with-previously-untreated-metastatic-colorectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07389265/continuacion-del-tratamiento-con-cetuximab-tras-la-progresion-en-primera-linea-en-el-cancer-colorrectal-metastasico 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07389265/continuation-of-cetuximab-beyond-first-line-progression-in-metastatic-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06833866/ensayo-de-fase-i-de-una-terapia-basada-en-5-fluorouracilo-5fu-en-combinacion-con-hidroxitirosol-ht-en-pacientes-con-cancer-colorrectal-avanzado-o-metastasico 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06833866/phase-i-trial-of-5-fluorouracil-5fu-based-therapy-in-combination-with-hydroxytyrosol-ht-in-patients-with-advanced-or-metastatic-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07392567/validacion-prospectiva-de-un-modelo-de-inteligencia-artificial-para-predecir-la-metastasis-hepatica-en-el-cancer-colorrectal 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07392567/prospective-validation-of-an-ai-model-for-predicting-liver-metastasis-in-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06456515/regorafenib-y-sintilimab-en-combinacion-con-electroacupuntura-en-crc-mss 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06456515/regorafenib-and-sintilimab-in-combination-with-electroacupuncture-in-mss-crc 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07167446/potencial-neuroprotector-del-cannabidiol-cbd-en-la-prevencion-de-la-neuropatia-inducida-por-oxaliplatino-ox 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07167446/neuroprotective-potential-of-cannabidiol-cbd-in-preventing-oxaliplatin-ox-induced-neuropathy 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT01763125/creacion-de-un-biobanco-de-tumores-a-partir-de-muestras-de-sangre 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT01763125/establishment-of-a-tumor-bank-for-blood-samples 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT02671435/un-estudio-de-durvalumab-medi4736-y-monalizumab-en-tumores-solidos 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT02671435/a-study-of-durvalumab-medi4736-and-monalizumab-in-solid-tumors 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05913674/viabilidad-tecnica-de-la-quimioterapia-intraperitoneal-modificada-en-las-primeras-etapas-del-periodo-postoperatorio-mepic 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05913674/technical-feasibility-of-modified-early-post-operative-intraperitoneal-chemotherapy-mepic 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05720559/estrategia-de-bloqueo-temprano-para-la-metastasis-hepatica-sincronica-del-cancer-colorrectal-basada-en-la-deteccion-prehepatica-de-ctc 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05720559/early-blocking-strategy-for-metachronous-liver-metastasis-of-colorectal-cancer-based-on-pre-hepatic-ctc-detection 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07397338/estudio-de-inhibidores-de-ras-on-en-combinacion-con-ivonescimab-en-pacientes-con-tumores-solidos 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07397338/study-of-ras-on-inhibitors-in-combination-with-ivonescimab-in-patients-with-solid-tumors 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07044921/estudio-clinico-de-un-tratamiento-combinado-basado-en-irinotecan-liposomal-ii-para-el-cancer-colorrectal-resistente-al-irinotecan 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07044921/clinical-study-of-irinotecan-liposome-ii-based-combination-treatment-for-irinotecan-resistant-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07405736/lubiprostone-en-combinacion-con-terapia-de-mantenimiento-para-la-prevencion-de-la-recurrencia-postoperatoria-en-cancer-colorrectal-con-metastasis-peritoneales 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07405736/lubiprostone-combined-with-maintenance-therapy-for-prevention-of-postoperative-recurrence-in-peritoneal-metastatic-colorectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT04547166/un-estudio-clinico-para-evaluar-la-eficacia-y-la-seguridad-de-serplulimab-hlx10-en-combinacion-con-bevacizumab-hlx04-y-quimioterapia-xelox-en-pacientes-con-cancer-colorrectal-metastasico-mcrc 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT04547166/a-clinical-study-to-evaluate-efficacy-and-safety-of-serplulimab-hlx10-combined-with-bevacizumab-hlx04-and-chemotherapy-xelox-in-patients-with-metastatic-colorectal-cancer-mcrc 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT04607421/un-estudio-de-encorafenib-mas-cetuximab-con-o-sin-quimioterapia-en-pacientes-con-cancer-colorrectal-metastasico-no-tratado-previamente 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT04607421/a-study-of-encorafenib-plus-cetuximab-with-or-without-chemotherapy-in-people-with-previously-untreated-metastatic-colorectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07133750/pm8002-bnt327-en-combinacion-con-quimioterapia-en-pacientes-con-cancer-colorrectal-metastasico 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07133750/pm8002-bnt327-in-combination-with-chemotherapy-in-patients-with-metastatic-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06130826/activacion-de-la-respuesta-inmune-para-el-tratamiento-del-cancer-colorrectal-metastasico-irresecable-o-del-cancer-de-mama-metastasico-con-niveles-elevados-de-cea 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06130826/immune-response-activation-for-the-treatment-of-unresectable-metastatic-colorectal-cancer-or-cea-positive-metastatic-breast-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT04491929/terapia-de-radiacion-interna-selectiva-con-microesferas-de-resina-de-90y-para-metastasis-hepaticas-de-cancer-colorrectal-refractario 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT04491929/selective-internal-radiation-therapy-with-90y-resin-micropheres-for-refractory-colorectal-cancer-liver-metastases 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06634875/isunakinra-en-monoterapia-y-en-combinacion-con-pembrolizumab-en-pacientes-con-cancer-colorrectal-mss 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06634875/isunakinra-alone-and-in-combination-with-pembrolizumab-in-patients-with-colorectal-cancer-mss 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07193862/estudio-piloto-de-un-microdispositivo-implantable-para-la-evaluacion-in-situ-de-la-respuesta-a-farmacos-en-pacientes-con-metastasis-hepaticas-de-cancer-colorrectal 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07193862/pilot-study-of-an-implantable-microdevice-for-in-situ-evaluation-of-drug-response-in-patients-with-colorectal-liver-metastasis 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07653685/un-estudio-clinico-de-tqb2930-inyectable-y-quimioterapia-con-o-sin-bevacizumab-en-el-tratamiento-del-cancer-colorrectal-avanzado 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07653685/a-clinical-study-of-tqb2930-injection-and-chemotherapy-with-or-without-bevacizumab-in-the-treatment-of-advanced-colorectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06853496/estudio-de-un-inhibidor-de-la-tanquirasa-el-rk-582-en-pacientes-con-cancer-colorrectal-metastasico-irresecable 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06853496/study-of-a-tankyrase-inhibitor-rk-582-for-patients-with-unresectable-metastatic-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06566755/cadonilimab-ak104-en-combinacion-con-quimioterapia-y-bevacizumab-como-tratamiento-de-primera-linea-para-el-cancer-colorrectal-metastasico-con-mutacion-en-ras-o-con-metastasis-en-el-lado-derecho-y-con 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06566755/cadonilimab-ak104-combined-with-chemotherapy-and-bevacizumab-as-first-line-treatment-for-ras-mutated-or-right-sided-metastatic-mss-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT01531595/estudio-de-bevacizumab-en-combinacion-con-esquemas-alternos-de-xeliri-y-xelox-en-cancer-colorrectal-metastasico 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT01531595/study-of-bevacizumab-in-combination-with-alternating-xeliri-and-xelox-in-metastatic-colorectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06746545/un-estudio-clinico-prospectivo-de-etiqueta-abierta-de-un-solo-brazo-de-fase-ii-para-evaluar-la-combinacion-de-fruquintinib-con-s-1-en-el-tratamiento-del-cancer-colorrectal-metastasico 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06746545/a-prospective-open-label-single-arm-phase-ii-clinical-study-of-fruquintinib-combined-with-s-1-for-the-treatment-of-metastatic-colorectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT04516681/combinacion-de-acido-ascorbico-intravenoso-y-adebrelimab-en-cancer-colorrectal-metastasico 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT04516681/combination-of-iv-ascorbic-acid-and-adebrelimab-in-metastatic-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07430527/revision-del-protocolo-para-el-tratamiento-del-cancer-colorrectal-en-atencion-secundaria 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07430527/secondary-care-colorectal-cancer-pathway-review 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT04776655/estudio-en-pacientes-con-mcrc-cancer-colorrectal-metastasico-que-compara-el-analisis-de-tejidos-ras-braf-salvajes-y-biopsias-liquidas-ras-mutadas-y-evalua-el-tratamiento-con-folfiri-mas-cetuximab-o 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT04776655/study-in-mcrc-patients-ras-braf-wt-tissue-and-ras-mutated-liquid-biopsy-to-compare-folfiri-plus-cetuximab-or-bevacizumab 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05296681/producto-microbiano-para-promover-la-salud-del-microbioma-y-mejorar-la-administracion-de-la-quimioterapia 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05296681/microbiotic-product-to-promote-microbiome-health-and-improve-chemotherapy-delivery 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07172282/infinitive-inmunoterapia-para-pacientes-con-metastasis-hepaticas-de-cancer-colorrectal 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07172282/infinitive-immunotherapy-for-patients-with-colorectal-liver-metastases 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07430540/optimizando-los-itinerarios-asistenciales-para-pacientes-con-cancer-colorrectal 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07430540/optimising-colorectal-cancer-patient-pathways 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06714903/efecto-de-la-microbiota-intestinal-y-sus-metabolitos-en-la-eficacia-de-la-inmunoterapia-en-el-cancer-colorrectal-metastasico 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06714903/effect-of-gut-microbiota-and-its-metabolites-on-the-efficacy-of-immunotherapy-in-metastatic-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06349590/manipulacion-de-la-microbiota-intestinal-mediante-una-dieta-preoperatoria-estandarizada-para-prevenir-la-recurrencia-y-la-metastasis-del-cancer-colorrectal-tras-la-cirugia 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06349590/manipulation-of-the-gut-microbiome-by-a-standardized-preoperative-diet-to-prevent-colorectal-cancer-recurrence-and-metastasis-following-surgery 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT04585750/evaluacion-de-pc14586-en-pacientes-con-tumores-solidos-avanzados-que-presentan-una-mutacion-y220c-en-el-gen-tp53-pynnacle 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT04585750/the-evaluation-of-pc14586-in-patients-with-advanced-solid-tumors-harboring-a-tp53-y220c-mutation-pynnacle 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06562543/un-ensayo-para-evaluar-la-seguridad-y-la-actividad-del-fruquintinib-en-poblaciones-minoritarias-con-cancer-colorrectal-avanzado-previamente-tratado 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06562543/a-trial-to-evaluate-the-safety-and-activity-of-fruquintinib-in-minority-populations-with-advanced-previously-treated-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07066657/un-estudio-de-mrg007-arr-217-en-pacientes-con-tumores-solidos-avanzados 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07066657/a-study-of-mrg007-arr-217-in-patients-with-advanced-solid-tumors 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07277270/un-estudio-de-gsk5764227-en-combinacion-con-el-tratamiento-estandar-soc-u-otros-agentes-en-participantes-con-tumores-solidos-avanzados 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07277270/a-study-of-gsk5764227-in-combination-with-standard-of-care-soc-or-other-agents-in-participants-with-advanced-solid-tumors 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06530303/terapia-con-linfocitos-infiltrantes-tumorales-mediante-inmunoterapia-para-el-cancer-de-colon-y-recto 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06530303/biological-tumor-infiltrating-lymphocytes-therapy-with-immunotherapy-for-colon-and-rectum-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07000305/un-estudio-de-cetuximab-combinado-con-envolimab-y-mfolfox6-en-sujetos-con-cancer-colorrectal-avanzado 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07000305/a-study-of-cetuximab-combined-with-envolimab-and-mfolfox6-in-subjects-with-advanced-colorectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06630624/determinacion-de-la-dosis-eficacia-y-respuesta-inmunologica-de-ip-001-tras-ablacion-por-microondas-mwa-o-ablacion-por-radiofrecuencia-irreversible-ire-en-pacientes-con-metastasis-hepaticas-de-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06630624/dose-finding-efficacy-and-immunological-response-of-ip-001-following-mwa-or-ire-for-crlm 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05322590/bxq-350-en-pacientes-con-carcinoma-colorrectal-metastasico-de-diagnostico-reciente 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05322590/bxq-350-in-newly-diagnosed-metastatic-colorectal-carcinoma 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07591597/un-ensayo-clinico-multicentrico-de-fase-ib-ii-para-evaluar-la-eficacia-y-la-seguridad-de-la-terapia-combinada-concurrente-de-s-531011-mas-fruquintinib-o-s-531011-mas-fruquintinib-mas-pembrolizumab-en 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07591597/a-multicenter-phase-ib-ii-clinical-trial-to-evaluate-the-efficacy-and-safety-of-concurrent-combination-therapy-of-s-531011-plus-fruquintinib-or-s-531011-plus-fruquintinib-plus-pembrolizumab-in 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07669454/un-estudio-aleatorizado-doble-ciego-controlado-con-placebo-de-grupos-paralelos-comparativo-de-fase-iii-para-evaluar-la-eficacia-y-la-seguridad-de-las-capsulas-de-nuvastatic-r-de-300-mg-en-la 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07669454/a-randomized-double-blind-placebo-controlled-parallel-group-comparative-phase-iii-study-to-evaluate-the-efficacy-and-safety-of-nuvastatic-r-300mg-capsule-in-reducing-cancer-tumor-in-patients-with 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06934538/ensayo-clinico-de-fase-i-de-stc-1010-una-inmunoterapia-en-pacientes-con-cancer-colorrectal-localmente-avanzado-o-metastasico-irresecable 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06934538/first-in-human-trial-of-stc-1010-an-immunotherapy-in-patients-with-unresectable-locally-advanced-or-metastatic-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07253896/eficacia-y-seguridad-de-ak104-en-combinacion-con-quimioterapia-y-cetuximab-o-bevacizumab 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07253896/efficacy-and-safety-of-ak104-combined-with-chemotherapy-and-cetuximab-or-bevacizumab 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07435584/everolimus-en-cancer-colorrectal-metastasico-con-deficiencia-de-cdk12-ever-recode 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07435584/everolimus-in-cdk12-deficient-metastatic-colorectal-cancer-ever-recode 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07204574/estudio-de-fase-1b-iia-abierto-de-escalada-y-expansion-de-dosis-para-evaluar-la-seguridad-la-tolerabilidad-y-la-eficacia-preliminar-de-la-combinacion-de-hcb101-cetuximab-bevacizumab-y-folfox-folfiri 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07204574/the-phase-1b-iia-open-label-dose-escalation-and-dose-expansion-to-evaluate-safety-tolerability-and-preliminary-efficacy-of-the-combination-of-hcb101-cetuximab-bevacizumab-and-folfox-folfiri-in 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06979908/un-estudio-clinico-sobre-la-eficacia-y-la-seguridad-de-fruquintinib-en-combinacion-con-un-anticuerpo-monoclonal-anti-pd-1-y-chidamide-en-el-cancer-colorrectal-metastasico-refractario-mss 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06979908/a-clinical-study-on-the-efficacy-and-safety-of-fruquintinib-in-combination-with-pd-1-monoclonal-antibody-and-chidamide-in-refractory-mss-metastatic-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT04595266/quimioembolizacion-lifepearls-irinotecan-en-pacientes-con-cancer-colorrectal-y-enfermedad-metastasica 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT04595266/chemoembolization-lifepearls-irinotecan-in-patients-with-colorectal-cancer-and-metastatic-disease 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07685236/un-estudio-de-exploracion-de-biomarcadores-para-predecir-la-localizacion-de-la-recurrencia-y-la-metastasis-en-el-cancer-colorrectal-estudio-probe 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07685236/a-biomarker-exploration-study-for-predicting-localization-of-recurrence-and-metastasis-in-colorectal-cancer-probe-study 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06253520/celulas-t-autologas-modificadas-geneticamente-para-expresar-receptores-reactivos-contra-las-mutaciones-de-kras-en-combinacion-con-una-vacuna-dirigida-contra-estos-antigenos-en-participantes-con 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06253520/autologous-t-cells-genetically-engineered-to-express-receptors-reactive-against-kras-mutations-in-conjunction-with-a-vaccine-directed-against-these-antigens-in-participants-with-metastatic-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06300463/estudio-de-plataforma-sobre-combinaciones-de-inmunoterapia-en-metastasis-hepaticas-del-cancer-colorrectal 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06300463/platform-study-of-immunotherapy-combinations-in-colorectal-cancer-liver-metastases 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06783569/un-estudio-de-escalada-y-expansion-en-humanos-el-primero-de-su-tipo-en-pacientes-con-tumores-solidos-avanzados 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06783569/a-first-in-human-escalation-and-expansion-study-of-patients-with-advanced-solid-tumors 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT04157322/marcadores-plasmaticos-de-5hmc-como-indicador-de-metastasis-peritoneal-en-cancer-colorrectal-apendicular 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT04157322/plasma-5hmc-signatures-as-a-marker-of-colorectal-appendiceal-peritoneal-metastasis 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07683403/savolitinib-mas-cetuximab-y-quimioterapia-con-folfox-para-el-cancer-colorrectal-metastasico-con-mutacion-ras-braf-silvestre 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07683403/savolitinib-plus-cetuximab-and-folfox-chemotherapy-for-ras-braf-wild-type-metastatic-colorectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06500052/un-estudio-de-bl-m17d1-en-pacientes-con-cancer-gastrointestinal-her2-positivo-de-baja-expresion-localmente-avanzado-o-metastasico-y-otros-tumores-solidos 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06500052/a-study-of-bl-m17d1-in-patients-with-locally-advanced-or-metastatic-her2-positive-lower-expression-gastrointestinal-cancer-and-other-solid-tumors 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07202364/un-estudio-de-yl202-en-pacientes-con-tumores-solidos-avanzados 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07202364/a-study-of-yl202-in-patients-with-advanced-solid-tumors 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07453875/ldrt-quimioterapia-inmunologica-secuencial-con-nips-para-metastasis-peritoneales-de-cancer-gastrico-y-colorrectal 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07453875/ldrt-sequential-nips-immunochemotherapy-for-peritoneal-metastasis-of-gastric-and-colorectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06763029/irinotecano-en-liposomas-combinado-con-cetuximab-y-vermofenib-en-pacientes-con-cancer-colorrectal-avanzado-que-han-fracasado-en-la-primera-linea-de-tratamiento 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06763029/irinotecan-liposomes-combined-with-cetuximab-vermofenib-in-first-line-failure-of-advanced-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05250648/ensayo-clinico-sobre-la-administracion-de-hipec-con-mitomicina-c-en-metastasis-peritoneales-del-cancer-de-colon-gecop-mmc 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05250648/clinical-trial-on-hipec-with-mitomycin-c-in-colon-cancer-peritoneal-metastases-gecop-mmc 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07079631/un-estudio-clinico-para-evaluar-si-un-tratamiento-experimental-denominado-bnt314-utilizado-en-combinacion-con-otro-tratamiento-experimental-bnt327-y-quimioterapia-es-beneficioso-y-seguro-para 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07079631/a-clinical-study-to-test-if-an-investigational-treatment-called-bnt314-when-used-in-combination-with-another-investigational-treatment-pumitamig-bnt327-and-chemotherapy-is-beneficial-and-safe-for 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07150403/quimioterapia-combinada-de-segunda-linea-folfox-o-folfiri-mas-fruquintinib-frente-a-quimioterapia-combinada-folfox-o-folfiri-mas-bevacizumab-en-cancer-colorrectal-metastasico 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07150403/second-line-doublet-chemotherapy-folfox-or-folfiri-plus-fruquintinib-versus-doublet-chemotherapy-folfox-or-folfiri-plus-bevacizumab-in-metastatic-colorectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06079242/estudio-observacional-sobre-la-terapia-con-sir-spheres-para-el-tratamiento-de-tumores-hepaticos-metastasicos-irresecables-procedentes-de-cancer-colorrectal-primario 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06079242/observational-study-for-sir-spheres-therapy-for-the-treatment-of-unresectable-metastatic-liver-tumors-from-primary-colorectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06563986/ftd-tpi-bevacizumab-y-radioembolizacion-con-microsferas-de-166ho-en-el-cancer-colorrectal-metastasico-refractario 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06563986/ftd-tpi-bevacizumab-and-radioembolization-with-166ho-microspheres-in-refractory-metastatic-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06462963/oligocare-twics-ensayos-dentro-de-cohortes-ensayo-comparativo-de-la-toxicidad-aguda-en-la-radioterapia-estereotactica-ablativa-sbrt-en-una-sola-fraccion-frente-a-multiples-fracciones-para-el 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06462963/oligocare-twics-trials-within-cohorts-trial-comparing-acute-toxicity-in-single-fraction-vs-multiple-fraction-sbrt-for-metastasis-directed-treatment-sprint 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07213570/stream-2-tratamiento-de-segunda-linea-con-regorafenib-en-cancer-colorrectal-avanzado-con-mutacion-en-ras 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07213570/stream-2-second-line-treatment-with-regorafenib-in-advanced-ras-mutant-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07085091/un-estudio-de-fase-i-en-humanos-con-alx2004-en-pacientes-con-tumores-solidos-avanzados-o-metastasicos-seleccionados 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07085091/a-first-in-human-study-of-alx2004-with-advanced-or-metastatic-selected-solid-tumors 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT03654131/ablacion-por-microondas-frente-a-radioterapia-estereotactica-para-metastasis-hepaticas-de-cancer-colorrectal-en-enfermedad-oligometastasica-un-ensayo-prospectivo-aleatorizado-de-fase-ii 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT03654131/microwave-ablation-versus-stereotactic-body-radiotherapy-for-colorectal-liver-metastases-in-oligometastatic-disease-a-prospective-randomised-phase-2-trial 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07094893/agentes-anti-egfr-en-pacientes-con-cancer-colorrectal-avanzado-del-lado-derecho-con-ras-de-tipo-salvaje-y-alto-nivel-de-expresion-de-areg-ereg 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07094893/anti-egfr-agents-in-patients-with-right-sided-advanced-colorectal-cancer-with-wild-type-ras-and-areg-ereg-high-status 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT03164486/primer-estudio-en-humanos-mediante-tomografia-por-emision-de-positrones-que-utiliza-el-peptido-18f-v6 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT03164486/first-in-human-positron-emission-tomography-study-using-the-18f-v6-binding-peptide 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07702032/estudio-de-petosemtamab-mas-quimioterapia-frente-a-cetuximab-mas-quimioterapia-en-cancer-colorrectal-irresecable-o-metastasico-del-lado-izquierdo-con-ras-y-braf-de-tipo-salvaje 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07702032/study-of-petosemtamab-plus-chemotherapy-versus-cetuximab-plus-chemotherapy-in-ras-and-braf-wild-type-unresectable-or-metastatic-left-sided-colorectal-cancer-liger-crc1 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07286695/fruquintinib-en-combinacion-con-trifluridina-tipiracil-frente-a-bevacizumab-en-combinacion-con-trifluridina-tipiracil-para-el-cancer-colorrectal-metastasico-avanzado 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07286695/fruquintinib-combined-with-trifluridine-tipiracil-versus-bevacizumab-combined-with-trifluridine-tipiracil-for-advanced-metastatic-colorectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06663839/un-estudio-de-nilk-2301-en-pacientes-con-cancer-colorrectal-localmente-avanzado-o-metastasico-con-bajo-volumen-tumoral-ltv 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06663839/a-study-of-nilk-2301-in-patients-with-locally-advanced-or-metastatic-low-tumor-volume-ltv-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05727163/folfox-administrado-por-via-hai-mas-irinotecan-intravenoso-con-o-sin-bevacizumab-frente-a-folfoxiri-sistemico-con-o-sin-bevacizumab-en-pacientes-con-metastasis-hepaticas-colorrectales-crlm 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05727163/folfox-via-hai-plus-intravenous-irinotecan-with-or-without-bevacizumab-versus-systemic-folfoxiri-with-or-without-bevacizumab-in-initially-unresectable-ras-mutated-crlm-patients 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT03326791/aspirina-en-metastasis-hepaticas-del-cancer-colorrectal 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT03326791/aspirin-in-colorectal-cancer-liver-metastases 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05171660/combinacion-con-sintilimab-y-xelox-bevacizumab-como-terapia-de-primera-linea-en-el-cancer-colorrectal-metastasico-con-mutacion-en-los-genes-ras 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05171660/combination-with-sintilimab-and-xelox-bevacizumab-as-1st-line-therapy-in-ras-mutant-metastatic-colorectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06525428/terapia-sistemica-estandar-combinada-con-radioterapia-en-dosis-altas-bajas-mas-toripalimab-para-el-cancer-colorrectal-metastasico 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06525428/standard-systemic-therapy-combined-with-high-low-dose-radiotherapy-plus-toripalimab-for-metastatic-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07059338/bloqueo-dual-de-egfr-her2-combinado-con-irinotecan-para-el-tratamiento-del-cancer-colorrectal-metastasico-her2-positivo 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07059338/dual-egfr-her2-blockade-combined-with-irinotecan-for-the-treatment-of-her2-positive-metastatic-colorectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05129774/quimiorradioterapia-seguida-de-cirugia-radical-en-pacientes-con-cancer-colorrectal-con-palnm 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05129774/chemoradiotherapy-sequenced-radical-surgery-for-colorectal-cancer-with-palnm 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05832138/ensayo-onloop-evaluacion-de-un-nuevo-sistema-de-seguimiento-y-apoyo-para-los-supervivientes-de-cancer-infantil-en-ontario 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05832138/onloop-trial-evaluating-a-new-surveillance-and-support-system-for-survivors-of-childhood-cancer-in-ontario 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06558773/inhibidor-de-la-sintetasa-gsl-en-combinacion-con-un-inhibidor-del-punto-de-control-inmunitario-y-o-regorafenib-en-pacientes-con-cancer-colorrectal-pmmr-mss-previamente-tratados 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06558773/gsl-synthetase-inhibitor-plus-immune-checkpoint-inhibitor-and-or-regorafenib-in-previously-treated-pmmr-mss-crc 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07244705/un-estudio-de-abt-301-mas-tislelizumab-con-bevacizumab-en-pacientes-con-cancer-colorrectal-localmente-avanzado-o-metastasico-pmmr-no-msi-h 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07244705/a-study-of-abt-301-plus-tislelizumab-with-bevacizumab-in-pmmr-non-msi-h-locally-advanced-or-mcrc 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05691491/evaluacion-de-la-combinacion-de-los-farmacos-antineoplasicos-temozolomida-y-m1774-para-determinar-su-seguridad-y-eficacia 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05691491/testing-the-combination-of-the-anti-cancer-drugs-temozolomide-and-m1774-to-evaluate-their-safety-and-effectiveness 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05705492/olanzapina-para-el-manejo-de-la-perdida-de-apetito-asociada-al-cancer-en-pacientes-con-cancer-avanzado-de-esofago-estomago-higado-pancreas-vias-biliares-colon-recto-o-pulmon 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05705492/olanzapine-for-the-management-of-cancer-associated-appetite-loss-in-patients-with-advanced-esophagogastric-hepatopancreaticobiliary-colorectal-or-lung-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06826092/metformina-para-el-tratamiento-de-pacientes-con-mcrc-que-reciben-folfiri-mas-terapia-dirigida 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06826092/metformin-for-the-treatment-of-mcrc-patients-undergoing-folfiri-plus-target-therapy 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07610707/ymn-a02-para-el-cancer-colorrectal-avanzado-con-pmmr-y-metastasis-hepaticas 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07610707/ymn-a02-for-advanced-pmmr-colorectal-cancer-with-liver-metastases 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07500298/estudio-de-fase-i-de-sar445877-en-combinacion-con-folfox6-y-bevacizumab-como-tratamiento-de-primera-linea-para-el-cancer-colorrectal-metastasico-con-estabilidad-de-microsatelites 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07500298/phase-1-study-of-sar445877-in-combination-with-folfox6-and-bevacizumab-as-first-line-treatment-for-microsatellite-stable-metastatic-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07114601/un-estudio-de-ly4257496-en-participantes-con-cancer-omniray 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07114601/a-study-of-ly4257496-in-participants-with-cancer-omniray 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06992648/trifluridina-tipiracil-mas-regorafenib-frente-a-trifluridina-tipiracil-mas-bevacizumab-para-el-cancer-colorrectal-metastasico-refractario 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06992648/trifluridine-tipiracil-plus-regorafenib-vs-trifluridine-tipiracil-plus-bevacizumab-for-refractory-metastatic-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07030257/estudio-de-cp-383-en-pacientes-con-tumores-solidos-avanzados-o-metastasicos 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07030257/study-of-cp-383-in-patients-with-advanced-or-metastatic-solid-tumors 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07228832/estudio-de-fase-iii-con-ivonescimab-o-bevacizumab-en-combinacion-con-folfox-en-pacientes-con-cancer-colorrectal-metastasico 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07228832/phase-iii-study-of-ivonescimab-or-bevacizumab-combined-with-folfox-in-patients-with-metastatic-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07621497/folfox8-frente-a-mfolfox6-con-bevacizumab-o-cetuximab-para-el-cancer-colorrectal-metastasico-irresecable-en-primera-linea-fase-ii 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07621497/folfox8-versus-mfolfox6-with-bevacizumab-or-cetuximab-for-first-line-unresectable-metastatic-colorectal-cancer-phase-ii 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06283134/un-estudio-clinico-de-biottt001-en-combinacion-con-toripalimab-y-regorafenib-en-pacientes-con-cancer-colorrectal 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06283134/a-clinical-study-of-biottt001-in-combination-with-toripalimab-and-regorafenib-in-patients-with-colorectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07221357/un-estudio-para-evaluar-la-seguridad-y-la-eficacia-de-pumitamig-en-combinacion-con-quimioterapia-frente-a-bevacizumab-en-combinacion-con-quimioterapia-en-participantes-con-cancer-colorrectal 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07221357/a-study-to-evaluate-the-safety-and-efficacy-of-pumitamig-in-combination-with-chemotherapy-versus-bevacizumab-in-combination-with-chemotherapy-in-participants-with-previously-untreated-unresectable-or 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06440005/un-estudio-para-evaluar-la-seguridad-la-tolerabilidad-y-la-actividad-preliminar-de-agx101-en-participantes-con-tumores-solidos-avanzados 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06440005/a-study-to-evaluate-safety-tolerability-and-preliminary-activity-of-agx101-in-participants-with-advanced-solid-tumors 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05299840/impacto-del-uso-del-dispositivo-oncogramme-r-en-la-seleccion-del-tratamiento-de-primera-linea-para-pacientes-con-cancer-colorrectal-metastasico 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05299840/impact-of-using-the-oncogramme-r-device-to-select-the-first-line-of-treatment-for-patients-with-metastatic-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07257653/seguridad-y-eficacia-de-cetuximab-beta-mas-fruquintinib-con-o-sin-inhibidores-de-los-puntos-de-control-inmunitario-en-el-tratamiento-de-primera-linea-del-cancer-colorrectal-metastasico-irresecable 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07257653/the-safety-and-efficacy-of-cetuximab-beta-plus-fruquintinib-with-or-without-immune-checkpoint-inhibitorrs-in-first-line-treatment-of-ras-braf-wild-type-unresectable-metastatic-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT03303495/un-estudio-comparativo-de-folfiri-en-segunda-linea-bevacizumab-frente-a-irinotecan-bevacizumab-en-pacientes-con-mcrc 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT03303495/a-study-of-2nd-line-folfiri-bevacizumab-vs-irinotecan-bevacizumab-in-mcrc 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07333651/implante-de-semillas-de-125i-mas-terapia-sistemica-para-el-cancer-de-pulmon-de-celulas-no-pequenas-cpcnp-u-el-cancer-colorrectal-oligoprogresivo 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07333651/125i-seed-implantation-plus-systemic-therapy-for-oligoprogressive-nsclc-or-colorectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06614192/un-estudio-que-evalua-los-eventos-adversos-y-la-actividad-de-la-enfermedad-al-comparar-la-administracion-intravenosa-iv-de-abbv-400-con-los-comprimidos-orales-de-trifluridina-y-tipiracil-lonsurf-mas 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06614192/a-study-assessing-adverse-events-and-disease-activity-of-intravenously-iv-infused-telisotuzumab-adizutecan-in-adult-participants-with-c-met-protein-above-cutoff-level-above-refractory-metastatic 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06907342/evaluacion-de-un-enfoque-de-medicina-de-precision-funcional-para-seleccionar-la-quimioterapia-en-el-cancer-colorrectal-metastasico-cosense-1 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06907342/testing-a-functional-precision-medicine-approach-to-select-chemotherapy-for-metastatic-colorectal-cancer-cosense-1 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07775287/study-of-petosemtamab-plus-chemotherapy-versus-cetuximab-or-bevacizumab-plus-chemotherapy-in-ras-and-braf-wild-type-recurrent-unresectable-or-metastatic-colorectal-cancer-liger-crc2 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT04730544/dos-esquemas-de-tratamiento-combinados-con-nivolumab-e-ipilimumab-en-pacientes-con-mcrc-dmmr-y-o-msi 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT04730544/two-combination-treatment-regimens-of-nivolumab-and-ipilimumab-in-patients-with-dmmr-and-or-msi-mcrc 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05201352/evaluacion-de-la-eficacia-de-trifluridina-tipiracil-mas-un-anticuerpo-humano-verdadero-anti-il-1-frente-a-trifluridina-tipiracil-mas-placebo-en-pacientes-con-cancer-colorrectal-metastasico-despues 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05201352/evaluation-of-efficacy-of-trifluridine-tipiracil-plus-an-anti-il-1-true-human-antibody-versus-trifluridine-tipiracil-plus-placebo-in-metastatic-colorectal-cancer-patients-after-failure-of-oxaliplatin 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06270017/evaluacion-de-la-enfermedad-metastasica-y-del-tratamiento-oncologico-en-pacientes-con-cancer-de-colon-mediante-el-uso-de-avatares-de-pez-cebra 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06270017/evaluation-of-metastatic-disease-and-oncological-treatment-in-patients-with-colon-cancer-using-zebra-fish-avatars 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07349043/ensayo-clinico-prospectivo-de-seguridad-y-eficacia-sobre-la-terapia-con-aerosol-intraperitoneal-presurizado-para-la-metastasis-peritoneal-del-cancer-colorrectal 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07349043/a-prospective-safety-and-efficacy-clinical-trial-of-pressurized-intraperitoneal-aerosol-therapy-for-peritoneal-metastasis-of-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06838338/jab-21822-en-combinacion-con-quimioterapia-y-bevacizumab-en-el-tratamiento-de-segunda-linea-del-ccrc-con-mutacion-kras-g12c 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06838338/jab-21822-combined-with-chemotherapy-and-bevacizumab-in-second-line-kras-g12c-crc 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07004413/cetuximab-en-administracion-continua-o-intermitente-combinado-con-folfiri-como-tratamiento-de-primera-linea-en-pacientes-con-cancer-colorrectal-metastasico-mcrc-con-ras-braf-tipo-salvaje 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07004413/continuous-or-intermittent-cetuximab-plus-folfiri-as-first-line-treatment-in-ras-braf-wild-type-mcrc-patients 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05870800/ensayo-de-fase-ii-abierto-y-no-aleatorizado-sobre-quimioinmunoterapia-neoadyuvante-para-el-cancer-colorrectal-no-metastasico-y-resecable-nicer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05870800/phase-ii-open-label-trial-of-neoadjuvant-immunochemotherapy-for-resectable-non-metastatic-colon-cancer-nicer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06484153/fruquintinib-y-pirfenidona-en-combinacion-con-un-anticuerpo-anti-pd-1-en-el-tratamiento-del-carcinoma-colorrectal-avanzado-o-metastasico-pmmr-mss 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06484153/fruquintinib-and-pirfenidone-in-combination-with-anti-pd-1-antibody-in-advanced-or-metastatic-pmmr-mss-colorectal-carcinoma 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07549412/un-estudio-de-precemtabart-tocentecan-con-o-sin-bevacizumab-en-comparacion-con-trifluridina-tipiracil-mas-bevacizumab-en-participantes-con-cancer-colorrectal-metastasico-previamente-tratado-proceade 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07549412/a-study-of-precemtabart-tocentecan-with-or-without-bevacizumab-compared-to-trifluridine-tipiracil-plus-bevacizumab-in-participants-with-previously-treated-metastatic-colorectal-cancer-proceade-crc-03 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT04940546/seguridad-del-tratamiento-neoadyuvante-con-sintilimab-xelox-bevacizumab-en-pacientes-con-metastasis-colorrectales-mcrlm-con-pmmr-mss 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT04940546/neoadjuvant-safety-of-sintilimab-xelox-bevacizumab-in-pmmr-mss-crlm-patients 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07359456/evaluacion-de-ivonescimab-en-combinacion-con-quimioterapia-en-pacientes-con-cancer-colorrectal-metastasico-sin-metastasis-hepaticas 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07359456/testing-ivonescimab-in-combination-with-chemotherapy-in-patients-with-metastatic-colorectal-cancers-without-liver-metastases 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT04221893/radioterapia-para-el-tratamiento-de-canceres-gastrointestinales-metastasicos 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT04221893/radiation-therapy-for-the-treatment-of-metastatic-gastrointestinal-cancers 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06645236/dhf-20-1839-2-protocolo-del-estudio-clinico-de-rendimiento-para-el-kit-therascreen-r-kras-rgq-pcr 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06645236/dhf-20-1839-2-clinical-performance-study-protocol-for-therascreen-r-kras-rgq-pcr-kit 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05360277/tratamiento-de-mantenimiento-con-tislelizumab-y-capecitabina-para-el-cancer-colorrectal-metastasico 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05360277/maintenance-tislelizumab-capecitabine-to-treat-metastatic-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05489211/estudio-de-dato-dxd-como-monoterapia-y-en-combinacion-con-agentes-antineoplasicos-en-pacientes-con-tumores-solidos-avanzados-tropion-pantumor03 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05489211/study-of-dato-dxd-as-monotherapy-and-in-combination-with-anti-cancer-agents-in-patients-with-advanced-solid-tumours-tropion-pantumor03 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07385521/el-uso-de-la-inteligencia-artificial-para-la-prediccion-de-la-recurrencia-tras-la-reseccion-de-metastasis-hepaticas-de-cancer-colorrectal 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07385521/the-use-of-artificial-intelligence-for-the-prediction-of-recurrence-after-resection-of-colorectal-liver-metastases 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05513716/caracterizacion-molecular-de-las-metastasis-peritoneales-del-cancer-colorrectal 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05513716/molecular-characterisation-of-colorectal-cancer-peritoneal-metastases 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06540326/estudio-clinico-del-tratamiento-de-segunda-linea-en-el-cancer-colorrectal-avanzado-con-quimioterapia-con-bevacizumab-o-cetuximab 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06540326/clinical-study-of-second-line-treatment-in-advanced-colorectal-cancer-with-chemotherapy-with-bevacizumab-or-cetuximab 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06008054/un-estudio-de-si-b003-bl-b01d1-si-b003-y-bl-b01d1-anticuerpo-monoclonal-anti-pd-1-en-pacientes-con-cancer-de-esofago-localmente-avanzado-o-metastasico-cancer-gastrico-cancer-colorrectal-y-otros 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06008054/a-study-of-si-b003-bl-b01d1-si-b003-and-bl-b01d1-pd-1-monoclonal-antibody-in-patients-with-locally-advanced-or-metastatic-esophageal-cancer-gastric-cancer-colorectal-cancer-and-other-gastrointestinal 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06341309/estudio-exploratorio-de-liposomas-de-irinotecan-en-la-terapia-de-mantenimiento-del-cancer-colorrectal-metastasico 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06341309/exploratory-study-of-irinotecan-liposomes-in-maintenance-therapy-of-metastatic-colorectal-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT06208397/resonancia-magnetica-para-la-evaluacion-de-los-patrones-de-crecimiento-histopatologicos-en-metastasis-hepaticas-de-cancer-colorrectal 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06208397/mre-for-assessment-of-histopathological-growth-patterns-in-colorectal-liver-metastases 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05962502/cetuximab-mas-irinotecan-en-pacientes-con-cancer-colorrectal-metastasico-con-tipo-salvaje-de-neoras-en-terapia-de-tercera-linea 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05962502/cetuximab-plus-irinotecan-in-patients-with-neoras-wild-type-metastatic-colorectal-cancer-in-third-line-therapy 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07177742/estudio-de-cohorte-prospectivo-sobre-la-relacion-entre-la-peroxiredoxina-1-exosomal-prdx1-y-la-metastasis-hepatica-postoperatoria 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07177742/prospective-cohort-study-on-the-relationship-between-exosomal-peroxiredoxin-1-prdx1-and-postoperative-liver-metastasis 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05195710/radioembolizacion-preoperatoria-con-y-90-para-el-control-tumoral-y-la-hipertrofia-del-futuro-remanente-hepatico-en-pacientes-con-metastasis-hepaticas-de-cancer-colorrectal 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05195710/preoperative-y-90-radioembolization-for-tumor-control-and-future-liver-remnant-hypertrophy-in-patients-with-colorectal-liver-metastases 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07277322/dupilumab-y-toripalimab-como-tratamiento-neoadyuvante-en-sujetos-con-crc-mss-y-metastasis-hepaticas-resecables 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07277322/neoadjuvant-dupilumab-and-toripalimab-in-mss-crc-subjects-with-resectable-liver-metastases 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT04743102/biopsia-multipunto-y-de-espesor-total-en-el-diagnostico-de-respuesta-clinica-completa-ccr-tras-la-terapia-neoadyuvante-para-el-cancer-de-recto 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT04743102/multi-points-and-full-thickness-biopsy-in-the-diagnosis-of-ccr-after-neoadjuvant-therapy-for-rectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT02906943/evaluacion-de-acidos-nucleicos-dirigida-a-tumores-en-toda-la-provincia-de-ontario 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT02906943/ontario-wide-cancer-targeted-nucleic-acid-evaluation 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT02980510/comparacion-de-folfirinox-con-panitumumab-frente-a-mfolfox6-con-panitumumab-en-pacientes-con-cancer-colorrectal-metastasico-con-ras-b-raf-de-tipo-salvaje 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT02980510/comparison-folfirinox-panitumumab-vs-mfolfox6-panitumumab-in-ras-b-raf-wild-type-metastatic-colorectal-cancer-patients 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT00569127/octreotido-acetato-e-interferon-alfa-2b-recombinante-o-bevacizumab-en-el-tratamiento-de-pacientes-con-tumor-neuroendocrino-metastasico-o-localmente-avanzado-de-alto-riesgo 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT00569127/octreotide-acetate-and-recombinant-interferon-alfa-2b-or-bevacizumab-in-treating-patients-with-metastatic-or-locally-advanced-high-risk-neuroendocrine-tumor 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT05379595/un-estudio-de-amivantamab-en-monoterapia-y-en-combinacion-con-la-quimioterapia-estandar-en-participantes-con-cancer-colorrectal-avanzado-o-metastasico 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05379595/a-study-of-amivantamab-monotherapy-and-in-addition-to-standard-of-care-chemotherapy-in-participants-with-advanced-or-metastatic-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05963490/regorafenib-solo-o-en-combinacion-con-radioterapia-hipofraccionada-de-baja-dosis-mas-toripalimab-para-el-cancer-colorrectal-metastasico 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05963490/regorafenib-alone-or-in-combination-with-hypofractionated-low-dose-radiotherapy-plus-toripalimab-for-metastatic-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT04579380/estudio-basket-con-tucatinib-y-trastuzumab-en-tumores-solidos-con-alteraciones-de-her2 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT04579380/basket-study-of-tucatinib-and-trastuzumab-in-solid-tumors-with-her2-alterations 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT02888743/durvalumab-y-tremelimumab-con-o-sin-radioterapia-en-dosis-altas-o-bajas-en-el-tratamiento-de-pacientes-con-cancer-colorrectal-metastasico-o-cancer-de-pulmon-no-microcitico 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT02888743/durvalumab-and-tremelimumab-with-or-without-high-or-low-dose-radiation-therapy-in-treating-patients-with-metastatic-colorectal-or-non-small-cell-lung-cancer 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT04938986/interes-del-immunoscore-r-como-herramienta-complementaria-postoperatoria-para-la-deteccion-del-riesgo-de-recurrencia-en-pacientes-con-cancer-colorrectal-no-metastasico 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT04938986/interest-of-the-immunoscore-r-as-a-post-operative-complementary-tool-for-the-detection-of-the-risk-of-recurrence-in-patients-with-nonmetastatic-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07009145/ql1706-mas-bevacizumab-para-el-cancer-colorrectal-irresecable-o-metastasico-msi-h-dmmr 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07009145/ql1706-plus-bevacizumab-for-unresectable-or-metastatic-msi-h-dmmr-crc 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07272642/un-estudio-de-fase-i-multicentrico-y-basado-en-imagenes-de-lnth-2403-en-participantes-con-tumores-solidos-localmente-avanzados-o-metastasicos 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT07272642/a-phase-1-multicenter-imaging-study-of-lnth-2403-in-participants-with-locally-advanced-or-metastatic-solid-tumors 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT03694938/deteccion-de-metastasis-cerebrales-mediante-resonancia-magnetica-en-pacientes-con-cancer-colorrectal-metastasico 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT03694938/detection-of-brain-metastasis-by-mri-in-metastatic-colorectal-cancer-patients 2026-08-22 weekly 0.6 https://crcwarriors.org/ensayo/NCT01479608/trasplante-hepatico-y-cancer-colorrectal 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT01479608/liver-transplantation-and-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06225843/sotevtamab-ab-16b5-en-combinacion-con-folfox-como-tratamiento-neoadyuvante-previo-a-la-reseccion-de-metastasis-hepaticas-del-cancer-colorrectal 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06225843/sotevtamab-ab-16b5-combined-with-folfox-as-neoadjuvant-treatment-prior-to-resection-of-colorectal-cancer-liver-metastasis 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06605430/cannabis-medicinal-en-pacientes-con-cancer-avanzado-de-pancreas-y-cancer-colorrectal 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06605430/medical-cannabis-in-patients-with-advanced-pancreatic-and-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06252649/estudio-de-sotorasib-panitumumab-y-folfiri-frente-a-folfiri-con-o-sin-bevacizumab-en-participantes-con-cancer-colorrectal-metastasico-con-mutacion-kras-p-g12c-que-no-han-recibido-tratamiento-previo 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT06252649/study-of-sotorasib-panitumumab-and-folfiri-versus-folfiri-with-or-without-bevacizumab-awwb-in-treatment-naive-participants-with-metastatic-colorectal-cancer-with-kras-p-g12c-mutation 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07263178/un-estudio-sobre-la-quimioterapia-paliativa-en-segunda-linea-y-posteriores-en-pacientes-con-cancer-colorrectal-metastasico 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT07263178/a-study-of-second-and-later-line-palliative-chemotherapy-in-patients-with-metastatic-colorectal-cancer 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05068531/deteccion-temprana-del-fracaso-del-tratamiento-en-pacientes-con-cancer-colorrectal-metastasico 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05068531/early-detection-of-treatment-failure-in-metastatic-colorectal-cancer-patients 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05283330/seguridad-y-tolerabilidad-de-212pb-dotam-grpr1-en-sujetos-adultos-con-tumores-recurrentes-o-metastasicos-que-expresan-grpr 2026-08-22 weekly 0.7 https://crcwarriors.org/ensayo/NCT05283330/safety-and-tolerability-of-212pb-dotam-grpr1-in-adult-subjects-with-recurrent-or-metastatic-grpr-expressing-tumors 2026-08-22 weekly 0.7 https://crcwarriors.org/medicamento/oxaliplatin 2026-08-21 weekly 0.7 https://crcwarriors.org/medicamento/oxaliplatin/ensayos 2026-08-21 weekly 0.6 https://crcwarriors.org/medicamento/uracil 2026-08-15 weekly 0.7 https://crcwarriors.org/medicamento/uracil/ensayos 2026-08-15 weekly 0.6 https://crcwarriors.org/medicamento/fluorouracil 2026-08-15 weekly 0.7 https://crcwarriors.org/medicamento/fluorouracil/ensayos 2026-08-15 weekly 0.6 https://crcwarriors.org/medicamento/5-fluorouracil 2026-08-15 weekly 0.7 https://crcwarriors.org/medicamento/5-fluorouracil/ensayos 2026-08-15 weekly 0.6 https://crcwarriors.org/medicamento/leucovorin 2026-08-21 weekly 0.7 https://crcwarriors.org/medicamento/leucovorin/ensayos 2026-08-21 weekly 0.6 https://crcwarriors.org/medicamento/bevacizumab 2026-08-21 weekly 0.7 https://crcwarriors.org/medicamento/bevacizumab/ensayos 2026-08-21 weekly 0.6 https://crcwarriors.org/medicamento/capecitabine 2026-08-11 weekly 0.7 https://crcwarriors.org/medicamento/capecitabine/ensayos 2026-08-11 weekly 0.6 https://crcwarriors.org/medicamento/irinotecan 2026-08-21 weekly 0.7 https://crcwarriors.org/medicamento/irinotecan/ensayos 2026-08-21 weekly 0.6 https://crcwarriors.org/medicamento/cetuximab 2026-08-21 weekly 0.7 https://crcwarriors.org/medicamento/cetuximab/ensayos 2026-08-21 weekly 0.6 https://crcwarriors.org/medicamento/pembrolizumab 2026-07-24 weekly 0.7 https://crcwarriors.org/medicamento/pembrolizumab/ensayos 2026-07-24 weekly 0.6 https://crcwarriors.org/medicamento/met 2026-07-24 weekly 0.7 https://crcwarriors.org/medicamento/met/ensayos 2026-07-24 weekly 0.6 https://crcwarriors.org/medicamento/panitumumab 2026-06-23 weekly 0.7 https://crcwarriors.org/medicamento/panitumumab/ensayos 2026-06-23 weekly 0.6 https://crcwarriors.org/medicamento/nivolumab 2026-07-16 weekly 0.7 https://crcwarriors.org/medicamento/nivolumab/ensayos 2026-07-16 weekly 0.6 https://crcwarriors.org/medicamento/regorafenib 2026-08-07 weekly 0.7 https://crcwarriors.org/medicamento/regorafenib/ensayos 2026-08-07 weekly 0.6 https://crcwarriors.org/medicamento/rego 2026-08-07 weekly 0.7 https://crcwarriors.org/medicamento/rego/ensayos 2026-08-07 weekly 0.6 https://crcwarriors.org/medicamento/tislelizumab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/tislelizumab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/fruquintinib 2026-07-30 weekly 0.7 https://crcwarriors.org/medicamento/fruquintinib/ensayos 2026-07-30 weekly 0.6 https://crcwarriors.org/medicamento/trastuzumab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/trastuzumab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/paclitaxel 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/paclitaxel/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/trifluridine 2026-07-30 weekly 0.7 https://crcwarriors.org/medicamento/trifluridine/ensayos 2026-07-30 weekly 0.6 https://crcwarriors.org/medicamento/cyclophosphamid 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/cyclophosphamid/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/cyclophosphamide 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/cyclophosphamide/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/atezolizumab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/atezolizumab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/carboplatin 2026-07-24 weekly 0.7 https://crcwarriors.org/medicamento/carboplatin/ensayos 2026-07-24 weekly 0.6 https://crcwarriors.org/medicamento/cisplatin 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/cisplatin/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/sintilimab 2026-07-31 weekly 0.7 https://crcwarriors.org/medicamento/sintilimab/ensayos 2026-07-31 weekly 0.6 https://crcwarriors.org/medicamento/durvalumab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/durvalumab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ipilimumab 2026-07-16 weekly 0.7 https://crcwarriors.org/medicamento/ipilimumab/ensayos 2026-07-16 weekly 0.6 https://crcwarriors.org/medicamento/gemcitabine 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/gemcitabine/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/pemetrexed 2026-07-24 weekly 0.7 https://crcwarriors.org/medicamento/pemetrexed/ensayos 2026-07-24 weekly 0.6 https://crcwarriors.org/medicamento/celecoxib 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/celecoxib/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/cele 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/cele/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/s-1 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/s-1/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/aldesleukin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/aldesleukin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/fludarabine 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/fludarabine/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/aspirin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/aspirin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/fulvestrant 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/fulvestrant/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/encorafenib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/encorafenib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/docetaxel 2026-08-06 weekly 0.7 https://crcwarriors.org/medicamento/docetaxel/ensayos 2026-08-06 weekly 0.6 https://crcwarriors.org/medicamento/aflibercept 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/aflibercept/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/binimetinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/binimetinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/trametinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/trametinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/tori 2026-06-26 weekly 0.7 https://crcwarriors.org/medicamento/tori/ensayos 2026-06-26 weekly 0.6 https://crcwarriors.org/medicamento/palbociclib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/palbociclib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/toripalimab 2026-06-26 weekly 0.7 https://crcwarriors.org/medicamento/toripalimab/ensayos 2026-06-26 weekly 0.6 https://crcwarriors.org/medicamento/erlotinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/erlotinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/everolimus 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/everolimus/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/nab-paclitaxel 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/nab-paclitaxel/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/serplulimab 2026-08-22 weekly 0.7 https://crcwarriors.org/medicamento/serplulimab/ensayos 2026-08-22 weekly 0.6 https://crcwarriors.org/medicamento/balstilimab 2026-07-31 weekly 0.7 https://crcwarriors.org/medicamento/balstilimab/ensayos 2026-07-31 weekly 0.6 https://crcwarriors.org/medicamento/botensilimab 2026-07-31 weekly 0.7 https://crcwarriors.org/medicamento/botensilimab/ensayos 2026-07-31 weekly 0.6 https://crcwarriors.org/medicamento/cadonilimab 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/cadonilimab/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/vemurafenib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/vemurafenib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/avelumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/avelumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cemiplimab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/cemiplimab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/sargramostim 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/sargramostim/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/metformin 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/metformin/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/olaparib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/olaparib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/temozolomide 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/temozolomide/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/dostarlimab 2026-08-04 weekly 0.7 https://crcwarriors.org/medicamento/dostarlimab/ensayos 2026-08-04 weekly 0.6 https://crcwarriors.org/medicamento/adebrelimab 2026-07-23 weekly 0.7 https://crcwarriors.org/medicamento/adebrelimab/ensayos 2026-07-23 weekly 0.6 https://crcwarriors.org/medicamento/trastuzumab+deruxteca 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/trastuzumab+deruxteca/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/trastuzumab+deruxtecan 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/trastuzumab+deruxtecan/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/adagrasib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/adagrasib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/dexamethasone 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/dexamethasone/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/tremelimumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tremelimumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tucatinib 2026-08-18 weekly 0.7 https://crcwarriors.org/medicamento/tucatinib/ensayos 2026-08-18 weekly 0.6 https://crcwarriors.org/medicamento/apatinib 2026-07-09 weekly 0.7 https://crcwarriors.org/medicamento/apatinib/ensayos 2026-07-09 weekly 0.6 https://crcwarriors.org/medicamento/cabozantinib 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/cabozantinib/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/peg 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/peg/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mitomycin 2026-07-14 weekly 0.7 https://crcwarriors.org/medicamento/mitomycin/ensayos 2026-07-14 weekly 0.6 https://crcwarriors.org/medicamento/sorafenib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/sorafenib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/tipiracil 2026-07-24 weekly 0.7 https://crcwarriors.org/medicamento/tipiracil/ensayos 2026-07-24 weekly 0.6 https://crcwarriors.org/medicamento/lidocaine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/lidocaine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/abemaciclib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/abemaciclib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/camrelizumab 2026-04-16 weekly 0.7 https://crcwarriors.org/medicamento/camrelizumab/ensayos 2026-04-16 weekly 0.6 https://crcwarriors.org/medicamento/ivonescimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ivonescimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/metronidazole 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/metronidazole/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/raltitrexed 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/raltitrexed/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pertuzumab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pertuzumab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ramucirumab 2026-07-24 weekly 0.7 https://crcwarriors.org/medicamento/ramucirumab/ensayos 2026-07-24 weekly 0.6 https://crcwarriors.org/medicamento/ribociclib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ribociclib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/amg 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/amg/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ql1706 2026-07-28 weekly 0.7 https://crcwarriors.org/medicamento/ql1706/ensayos 2026-07-28 weekly 0.6 https://crcwarriors.org/medicamento/sirolimus 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sirolimus/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/envafolimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/envafolimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sotorasib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/sotorasib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/selumetinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/selumetinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/letrozole 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/letrozole/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/dabrafenib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/dabrafenib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/sunitinib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/sunitinib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/tas 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/tas/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ak112 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ak112/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/lenvatinib 2026-07-08 weekly 0.7 https://crcwarriors.org/medicamento/lenvatinib/ensayos 2026-07-08 weekly 0.6 https://crcwarriors.org/medicamento/hydroxychloroquine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hydroxychloroquine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/osimertinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/osimertinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/gefitinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gefitinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bortezomib 2026-05-06 weekly 0.7 https://crcwarriors.org/medicamento/bortezomib/ensayos 2026-05-06 weekly 0.6 https://crcwarriors.org/medicamento/lapatinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/lapatinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/axitinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/axitinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/filgrastim 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/filgrastim/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/iparomlimab 2026-08-20 weekly 0.7 https://crcwarriors.org/medicamento/iparomlimab/ensayos 2026-08-20 weekly 0.6 https://crcwarriors.org/medicamento/infliximab 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/infliximab/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/amivantamab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/amivantamab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/vandetanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/vandetanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cediranib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/cediranib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/chidamide 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/chidamide/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sulindac 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sulindac/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/dasatinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dasatinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/melphala 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/melphala/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/retifanlimab 2026-07-02 weekly 0.7 https://crcwarriors.org/medicamento/retifanlimab/ensayos 2026-07-02 weekly 0.6 https://crcwarriors.org/medicamento/vorinosta 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/vorinosta/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/vorinostat 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/vorinostat/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/melphalan 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/melphalan/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/midazolam 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/midazolam/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/afatinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/afatinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/tuvonralimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tuvonralimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cobimetinib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/cobimetinib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/doxorubicin 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/doxorubicin/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/indocyanine+green 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/indocyanine+green/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tegafu 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tegafu/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/sasanlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sasanlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/temsirolimus 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/temsirolimus/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/zanidatamab 2026-06-09 weekly 0.7 https://crcwarriors.org/medicamento/zanidatamab/ensayos 2026-06-09 weekly 0.6 https://crcwarriors.org/medicamento/veliparib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/veliparib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/azacitidine 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/azacitidine/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/tegafur 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tegafur/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/chemo 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/chemo/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/enzalutamide 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/enzalutamide/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/pumitamig 2026-07-02 weekly 0.7 https://crcwarriors.org/medicamento/pumitamig/ensayos 2026-07-02 weekly 0.6 https://crcwarriors.org/medicamento/other 2026-05-16 weekly 0.7 https://crcwarriors.org/medicamento/other/ensayos 2026-05-16 weekly 0.6 https://crcwarriors.org/medicamento/g17dt 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/g17dt/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/eflornithine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/eflornithine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/decitabine 2026-07-10 weekly 0.7 https://crcwarriors.org/medicamento/decitabine/ensayos 2026-07-10 weekly 0.6 https://crcwarriors.org/medicamento/bkm120 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/bkm120/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/moviprep 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/moviprep/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/g17d 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/g17d/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/jab-21822 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/jab-21822/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/propofol 2026-08-01 weekly 0.7 https://crcwarriors.org/medicamento/propofol/ensayos 2026-08-01 weekly 0.6 https://crcwarriors.org/medicamento/trifluridine-tipiracil 2026-07-24 weekly 0.7 https://crcwarriors.org/medicamento/trifluridine-tipiracil/ensayos 2026-07-24 weekly 0.6 https://crcwarriors.org/medicamento/sol 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/sol/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/entinostat 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/entinostat/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/nw-301v 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/nw-301v/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/adc 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/adc/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/pdr001 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pdr001/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tno155 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/tno155/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/hlx10 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hlx10/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/pazopanib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pazopanib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/t3011 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/t3011/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/anlotinib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/anlotinib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/hrs-4642 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hrs-4642/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/nktr 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/nktr/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/omeprazole 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/omeprazole/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rmc-6236 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rmc-6236/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/crizotinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/crizotinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/dexmedetomidine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dexmedetomidine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tocilizumab 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/tocilizumab/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/fianlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/fianlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/etrumadenant 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/etrumadenant/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ropivacaine 2026-06-05 weekly 0.7 https://crcwarriors.org/medicamento/ropivacaine/ensayos 2026-06-05 weekly 0.6 https://crcwarriors.org/medicamento/ts-1 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ts-1/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/shr-8068 2026-04-02 weekly 0.7 https://crcwarriors.org/medicamento/shr-8068/ensayos 2026-04-02 weekly 0.6 https://crcwarriors.org/medicamento/nintedanib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/nintedanib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/lenalidomide 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/lenalidomide/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/methotrexate 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/methotrexate/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/prednisone 2026-08-06 weekly 0.7 https://crcwarriors.org/medicamento/prednisone/ensayos 2026-08-06 weekly 0.6 https://crcwarriors.org/medicamento/itraconazole 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/itraconazole/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/sym004 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sym004/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/penpulimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/penpulimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ruxolitinib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/ruxolitinib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/lorigerlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/lorigerlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/spartalizumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/spartalizumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/nw-301d 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/nw-301d/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/riluzole 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/riluzole/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tiragolumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tiragolumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pegfilgrastim 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pegfilgrastim/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/zanzalintinib 2026-08-11 weekly 0.7 https://crcwarriors.org/medicamento/zanzalintinib/ensayos 2026-08-11 weekly 0.6 https://crcwarriors.org/medicamento/saline 2026-06-05 weekly 0.7 https://crcwarriors.org/medicamento/saline/ensayos 2026-06-05 weekly 0.6 https://crcwarriors.org/medicamento/nktr- 2026-05-16 weekly 0.7 https://crcwarriors.org/medicamento/nktr-/ensayos 2026-05-16 weekly 0.6 https://crcwarriors.org/medicamento/sevoflurane 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sevoflurane/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/daraxonrasib 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/daraxonrasib/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/epacadostat 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/epacadostat/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/imatinib 2026-05-27 weekly 0.7 https://crcwarriors.org/medicamento/imatinib/ensayos 2026-05-27 weekly 0.6 https://crcwarriors.org/medicamento/tivozanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tivozanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/shr-a1811 2026-07-01 weekly 0.7 https://crcwarriors.org/medicamento/shr-a1811/ensayos 2026-07-01 weekly 0.6 https://crcwarriors.org/medicamento/sgm-101 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sgm-101/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bbi608 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bbi608/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bi-1701963 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/bi-1701963/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/bp102 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bp102/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pf-07220060 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pf-07220060/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/imiquimod 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/imiquimod/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/naliri 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/naliri/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/abbv-400 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/abbv-400/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/hmn14 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hmn14/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/allostim 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/allostim/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/neratinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/neratinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/bibf 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bibf/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/radiotherapy 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/radiotherapy/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/inavolisib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/inavolisib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ganitumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ganitumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/e7386 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/e7386/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/semaxanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/semaxanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ibi363 2026-07-28 weekly 0.7 https://crcwarriors.org/medicamento/ibi363/ensayos 2026-07-28 weekly 0.6 https://crcwarriors.org/medicamento/osi-906 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/osi-906/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/rmc-9805 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rmc-9805/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/etbx-011 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/etbx-011/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bupivacain 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bupivacain/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/hdm201 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/hdm201/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/thymalfasin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/thymalfasin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/hs-20093 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hs-20093/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/tucidinosta 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tucidinosta/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/indomethacin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/indomethacin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tucidinostat 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tucidinostat/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/doxycycline 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/doxycycline/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/enadenotucirev 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/enadenotucirev/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/regn7075 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/regn7075/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/defactinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/defactinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/romidepsi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/romidepsi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/calderasib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/calderasib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/amg-655 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/amg-655/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mk-2206 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mk-2206/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/eniluracil 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/eniluracil/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/vedolizumab 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/vedolizumab/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/indomethaci 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/indomethaci/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/fleet 2026-07-11 weekly 0.7 https://crcwarriors.org/medicamento/fleet/ensayos 2026-07-11 weekly 0.6 https://crcwarriors.org/medicamento/nilotinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/nilotinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/plenvu 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/plenvu/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pucotenlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pucotenlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rosuvastati 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rosuvastati/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/selpercatinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/selpercatinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/romidepsin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/romidepsin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gvax 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gvax/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/panobinosta 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/panobinosta/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mangafodipir 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/mangafodipir/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/relatlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/relatlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/m9140 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/m9140/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/mcla-129 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/mcla-129/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/flucytosine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/flucytosine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/thymalfasi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/thymalfasi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/talazoparib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/talazoparib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/etrolizumab 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/etrolizumab/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/nimotuzumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/nimotuzumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cs-1008 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cs-1008/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/dalotuzumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dalotuzumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/selinexo 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/selinexo/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ulixertinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ulixertinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/vismodegib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/vismodegib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/zimberelimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/zimberelimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/egfr 2026-05-16 weekly 0.7 https://crcwarriors.org/medicamento/egfr/ensayos 2026-05-16 weekly 0.6 https://crcwarriors.org/medicamento/selinexor 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/selinexor/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/amg-479 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/amg-479/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/niraparib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/niraparib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/incb001158 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/incb001158/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gv20-0251 2026-06-04 weekly 0.7 https://crcwarriors.org/medicamento/gv20-0251/ensayos 2026-06-04 weekly 0.6 https://crcwarriors.org/medicamento/bibf-1120 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/bibf-1120/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/n-803 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/n-803/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/e7820 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/e7820/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/abx-egf 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/abx-egf/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/onvansertib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/onvansertib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pd-0325901 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pd-0325901/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/chemoradiotherapy 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/chemoradiotherapy/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/brivanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/brivanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sg001 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/sg001/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/cyclosporine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cyclosporine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rosuvastatin 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rosuvastatin/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ner1006 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ner1006/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/alectinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/alectinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/panobinostat 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/panobinostat/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mangafodipi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/mangafodipi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hs-10370 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hs-10370/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/mw4911 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/mw4911/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/neomyci 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/neomyci/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/maraviroc 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/maraviroc/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/eribulin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/eribulin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/magrolimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/magrolimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bbo-10203 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/bbo-10203/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/rnk08954 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/rnk08954/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/ci-1040 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ci-1040/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/nis793 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/nis793/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/cv301 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cv301/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ivosidenib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ivosidenib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/imc-a12 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/imc-a12/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tinzaparin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tinzaparin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/napabucasi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/napabucasi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hs-10502 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hs-10502/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rimiducid 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/rimiducid/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pralsetinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pralsetinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/calmangafodipir 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/calmangafodipir/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gdc-1971 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gdc-1971/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/reolysi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/reolysi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/st316 2026-07-30 weekly 0.7 https://crcwarriors.org/medicamento/st316/ensayos 2026-07-30 weekly 0.6 https://crcwarriors.org/medicamento/conatumumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/conatumumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/s-531011 2026-07-23 weekly 0.7 https://crcwarriors.org/medicamento/s-531011/ensayos 2026-07-23 weekly 0.6 https://crcwarriors.org/medicamento/ceralasertib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ceralasertib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/masitinib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/masitinib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/d-1553 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/d-1553/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rec-4881 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/rec-4881/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/budigalimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/budigalimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bms-986340 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bms-986340/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/inc280 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/inc280/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/kd018 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/kd018/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/arfolitixorin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/arfolitixorin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sgn1 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/sgn1/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/ca102n 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ca102n/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/udenafil 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/udenafil/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/volrustomig 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/volrustomig/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/foxy-5 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/foxy-5/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cmab009 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cmab009/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/anastrozole 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/anastrozole/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/amt2003 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/amt2003/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/exemestane 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/exemestane/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/alt-803 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/alt-803/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/imlunestrant 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/imlunestrant/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/pro95780 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/pro95780/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/azd5305 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/azd5305/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ak119 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ak119/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/e7070 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/e7070/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/elimusertib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/elimusertib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/bevacizumab-irdye800cw 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bevacizumab-irdye800cw/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pirfenidone 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/pirfenidone/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/enzastaurin 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/enzastaurin/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/nv1020 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/nv1020/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/entrectinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/entrectinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/bibw-2992 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bibw-2992/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/erdafitinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/erdafitinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ssgj-612 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/ssgj-612/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/dovitinib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/dovitinib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/enoxaparin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/enoxaparin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/denosumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/denosumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/vatalanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/vatalanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/fmt 2026-05-27 weekly 0.7 https://crcwarriors.org/medicamento/fmt/ensayos 2026-05-27 weekly 0.6 https://crcwarriors.org/medicamento/floxuridine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/floxuridine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rivaroxaba 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/rivaroxaba/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/xilonix 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/xilonix/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/artesunate 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/artesunate/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/bms-986016 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bms-986016/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bli850 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bli850/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hs-20117 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hs-20117/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/hlx208 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hlx208/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/nns309 2026-06-06 weekly 0.7 https://crcwarriors.org/medicamento/nns309/ensayos 2026-06-06 weekly 0.6 https://crcwarriors.org/medicamento/fluzoparib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/fluzoparib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/capivasertib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/capivasertib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/copanlisib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/copanlisib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rezatapop 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rezatapop/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/leflunomide 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/leflunomide/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ipatasertib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ipatasertib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/camizestrant 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/camizestrant/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/larotrectinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/larotrectinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/dato-dxd 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/dato-dxd/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rmc-4630 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rmc-4630/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/bi-765049 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bi-765049/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/dulanermin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dulanermin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cannabidiol 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/cannabidiol/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ridaforolimus 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ridaforolimus/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ga-nns309 2026-06-06 weekly 0.7 https://crcwarriors.org/medicamento/ga-nns309/ensayos 2026-06-06 weekly 0.6 https://crcwarriors.org/medicamento/naproxen 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/naproxen/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/lubiprostone 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/lubiprostone/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/neomycin 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/neomycin/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/nalirifox 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/nalirifox/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/bupivacaine 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bupivacaine/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ufox 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ufox/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mrg007 2026-07-31 weekly 0.7 https://crcwarriors.org/medicamento/mrg007/ensayos 2026-07-31 weekly 0.6 https://crcwarriors.org/medicamento/dsp107 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dsp107/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gi-4000 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gi-4000/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/oleclumab 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/oleclumab/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/trk-950 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/trk-950/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/hua33 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hua33/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bisacodyl 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bisacodyl/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hf50 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/hf50/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/jab-3312 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jab-3312/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bgb-43395 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/bgb-43395/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/cb-839 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cb-839/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pm8002 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pm8002/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/pemigatinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pemigatinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/gastrografin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gastrografin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/plerixafo 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/plerixafo/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/sgi-110 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sgi-110/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/citrafleet 2026-07-11 weekly 0.7 https://crcwarriors.org/medicamento/citrafleet/ensayos 2026-07-11 weekly 0.6 https://crcwarriors.org/medicamento/mm-151 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mm-151/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/carmustine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/carmustine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/abiraterone 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/abiraterone/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/ompenaclid 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ompenaclid/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mm-398 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mm-398/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rivaroxaban 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/rivaroxaban/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/js207 2026-05-06 weekly 0.7 https://crcwarriors.org/medicamento/js207/ensayos 2026-05-06 weekly 0.6 https://crcwarriors.org/medicamento/thalidomide 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/thalidomide/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/il2 2026-05-06 weekly 0.7 https://crcwarriors.org/medicamento/il2/ensayos 2026-05-06 weekly 0.6 https://crcwarriors.org/medicamento/hsk42360 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/hsk42360/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/silymarin 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/silymarin/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/desflurane 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/desflurane/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/rapamyci 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/rapamyci/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/utidelone 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/utidelone/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/loperamide 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/loperamide/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/gh21 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/gh21/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/si-b003 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/si-b003/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/etbx-051 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/etbx-051/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/can04 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/can04/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/etbx-061 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/etbx-061/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gi-6301 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gi-6301/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/grt-c901 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/grt-c901/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/grt-r902 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/grt-r902/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/nc410 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/nc410/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/a166 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/a166/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rifaximi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/rifaximi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ly3214996 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ly3214996/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/rapamycin 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/rapamycin/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/avzo-021 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/avzo-021/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/famitinib 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/famitinib/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/bmx-001 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bmx-001/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/shr-1701 2026-04-02 weekly 0.7 https://crcwarriors.org/medicamento/shr-1701/ensayos 2026-04-02 weekly 0.6 https://crcwarriors.org/medicamento/prexasertib 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/prexasertib/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/tovorafenib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tovorafenib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/flox 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/flox/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/sph5030 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/sph5030/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/plerixafor 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/plerixafor/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/simvastatin 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/simvastatin/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/resveratrol 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/resveratrol/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/cm-24 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cm-24/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cp-675 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/cp-675/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/g-csf 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/g-csf/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/gemnabp 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/gemnabp/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rezatapopt 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rezatapopt/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ono-4578 2026-04-18 weekly 0.7 https://crcwarriors.org/medicamento/ono-4578/ensayos 2026-04-18 weekly 0.6 https://crcwarriors.org/medicamento/piritramid 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/piritramid/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mm-121 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mm-121/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/curcumin 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/curcumin/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/savolitinib 2026-07-07 weekly 0.7 https://crcwarriors.org/medicamento/savolitinib/ensayos 2026-07-07 weekly 0.6 https://crcwarriors.org/medicamento/bms-986504 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/bms-986504/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/dtx 2026-03-29 weekly 0.7 https://crcwarriors.org/medicamento/dtx/ensayos 2026-03-29 weekly 0.6 https://crcwarriors.org/medicamento/pds0101 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pds0101/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/acetaminophen 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/acetaminophen/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/m7824 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/m7824/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/silymari 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/silymari/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/simvastati 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/simvastati/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/golytely 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/golytely/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/bl-b01d1 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bl-b01d1/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/byl719 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/byl719/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/aipalolitovorelizumab 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/aipalolitovorelizumab/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mgd007 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/mgd007/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/vactosertib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/vactosertib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/sym021 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sym021/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/xl092 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/xl092/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/adalimumab 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/adalimumab/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/incb106385 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/incb106385/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/interferon 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/interferon/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ly3023414 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/ly3023414/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/tegavivint 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/tegavivint/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/rp2 2026-05-27 weekly 0.7 https://crcwarriors.org/medicamento/rp2/ensayos 2026-05-27 weekly 0.6 https://crcwarriors.org/medicamento/levoleucovori 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/levoleucovori/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mesalamine 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/mesalamine/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/tg6002 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tg6002/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/jab-23e73 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/jab-23e73/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/yl-17231 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/yl-17231/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/alpelisib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/alpelisib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ropidoxuridine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ropidoxuridine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/citraflee 2026-07-11 weekly 0.7 https://crcwarriors.org/medicamento/citraflee/ensayos 2026-07-11 weekly 0.6 https://crcwarriors.org/medicamento/cyad-101 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cyad-101/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/glutamine 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/glutamine/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/kqb198 2026-05-27 weekly 0.7 https://crcwarriors.org/medicamento/kqb198/ensayos 2026-05-27 weekly 0.6 https://crcwarriors.org/medicamento/lazertinib 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/lazertinib/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/ezabenlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ezabenlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ngm438 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ngm438/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/isis 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/isis/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/vs-7375 2026-06-23 weekly 0.7 https://crcwarriors.org/medicamento/vs-7375/ensayos 2026-06-23 weekly 0.6 https://crcwarriors.org/medicamento/epinephrine 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/epinephrine/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/propranolol 2026-05-01 weekly 0.7 https://crcwarriors.org/medicamento/propranolol/ensayos 2026-05-01 weekly 0.6 https://crcwarriors.org/medicamento/naproxe 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/naproxe/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/nsaid 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/nsaid/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/sc-201 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/sc-201/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/tegavivi 2026-03-29 weekly 0.7 https://crcwarriors.org/medicamento/tegavivi/ensayos 2026-03-29 weekly 0.6 https://crcwarriors.org/medicamento/ethynyluracil 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ethynyluracil/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/gsk5764227 2026-08-04 weekly 0.7 https://crcwarriors.org/medicamento/gsk5764227/ensayos 2026-08-04 weekly 0.6 https://crcwarriors.org/medicamento/avx701 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/avx701/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tinzapari 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tinzapari/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hmbd-001 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hmbd-001/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/surufatinib 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/surufatinib/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/ixabepilone 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ixabepilone/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/selenium 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/selenium/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hlx07 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/hlx07/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/jdq443 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jdq443/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tazemetostat 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/tazemetostat/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/pds01adc 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pds01adc/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/krn330 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/krn330/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/inca33890 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/inca33890/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ensartinib 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/ensartinib/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/rmc-6291 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rmc-6291/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/levoleucovorin 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/levoleucovorin/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/pf-07799933 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pf-07799933/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rifaximin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/rifaximin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/jx-594 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jx-594/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/reolysin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/reolysin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tas-102 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tas-102/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/star0602 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/star0602/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ferumoxytol 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ferumoxytol/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/jmt101 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jmt101/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bl-m17d1 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/bl-m17d1/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/b1962 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/b1962/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cibisatamab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cibisatamab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/elironrasib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/elironrasib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/obinutuzumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/obinutuzumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/regimen/folfox 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfiri 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/capox 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfoxiri 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfox-bevacizumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfiri-bevacizumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfiri-cetuximab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfiri-panitumumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfoxiri-bevacizumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/capecitabine-mono 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/pembrolizumab-mono 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/encorafenib-cetuximab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/trastuzumab-pertuzumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/trifluridine-tipiracil 2026-02-13 monthly 0.8 https://crcwarriors.org/articulo/2890/terapia-con-un-inhibidor-de-puntos-de-control-inmunitario-en-combinacion-o-como-agente-unico-en-cancer-colorrectal-metastasico-con-alta-inestabilidad-de-microsatelites-un-analisis-basado-en-datos-de 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2890/dual-versus-single-agent-immune-checkpoint-inhibitor-therapy-in-microsatellite-instability-high-metastatic-colorectal-cancer-an-analysis-based-on-reconstructed-patient-data 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2883/creacion-de-modelos-tridimensionales-de-cancer-colorrectal-mediante-bioimpresion-y-evaluacion-de-su-eficacia-y-sensibilidad-a-los-farmacos 2026-08-18 monthly 0.5 https://crcwarriors.org/articulo/2883/construction-of-3d-bioprinted-colorectal-cancer-models-and-evaluation-of-their-efficacy-and-drug-sensitivity 2026-08-18 monthly 0.5 https://crcwarriors.org/articulo/2881/las-metastasis-peritoneales-en-el-cancer-de-colon-en-estadio-ii-iii-representan-un-punto-ciego-para-la-vigilancia-del-adn-tumoral-circulante 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2881/peritoneal-metastases-in-stage-ii-iii-colon-cancer-represent-a-blind-spot-for-circulating-tumor-dna-surveillance 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2850/aspirina-para-la-prevencion-del-cancer-en-individuos-con-sindrome-de-lynch-primeros-resultados-del-ensayo-multicentrico-aleatorizado-doble-ciego-de-no-inferioridad-capp3 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2850/aspirin-for-cancer-prevention-in-individuals-with-lynch-syndrome-first-results-from-the-capp3-multicentre-randomised-double-blind-non-inferiority-trial 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2828/efectos-antitumorales-de-las-celulas-car-nk92mi-dirigidas-contra-cd133-en-el-cancer-colorrectal 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2828/anti-tumor-effects-of-cd133-targeted-car-nk92mi-cells-in-colorectal-cancer 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2826/estrategias-de-administracion-de-virus-oncoliticos-en-los-canceres-gastrointestinales-avances-mecanismos-y-traslacion-clinica 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2826/delivery-strategies-for-oncolytic-viruses-in-gastrointestinal-cancers-progress-mechanisms-and-clinical-translations 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2810/arid1a-regula-la-metastasis-del-cancer-colorrectal-a-traves-de-la-via-akt-mtor-p70s6k 2026-08-12 monthly 0.5 https://crcwarriors.org/articulo/2810/arid1a-regulates-colorectal-cancer-metastasis-through-the-akt-mtor-p70s6k-pathway 2026-08-12 monthly 0.5 https://crcwarriors.org/articulo/2802/factores-pronosticos-en-el-borde-de-invasion-y-en-el-area-peritumoral-del-cancer-colorrectal-perspectivas-actuales-y-consideraciones-futuras 2026-08-12 monthly 0.5 https://crcwarriors.org/articulo/2802/invasive-front-and-peritumoral-prognostic-factors-in-colorectal-cancer-current-perspectives-and-future-considerations 2026-08-12 monthly 0.5 https://crcwarriors.org/articulo/2783/dependencia-de-la-enzima-tipo-furina-en-el-cancer-colorrectal-con-mutacion-en-kras-como-diana-para-estrategias-de-tratamiento-personalizadas 2026-08-21 monthly 0.5 https://crcwarriors.org/articulo/2783/furin-like-enzyme-dependency-in-kras-mutant-colorectal-cancer-as-a-target-for-personalized-treatment-strategies 2026-08-21 monthly 0.5 https://crcwarriors.org/articulo/2687/dirigirse-a-lig1-para-superar-la-resistencia-al-oxaliplatino-mediante-la-induccion-de-la-panoptosis-en-el-cancer-colorrectal 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2687/targeting-lig1-to-overcome-oxaliplatin-resistance-by-inducing-panoptosis-in-colorectal-cancer 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2686/analisis-del-microambiente-inmunosupresor-en-el-cancer-colorrectal-resistente-a-la-quimioterapia-mediante-el-analisis-transcriptomico-de-celulas-individuales 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2686/dissecting-immunosuppressive-microenvironment-in-chemotherapy-resistant-colorectal-cancer-through-single-cell-transcriptomic-analysis 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2675/la-furina-mantiene-las-senales-promotoras-de-tumores-en-el-cancer-colorrectal-con-mutaciones-en-los-genes-kras-y-braf-al-interactuar-con-el-eje-tgf-1-cox-2-en-una-red-de-regulacion-reciproca 2026-08-21 monthly 0.5 https://crcwarriors.org/articulo/2675/furin-sustains-tumor-promoting-signals-in-kras-and-braf-mutated-colorectal-cancer-by-engaging-the-tgf-1-cox-2-axis-in-a-reciprocal-regulatory-network 2026-08-21 monthly 0.5 https://crcwarriors.org/articulo/2504/quien-rechaza-el-asesoramiento-genetico-evaluacion-del-rechazo-al-asesoramiento-genetico-entre-los-participantes-en-un-programa-de-cribado-genomico-a-nivel-poblacional 2026-08-03 monthly 0.5 https://crcwarriors.org/articulo/2504/who-declines-genetic-counseling-an-assessment-of-genetic-counseling-declination-among-individuals-participating-in-a-population-wide-genomic-screening-program 2026-08-03 monthly 0.5 https://crcwarriors.org/articulo/2483/identificacion-sistematica-de-biomarcadores-genomicos-de-falta-de-respuesta-a-los-tratamientos-contra-el-cancer 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2483/systematic-identification-of-genomic-nonresponse-biomarkers-to-cancer-therapies 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2479/mecanismos-y-avances-en-la-resistencia-a-los-farmacos-en-el-cancer-colorrectal-una-revision-sistematica-de-las-redes-reguladoras-multicapa 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2479/mechanisms-and-advances-of-drug-resistance-in-colorectal-cancer-a-systematic-overview-of-multi-layered-regulatory-networks 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2476/mecanismos-y-desafios-clinicos-de-la-remodelacion-del-microambiente-tumoral-mediada-por-la-inmunoterapia-con-inhibidores-de-puntos-de-control-en-el-carcinoma-nasofaringeo 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2476/mechanisms-and-clinical-challenges-of-icb-mediated-remodeling-of-the-tumor-microenvironment-in-nasopharyngeal-carcinoma 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2475/los-genes-relacionados-con-la-ferroptosis-asociados-con-las-metastasis-hepaticas-del-cancer-colorrectal-modulan-la-peroxidacion-lipidica-en-las-celulas-del-cancer-colorrectal 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2475/colorectal-cancer-liver-metastasis-associated-ferroptosis-related-genes-modulate-lipid-peroxidation-in-colorectal-cancer-cells 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2429/redes-regulatorias-multidimensionales-de-la-resistencia-a-los-farmacos-en-el-cancer-colorrectal-desde-los-mecanismos-moleculares-hasta-nuevas-estrategias-terapeuticas 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2429/multidimensional-regulatory-networks-of-drug-resistance-in-colorectal-cancer-from-molecular-mechanisms-to-novel-therapeutic-counterstrategies 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2415/adcs-para-el-carcinoma-colorrectal-analisis-de-la-evidencia-clinica-para-la-innovacion-en-el-diseno-molecular 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2415/adcs-for-colorectal-carcinoma-decoding-clinical-evidence-for-molecular-design-innovation 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2317/alteraciones-especificas-del-subtipo-en-el-transporte-de-cobre-asociadas-con-las-mutaciones-de-kras-en-lineas-celulares-isogenicas-de-cancer-colorrectal 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2317/subtype-specific-alterations-in-copper-trafficking-associated-with-kras-mutations-in-isogenic-colorectal-cancer-cell-lines 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2303/sintesis-y-evaluacion-preclinica-de-89-zr-dfo-atezolizumab-para-la-imagen-pet-inmunitaria-en-el-cancer-colorrectal 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2303/synthesis-and-preclinical-evaluation-of-89-zr-dfo-atezolizumab-for-immuno-pet-imaging-in-colorectal-cancer 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2237/la-arn-polimerasa-i-endotelial-que-esta-regulada-por-spen-es-un-objetivo-para-mejorar-la-inmunoterapia-anti-pd-1-en-el-tratamiento-del-cancer 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2237/endothelial-rna-polymerase-i-which-is-regulated-by-spen-is-a-target-for-improving-anti-pd-1-immunotherapy-of-cancer 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2156/caracterizacion-preclinica-y-resultados-de-la-fase-1-de-tqb2102-un-conjugado-anticuerpo-farmaco-biparatopico-her2-de-primera-generacion-en-pacientes-con-tumores-solidos-avanzados 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2156/preclinical-characterization-and-phase-i-results-of-tqb2102-a-first-in-class-her2-biparatopic-antibody-drug-conjugate-in-patients-with-advanced-solid-tumors 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2130/evaluaciones-endoscopicas-y-radiologicas-de-la-inmunoterapia-neoadyuvante-en-pacientes-con-cancer-colorrectal-localmente-avanzado-con-dmmr-msi-h-o-mutacion-en-los-genes-pole-pold1 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2130/endoscopic-and-imaging-evaluations-of-neoadjuvant-immunotherapy-in-patients-with-locally-advanced-colorectal-cancer-with-dmmr-msi-h-or-pole-pold1-mutation 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/1783/virus-oncoliticos-recubiertos-basados-en-una-estrategia-de-doble-ataque-que-desencadena-la-terapia-car-t-dirigida-a-cd19-en-tumores-gastrointestinales 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/1783/coated-oncolytic-viruses-based-double-strike-strategy-triggering-cd19-car-t-therapy-in-gastrointestinal-tumors 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2950/comparison-of-pcr-based-high-resolution-melting-curve-analysis-and-immunohistochemistry-in-detecting-microsatellite-instability-in-colorectal-cancer-a-retrospective-consistency-study 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2948/cps1-promotes-colorectal-cancer-progression-by-inducing-emt-and-activating-tgf-smad-signaling-pathway 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2947/importancia-clinica-de-la-amplificacion-de-erbb2-detectada-mediante-wes-en-el-cancer-colorrectal-resecable 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2947/clinical-significance-of-wes-defined-erbb2-amplification-in-resectable-colorectal-cancer 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2946/mechanism-of-neoantigen-generation-and-advances-in-neoantigen-based-immunotherapies-in-colorectal-cancer 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2943/telisotuzumab-adizutecan-para-el-cancer-colorrectal-metastasico-un-conjugado-anticuerpo-farmaco-dirigido-a-c-met-con-una-carga-de-inhibidor-de-la-topoisomerasa 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2943/telisotuzumab-adizutecan-for-metastatic-colorectal-cancer-a-c-met-targeted-antibody-drug-conjugate-with-a-topoisomerase-inhibitor-payload 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2939/avances-y-retos-en-el-diseno-y-desarrollo-de-farmacos-selectivos-dirigidos-a-la-mutacion-kras-g12d-inhibidores-degradadores-y-estrategias-terapeuticas-emergentes 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2939/progress-and-challenges-in-the-design-and-development-of-selective-kras-g12d-targeted-drug-discovery-inhibitors-degraders-and-emerging-therapeutic-strategies 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2937/seguridad-y-eficacia-de-sotorasib-en-combinacion-con-panitumumab-y-folfiri-en-pacientes-con-cancer-colorrectal-metastasico-con-mutacion-kras-g12c-previamente-tratados-en-el-estudio-codebreak-101-de 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2937/safety-and-efficacy-of-sotorasib-plus-panitumumab-and-folfiri-for-previously-treated-kras-g12c-mutated-metastatic-colorectal-cancer-in-the-codebreak-101-phase-ib-study 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2933/asociacion-entre-el-numero-de-ganglios-linfaticos-centinela-y-el-pronostico-en-pacientes-con-cancer-de-mama-en-estadio-ct1-2n0m0-y-ganglios-linfaticos-centinela-negativos-un-estudio-retrospectivo-de 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2933/association-between-sentinel-lymph-node-number-and-prognosis-in-ct1-2n0m0-early-breast-cancer-patients-with-negative-sentinel-lymph-nodes-a-single-center-retrospective-cohort-study 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2932/un-ensayo-de-fase-ii-multicohorte-y-basado-en-biomarcadores-que-evalua-una-terapia-neoadyuvante-total-personalizada-con-agentes-dirigidos-para-el-cancer-de-recto-de-alto-riesgo-el-estudio-trainer 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2932/a-multicohort-biomarker-driven-phase-2-trial-of-personalized-total-neoadjuvant-therapy-with-targeted-agents-for-high-risk-rectal-cancer-the-trainer-study 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2931/capacidad-de-deteccion-de-biomarcadores-de-ctdna-en-diversos-tipos-de-cancer-en-poblaciones-asiaticas-implicaciones-para-la-deteccion-en-un-amplio-espectro-de-canceres 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2931/cross-cancer-detectability-of-ctdna-biomarkers-in-asian-populations-implications-for-pan-cancer-detection 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2930/monoterapia-antitumoral-anti-pd-1-neoadyuvante-seguida-de-una-estrategia-de-observacion-en-pacientes-con-cancer-colorrectal-dmmr-msi-h-un-estudio-multicentrico-en-el-mundo-real 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2930/neoadjuvant-anti-pd-1-monotherapy-followed-by-watch-and-wait-strategy-in-dmmr-msi-h-colorectal-cancer-a-multicenter-real-world-study 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2929/cancer-colorrectal-metastasico-con-mutacion-kras-g12c-estrategias-terapeuticas-actuales-y-perspectivas-futuras 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2929/kras-g12c-mutated-metastatic-colorectal-cancer-current-therapeutic-strategies-and-future-directions 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2928/los-niveles-basales-de-celulas-t-circulantes-y-tumorales-asi-como-la-expansion-temprana-de-celulas-cd8-pd1-circulantes-predicen-la-respuesta-a-atezolizumab-bevacizumab-en-el-carcinoma-hepatocelular 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2928/baseline-circulating-and-tumor-t-cells-and-early-circulating-cd8-pd1-expansion-predict-response-to-atezolizumab-bevacizumab-in-hcc 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2927/inmunoterapia-neoadyuvante-en-el-cancer-colorrectal-localizado-con-dmmr-msi-h-una-revision-sistematica-de-la-respuesta-patologica-y-los-resultados-quirurgicos 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2927/neoadjuvant-immunotherapy-in-localized-dmmr-msi-h-colon-cancer-a-systematic-review-of-pathological-response-and-surgical-outcomes 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2926/nuevas-estrategias-inmunoterapeuticas-para-el-tratamiento-del-cancer-colorrectal-avances-desafios-y-perspectivas-futuras 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2926/novel-immunotherapeutic-strategies-for-colorectal-cancer-treatment-advances-challenges-and-future-directions 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2925/la-dihidropirimidina-deshidrogenasa-modula-la-respuesta-inmune-a-la-inhibicion-de-los-puntos-de-control-en-el-cancer-colorrectal-con-deficiencia-en-la-reparacion-del-desajuste-y-alta-inestabilidad-de 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2925/dihydropyrimidine-dehydrogenase-modulates-immune-response-to-checkpoint-inhibition-in-mismatch-repair-deficient-microsatellite-instability-high-colorectal-cancer 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2921/la-calibracion-de-la-senalizacion-de-las-celulas-car-promueve-la-division-celular-asimetrica-para-dirigir-el-destino-de-las-celulas-car-t-y-potenciar-su-actividad-antitumoral 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2921/calibration-of-car-signaling-promotes-asymmetric-cell-division-to-direct-car-t-cell-fate-and-antitumor-potency 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2919/nanomedicamentos-bioactivos-para-el-cancer-colorrectal-resistente-a-multiples-farmacos-mecanismos-relevantes-nuevas-clases-de-particulas-y-obstaculos-para-la-traslacion-clinica 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2919/bioactive-nanomedicines-for-multidrug-resistant-colorectal-cancer-actionable-mechanisms-emerging-particle-classes-and-translational-barriers 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2918/comunidades-microbianas-sinteticas-nuevas-terapias-biologicas-vivas-para-la-modulacion-dirigida-del-microbioma-intestinal 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2918/synthetic-microbial-communities-emerging-live-biotherapeutics-for-targeted-gut-microbiome-modulation 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2916/las-soluciones-activadas-con-plasma-potencian-los-efectos-antitumorales-de-la-quimioterapia-hiperermica-intraperitoneal-hipec-a-traves-de-la-apoptosis-mediada-por-el-estres-del-reticulo-endoplasmico 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2916/plasma-activated-solutions-potentiate-the-antitumor-effects-of-hipec-via-endoplasmic-reticulum-stress-mediated-apoptosis 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2913/inmunoterapia-en-el-cancer-colorrectal-nuevas-perspectivas-y-proximos-pasos 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2913/immunotherapy-in-colorectal-cancer-novel-perspectives-and-next-steps 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2910/el-tratamiento-pasado-presente-y-futuro-del-cancer-colorrectal-metastasico-con-mutacion-braf-v600-una-revision-exhaustiva 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2910/the-past-present-and-future-treatment-of-braf-v600-mutant-metastatic-colorectal-cancer-a-comprehensive-review 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2909/modelado-de-los-resultados-clinicos-y-el-impacto-economico-de-la-inmunoterapia-anti-pd-1-pd-l1-en-los-paises-del-golfo-emiratos-arabes-unidos-oman-y-kuwait 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2909/modeling-cancer-outcomes-and-economic-impact-of-the-anti-pd-1-pd-l1-immunotherapy-in-the-gulf-united-arab-emirates-oman-and-kuwait 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2908/eficacia-y-seguridad-de-diferentes-tamanos-de-microesferas-liberadoras-de-farmacos-en-el-tratamiento-de-la-metastasis-hepatica-del-cancer-colorrectal-mediante-tace 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2908/efficacy-and-safety-of-different-sizes-drug-eluting-beads-in-the-treatment-of-colorectal-cancer-liver-metastasis-by-tace 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2906/aspirina-tras-la-finalizacion-de-la-terapia-adyuvante-estandar-para-el-cancer-colorrectal-ascolt-una-revision-sistematica-y-metaanalisis 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2906/aspirin-after-completion-of-standard-adjuvant-therapy-for-colorectal-cancer-ascolt-a-systematic-review-and-meta-analysis 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2905/topografia-de-la-heterogeneidad-tumoral-global-wtht-un-nuevo-enfoque-para-la-evaluacion-de-la-heterogeneidad-mutacional-intratumoral-en-adenomas-colorrectales 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2905/whole-tumor-heterogeneity-topography-wtht-a-new-approach-for-assessment-of-intratumor-mutational-heterogeneity-in-colorectal-adenomas 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2904/secuenciacion-de-nueva-generacion-en-el-cancer-colorrectal-perfilado-molecular-en-la-practica-clinica-y-correlaciones-clinicas 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2904/next-generation-sequencing-in-colorectal-cancer-real-world-molecular-profiling-and-clinical-correlations 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2903/inmunoterapia-neoadyuvante-basada-en-pd-1-en-el-cancer-colorrectal-localizado-con-dmmr-msi-h-una-revision-sistematica-y-un-metaanalisis-basado-en-grupos 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2903/neoadjuvant-pd-1-based-immunotherapy-in-localized-dmmr-msi-h-colorectal-cancer-a-systematic-review-and-arm-based-meta-analysis 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2902/factores-asociados-con-el-momento-de-aparicion-de-metastasis-hepaticas-tras-la-cirugia-de-cancer-colorrectal-un-estudio-multicentrico-retrospectivo 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2902/factors-associated-with-the-timing-of-liver-metastasis-after-colorectal-cancer-surgery-a-retrospective-multicenter-study 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2900/el-panorama-genetico-del-cancer-colorrectal-desde-las-alteraciones-moleculares-hasta-las-vias-de-decision-terapeutica 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2900/the-genetic-landscape-of-colorectal-cancer-from-molecular-alterations-to-therapeutic-decision-pathways 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2895/los-n-glicanos-presentes-en-las-celulas-del-microambiente-tumoral-no-maligno-disminuyen-la-funcion-de-las-celulas-car-t-en-tumores-solidos 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2895/n-glycans-in-non-malignant-tumor-microenvironment-cells-dampen-car-t-cell-function-in-solid-tumors 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2893/edicion-precisa-de-las-mutaciones-de-tp53-mediante-la-tecnica-prime-editing-para-lograr-la-supresion-funcional-del-tumor-en-el-cancer-colorrectal 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2893/precision-prime-editing-of-tp53-mutations-for-functional-tumor-suppression-in-colorectal-cancer 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2892/prediccion-de-la-inestabilidad-de-microsatelites-en-el-cancer-colorrectal-basada-en-fenotipos-tisulares-inferidos-a-partir-de-imagenes-histopatologicas-completas-mediante-autodestilacion 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2892/prediction-of-microsatellite-instability-in-colorectal-cancer-based-on-tissue-phenotypes-inferred-from-pathological-whole-slide-images-using-self-distillation 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2891/nanocables-de-adn-programables-que-median-la-dispersion-y-la-localizacion-en-el-ensamblaje-catalitico-de-horquillas-para-la-deteccion-y-la-obtencion-de-imagenes-de-alta-resolucion-de-microarn 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2891/programmable-dna-nanowires-mediated-dispersion-to-localization-catalytic-hairpin-assembly-for-high-contrast-mirna-detection-and-imaging 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2887/panorama-emergente-de-la-terapia-con-celulas-car-t-en-el-cancer-de-colon-aspectos-mecanisticos-avances-clinicos-desafios-y-perspectivas-futuras 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2887/emerging-landscape-of-car-t-cell-therapy-in-colon-cancer-mechanistic-insights-clinical-advances-challenges-and-future-directions 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2885/estudio-exhaustivo-del-mecanismo-por-el-cual-xiao-chai-hu-tang-atenua-la-toxicidad-intestinal-inducida-por-irinotecan-y-mejora-la-inmunidad-antitumoral-a-traves-de-la-microbiota-intestinal-y-la 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2885/in-depth-study-on-the-mechanism-of-xiao-chai-hu-tang-in-ameliorating-irinotecan-induced-intestinal-toxicity-and-enhancing-antitumor-immunity-via-intestinal-microbiota-and-fecal-metabolomics 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2884/el-extracto-de-paliurus-ramosissimus-alivia-parcialmente-la-colitis-asociada-al-cancer-colorrectal-inducido-por-aom-dss-en-ratones-hallazgos-obtenidos-a-partir-de-analisis-transcriptomicos-y-del 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2884/paliurus-ramosissimus-extract-partially-ameliorates-aom-dss-induced-colitis-associated-colorectal-cancer-in-mice-insights-from-transcriptomic-and-gut-microbiota-analyses 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2882/el-metabolismo-mitocondrial-y-las-firmas-genicas-relacionadas-con-la-succinilacion-como-predictores-del-pronostico-y-la-resistencia-a-los-farmacos-en-el-adenocarcinoma-de-colon 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2882/mitochondrial-metabolism-and-succinylation-related-gene-signatures-for-predicting-prognosis-and-drug-resistance-in-colon-adenocarcinoma 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2880/caracterizacion-molecular-de-las-metastasis-ovaricas-derivadas-del-cancer-colorrectal-mediante-el-analisis-del-adn-tumoral-circulante 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2880/molecular-characterization-of-ovarian-metastases-from-colorectal-cancer-using-circulating-tumor-dna-analysis 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2879/desarrollo-de-inmunoterapia-con-criterios-farmacodinamicos-pd-y-adaptada-a-las-caracteristicas-del-tumor-en-el-cancer-colorrectal-mss-pmmr 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2879/barrier-matched-pharmacodynamic-pd-gated-immunotherapy-development-in-mss-pmmr-colorectal-cancer 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2878/supresion-dirigida-de-kras-en-el-cancer-colorrectal-mediante-arn-de-interferencia-de-doble-cadena-siarn-autoensamblados-in-vivo-y-encapsulados-en-pequenas-vesiculas-extracelulares-endogenas 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2878/targeted-kras-suppression-in-colorectal-cancer-via-in-vivo-self-assembled-sirnas-encapsulated-in-endogenous-small-extracellular-vesicles 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2873/proceso-de-radiomica-de-tc-coclinica-para-identificar-posibles-biomarcadores-de-imagen-para-el-cancer-colorrectal 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2873/co-clinical-ct-radiomics-pipeline-to-establish-candidate-imaging-biomarkers-for-colorectal-cancer 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2872/el-lncrna-miat-modificado-con-m-6-a-promueve-la-resistencia-a-la-anoikis-y-la-metastasis-peritoneal-del-cancer-colorrectal-a-traves-del-eje-de-senalizacion-mir-181a-5p-mcl1 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2872/m-6-a-modified-lncrna-miat-promotes-anoikis-resistance-and-peritoneal-metastasis-of-colorectal-cancer-through-mir-181a-5p-mcl1-signaling-axis 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2871/analisis-de-coste-efectividad-de-nivolumab-mas-ipilimumab-frente-a-nivolumab-en-monoterapia-en-pacientes-con-cancer-colorrectal-metastasico-previamente-tratados-y-con-deficiencia-en-la-reparacion-del 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2871/cost-effectiveness-analysis-of-nivolumab-plus-ipilimumab-versus-nivolumab-monotherapy-in-previously-treated-metastatic-colorectal-cancer-patients-with-dna-mismatch-repair-deficient-microsatellite 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2870/desde-la-inhibicion-de-kras-hasta-la-adaptacion-tumoral-mecanismos-de-resistencia-y-estrategias-terapeuticas 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2870/from-kras-inhibition-to-tumor-adaptation-mechanistic-layers-of-resistance-and-therapeutic-strategies 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2863/panorama-de-los-ensayos-clinicos-y-perspectivas-traslacionales-de-la-inmunoterapia-basada-en-celulas-asesinas-naturales-un-analisis-basado-en-la-base-de-datos-informa 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2863/clinical-trial-landscape-and-translational-prospects-of-natural-killer-cell-based-immunotherapy-an-analysis-based-on-the-informa-database 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2862/informe-breve-beneficio-terapeutico-de-isa-2011b-en-el-cancer-colorrectal 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2862/brief-report-therapeutic-benefit-of-isa-2011b-in-colorectal-cancer 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2861/modulacion-de-la-microbiota-intestinal-en-los-canceres-gastrointestinales-desde-las-caracteristicas-de-la-disbiosis-hasta-las-intervenciones-terapeuticas 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2861/gut-microbiota-modulation-of-gastrointestinal-cancers-from-dysbiosis-signatures-to-therapeutic-interventions 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2859/relacion-entre-los-sitios-de-mutacion-del-gen-kras-y-las-caracteristicas-clinicas-en-el-cancer-colorrectal 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2859/relationship-between-kras-gene-mutation-sites-and-clinical-characteristics-in-colorectal-cancer 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2858/panorama-genomico-e-implicaciones-terapeuticas-del-cancer-colorrectal-con-fusion-de-alk 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2858/genomic-landscape-and-therapeutic-implications-of-anaplastic-lymphoma-kinase-fusion-positive-colorectal-cancer 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2857/predictores-genomicos-transcriptomicos-y-moleculares-de-la-respuesta-a-la-terapia-neoadyuvante-en-el-cancer-colorrectal-localmente-avanzado-una-revision-narrativa 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2857/genomic-transcriptomic-and-molecular-predictors-of-response-to-neoadjuvant-therapy-in-locally-advanced-rectal-cancer-a-narrative-review 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2852/un-modelo-de-radiomica-predice-la-eficacia-de-un-inhibidor-de-cdk4-6-en-primera-linea-combinado-con-terapia-endocrina-en-el-cancer-de-mama-avanzado-hr-her2 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2852/radiomics-model-predicts-efficacy-of-first-line-cdk4-6-inhibitor-combined-with-endocrine-therapy-in-hr-her2-advanced-breast-cancer 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2847/fototerapia-inmunoterapia-del-carcinoma-de-colon-mediante-un-complejo-de-nanoparticulas-de-carbono-y-fe-ii-con-un-inmunoadyuvante 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2847/photothermal-immunotherapy-of-colon-carcinoma-by-carbon-nanoparticle-fe-ii-complex-with-immunoadjuvant 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2846/prediccion-multimodelo-del-pronostico-especifico-por-estadio-del-cancer-colorrectal-mediante-el-aprendizaje-profundo-en-conjunto-basado-en-la-atencion-aplicado-a-datos-de-perfiles-genomicos 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2846/a-multi-model-prediction-of-a-stage-specific-prognosis-for-colorectal-cancer-using-attention-driven-deep-ensemble-learning-on-genomic-profiling-data 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2839/adicion-de-altas-dosis-de-vitamina-d3-al-tratamiento-estandar-en-pacientes-con-cancer-colorrectal-metastasico-el-ensayo-clinico-aleatorizado-solaris-alliance-a021703 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2839/addition-of-high-dose-vitamin-d3-to-standard-treatment-in-patients-with-metastatic-colorectal-cancer-the-solaris-randomized-clinical-trial-alliance-a021703 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2838/el-analisis-especifico-de-variantes-del-fenomeno-de-exclusion-mutua-entre-los-oncogenes-braf-egfr-y-kras-revela-una-superposicion-con-pares-de-mutantes-funcionalmente-antagonicos 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2838/variant-specific-landscape-of-mutual-exclusivity-among-braf-egfr-and-kras-oncogenes-reveals-overlap-with-functionally-antagonistic-mutant-pairs 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2834/asociacion-de-los-macrofagos-intratumorales-cd68-cd163-de-tipo-m2-con-la-supervivencia-en-el-cancer-colorrectal-metastasico-tratado-con-quimioterapia-mas-bevacizumab 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2834/association-of-intratumoral-cd68-cd163-m2-like-macrophages-with-survival-in-metastatic-colorectal-cancer-treated-with-chemotherapy-plus-bevacizumab 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2829/la-optimizacion-del-proceso-de-fabricacion-y-de-la-superficie-electrostatica-de-las-celulas-car-t-mejora-la-eficacia-terapeutica-en-las-neoplasias-hepaticas 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2829/manufacturing-and-electrostatic-surface-optimization-of-car-t-cells-improve-therapeutic-efficacy-in-liver-malignancies 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2824/perfil-genomico-y-caracteristicas-clinicas-de-los-canceres-colorrectales-con-mutaciones-en-erbb2-her2 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2824/genomic-landscape-and-clinical-characteristics-of-erbb2-her2-mutated-colorectal-cancers 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2823/respuesta-prolongada-a-la-inhibicion-combinada-de-braf-y-mek-en-cancer-colorrectal-con-mutacion-braf-un-caso-clinico 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2823/prolonged-response-to-combined-braf-and-mek-inhibition-in-braf-mutant-colorectal-cancer-a-case-report 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2820/quimioterapia-neoadyuvante-y-bevacizumab-para-metastasis-peritoneales-de-cancer-colorrectal-resultados-clinicos-y-traslacionales-del-ensayo-de-fase-ii-bev-ip 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2820/neoadjuvant-chemotherapy-and-bevacizumab-for-colorectal-peritoneal-metastases-clinical-and-translational-outcomes-of-the-phase-ii-bev-ip-trial 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2819/administracion-de-sirna-mediante-coacervados-peptidicos-para-el-bloqueo-dual-de-pd-1-pd-l1-con-el-fin-de-mejorar-la-inmunoterapia-del-cancer-colorrectal 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2819/peptide-coacervate-mediated-sirna-delivery-for-dual-pd-1-pd-l1-blockade-to-enhance-colorectal-cancer-immunotherapy 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2818/evaluacion-del-rendimiento-de-un-ensayo-de-genotipado-de-regiones-criticas-basado-en-massarray-para-el-diagnostico-de-cancer-colorrectal-que-analiza-los-genes-kras-nras-braf-y-pik3ca-utilizando 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2818/performance-evaluation-of-a-colorectal-cancer-associated-massarray-based-hotspot-genotyping-assay-for-kras-nras-braf-and-pik3ca-using-solid-tumor-specimens 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2807/commit-estudio-aleatorizado-de-mfolfox6-bevacizumab-atezolizumab-frente-a-atezolizumab-en-monoterapia-como-tratamiento-de-primera-linea-del-cancer-colorrectal-metastasico-con-deficiencia-en-la 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2807/commit-a-randomized-study-of-mfolfox6-bevacizumab-atezolizumab-or-atezolizumab-alone-as-first-line-treatment-of-deficient-dna-mismatch-repair-metastatic-colorectal-cancer 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2804/afinacion-y-caracterizacion-de-la-maduracion-del-nuevo-anticuerpo-monoclonal-mab-pb-223-dirigido-contra-los-o-glicanos-especificos-del-cancer-que-terminan-en-2-6-acidos-sialicos 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2804/affinity-maturation-and-characterization-of-the-novel-monoclonal-antibody-mab-pb-223-targeting-cancer-specific-o-glycans-terminating-with-2-6-sialic-acids 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2803/comparacion-de-la-eficacia-y-la-seguridad-de-las-diferentes-opciones-de-tratamiento-en-tercera-linea-para-pacientes-con-cancer-colorrectal-metastasico-una-revision-sistematica-y-un-metaanalisis-de 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2803/comparing-the-effectiveness-and-safety-of-different-third-line-management-options-for-patients-with-metastatic-colorectal-cancer-a-systematic-review-and-reconstructed-individual-patient-data-meta 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2798/superar-la-resistencia-a-los-tratamientos-anti-egfr-mecanismos-de-resistencia-al-cetuximab-y-al-panitumumab-y-nuevas-estrategias-de-combinacion 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2798/overcoming-resistance-to-anti-egfr-therapies-mechanisms-of-cetuximab-and-panitumumab-resistance-and-emerging-combination-strategies 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2792/analisis-de-la-incidencia-y-los-resultados-perioperatorios-de-las-reacciones-adversas-relacionadas-con-el-sistema-inmunitario-en-la-inmunoterapia-preoperatoria-para-el-cancer-colorrectal-basado-en 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2792/analysis-on-the-incidence-and-perioperative-outcomes-of-immune-related-adverse-events-in-preoperative-immunotherapy-for-colorectal-cancer-based-on-multicenter-real-world-data 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2791/informe-de-la-27-a-conferencia-anual-de-consenso-sobre-el-cancer-gastrointestinal-del-oeste-de-canada-dedicada-al-cancer-colorrectal-celebrada-en-calgary-alberta-los-dias-26-y-27-de-septiembre-de 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2791/report-from-the-27th-annual-western-canadian-gastrointestinal-cancer-consensus-conference-on-colorectal-cancer-calgary-alberta-26-27-september-2025-advances-in-colon-and-rectal-cancer 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2790/sobreexpresion-amplificacion-de-her2-en-el-cancer-colorrectal-la-heterogeneidad-espacial-intratumoral-como-factor-clave-de-la-discordancia-en-la-deteccion-y-la-respuesta-al-tratamiento 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2790/her2-overexpression-amplification-in-colorectal-cancer-spatial-intratumoral-heterogeneity-as-a-key-determinant-of-detection-discordance-and-therapy-response 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2789/avances-recientes-en-la-investigacion-clinica-y-de-biologia-molecular-sobre-las-lesiones-serriladas-rectales 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2789/recent-progress-in-clinical-and-molecular-biological-research-in-rectal-serrated-lesions 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2784/dirigirse-a-las-vias-moleculares-y-geneticas-que-impulsan-la-tumorigenesis-para-lograr-una-terapia-de-precision-en-el-cancer-colorrectal 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2784/targeting-molecular-and-genetic-pathways-driving-tumorigenesis-for-precision-therapy-in-colorectal-cancer 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2774/las-celulas-t-derivadas-de-ipsc-alogenicas-demuestran-eficacia-antitumoral-frente-a-tejidos-derivados-de-pacientes 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2774/allogeneic-ipsc-derived-t-cells-demonstrate-antitumor-efficacy-against-patient-derived-tissues 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2773/un-nuevo-anticuerpo-monoclonal-anti-caderina-17-ca-17-mab-5-para-multiples-aplicaciones 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2773/a-novel-anti-cadherin-17-monoclonal-antibody-ca-17-mab-5-for-multiple-applications 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2770/terapia-neoadyuvante-total-basada-en-radioterapia-de-corta-duracion-mas-tislelizumab-para-el-cancer-colorrectal-localmente-avanzado-neo-star-resultados-preliminares-de-un-ensayo-aleatorizado-de-fase 2026-08-22 monthly 0.5 https://crcwarriors.org/articulo/2770/short-course-radiotherapy-based-total-neoadjuvant-therapy-plus-tislelizumab-for-locally-advanced-rectal-cancer-neo-star-early-outcomes-of-a-randomized-phase-ii-trial 2026-08-22 monthly 0.5 https://crcwarriors.org/news-detail.php?id=nuevas-funcionalidades-en-el-buscador-de-ensayos-clinicos-mapa-interactivo-filtros-avanzados-y-mas 2026-08-22 monthly 0.5 https://crcwarriors.org/news-detail.php?id=nueva-experiencia-de-noticias-cientificas-ia-personalizada-traduccion-en-tiempo-real-y-mucho-mas 2026-08-20 monthly 0.5 https://crcwarriors.org/news-detail.php?id=lanzamos-la-beta-de-crc-warriors-buscamos-testers 2026-08-21 monthly 0.5 https://crcwarriors.org/news-detail.php?id=glosario-de-farmacos-2-0-mas-inteligente-mas-completo-mas-potente 2026-08-20 monthly 0.5 https://crcwarriors.org/combinaciones/63 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/62 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/33 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/34 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/36 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/52 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/11 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/45 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/42 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/1 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/12 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/48 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/13 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/30 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/53 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/3 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/5 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/50 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/15 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/39 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/59 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/2 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/49 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/56 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/64 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/38 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/4 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/16 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/19 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/54 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/51 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/40 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/55 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/18 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/61 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/41 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/20 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/21 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/22 2025-12-07 monthly 0.5 https://crcwarriors.org/help/getting-started.php 2026-08-01 monthly 0.4 https://crcwarriors.org/help/clinical-trials-guide.php 2026-08-01 monthly 0.4 https://crcwarriors.org/help/understanding-mutations.php 2026-08-01 monthly 0.4 https://crcwarriors.org/help/medication-database.php 2026-08-01 monthly 0.4 https://crcwarriors.org/help/privacy-security.php 2026-08-01 monthly 0.4 https://crcwarriors.org/help/faq.php 2026-08-01 monthly 0.4